



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)
Stock code 股份代號: 1477

2025

ANNUAL REPORT
年度報告

Virtus et Lumen
勇氣和光明

Contents

Corporate Information	2
Chairman's Statement	4
Financial Summary	7
Management Discussion and Analysis	9
Profiles of Directors and Senior Management	24
Corporate Governance Report	32
Report of Directors	49
Independent Auditor's Report	82
Consolidated Statement of Profit or Loss and Other Comprehensive Income	87
Consolidated Statement of Financial Position	88
Consolidated Statement of Changes in Equity	89
Consolidated Statement of Cash Flows	90
Notes to the Consolidated Financial Statements	92
Definitions and Acronyms	155

Corporate Information

BOARD OF DIRECTORS

Executive Directors

Mr. Ye LIU (*Chief Executive Officer*)
Dr. Zhaopeng HU

Non-executive Directors

Dr. Lian Yong CHEN (*Chairman of the Board*)
Dr. Wei LI (*resigned on January 16, 2025*)
Mr. Yanling CAO
Dr. Qin XIE (*appointed on January 16, 2025*)

Independent Non-executive Directors

Mr. Ting Yuk Anthony WU
Mr. Yiran HUANG
Mr. Zhenyu ZHANG

AUDIT COMMITTEE

Mr. Ting Yuk Anthony WU (*Chairman*)
Mr. Yiran HUANG
Mr. Zhenyu ZHANG

REMUNERATION COMMITTEE

Mr. Zhenyu ZHANG (*Chairman*)
Mr. Ting Yuk Anthony WU
Mr. Yiran HUANG

NOMINATION COMMITTEE

Dr. Lian Yong CHEN (*Chairman*)
Mr. Ting Yuk Anthony Wu (*appointed on June 30, 2025*)
Dr. Qin XIE (*appointed on June 30, 2025*)
Mr. Yiran HUANG
Mr. Zhenyu ZHANG

JOINT COMPANY SECRETARIES

Mr. Tim RUAN
Ms. Tingchan CHEN (*HKACG, ACG*)

AUTHORIZED REPRESENTATIVES

Mr. Ye LIU
Mr. Tim RUAN

REGISTERED OFFICE

The offices of Vistra (Cayman) Limited
P.O. Box 31119 Grand Pavilion
Hibiscus Way
802 West Bay Road
Grand Cayman KY1-1205
Cayman Islands

CORPORATE HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
Suzhou
Jiangsu Province
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 417, 4th Floor, Lippo Centre
Tower Two, No. 89 Queensway
Admiralty
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN CAYMAN ISLANDS

Vistra (Cayman) Limited
P.O. Box 31119 Grand Pavilion
Hibiscus Way, 802 West Bay Road
Grand Cayman, KY1-1205
Cayman Islands

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716
17th Floor Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

HONG KONG LEGAL ADVISER

Kirkland & Ellis
26th Floor, Gloucester Tower
The Landmark
15 Queen's Road Central
Hong Kong

AUDITOR

Deloitte Touche Tohmatsu
Certified Public Accountants
Registered Public Interest Entity Auditor
35/F, One Pacific Place
88 Queensway, Admiralty
Hong Kong

STOCK CODE

1477

COMPANY WEBSITE

www.ocumension.com

Chairman's Statement

Dear Shareholders,

The year 2025 marked a milestone in Ocumension's development journey. Amid a complex and ever-changing global economic environment alongside mounting challenges within the pharmaceutical industry, our Company achieved steady growth over the past year with a leap in operating performance and significant improvements in operational quality – all attributable to our clear strategic plans and strong execution. Today, Ocumension is steadily evolving into a high-growth enterprise driven by innovative products and centered on robust commercialization capabilities. On behalf of the Board, I extend our most sincere gratitude to all our investors, partners, employees, and friends from various sectors who have shown understanding and support for Ocumension's development.

I. MILESTONE BREAKTHROUGH IN PERFORMANCE AND CONTINUOUS IMPROVEMENT IN OPERATIONAL QUALITY

In 2025, our Company recorded operating revenue of RMB804.4 million, representing a year-on-year increase of approximately 92.7% and maintaining rapid growth momentum for consecutive years. Notably, our Company's non-IFRS adjusted net loss reduced significantly to RMB89.9 million, while non-IFRS adjusted EBITDA turned positive for the first time, reaching RMB50.3 million. The shift of this key financial indicator into positive territory signifies that we have successfully transitioned beyond the scale expansion stage and formally entered a new development cycle featuring continuously improving operating efficiency and steadily enhanced self-sustaining capabilities.

The robust growth in performance was primarily driven by the following key factors:

- (i) **Accelerated Ramp-up of Core Products:** Following its inclusion in the NRDL, Youshiying® (OT-401) has achieved rapid growth in market penetration, thus establishing itself as a benchmark product in the uveitis treatment sector. Meanwhile, the innovative anti-allergy drug ZERVIATE® (OT-1001) has rapidly penetrated both pediatric and adult markets since its launch, steadily emerging as a new growth driver.
- (ii) **Notable Achievements Made in International Strategic Collaboration:** The strategic partnership established in 2024 with Alcon, a global leader in ophthalmology, was fully rolled out during 2025. Our Company successfully integrated eight dry eye and surgical eye drop products licensed from Alcon. In addition to delivering substantial incremental revenue, these established products have further strengthened our leading position in the dry eye disease segment – the third-largest ophthalmic disease segment in China – through channel synergies.
- (iii) **Extensive Coverage of the Commercial Network:** As of the end of 2025, the Company's products had reached over 22,720 hospitals nationwide, including 2,858 Grade III hospitals, thereby establishing one of the most extensive and deeply penetrated commercial networks in China's ophthalmic sector.

II. STEADY ADVANCEMENT IN R&D PIPELINE DRIVEN BY ROBUST INNOVATION

As a leading platform company in China's ophthalmic innovative drug sector, we are always considering R&D innovation as the core driver of our development. As of the end of 2025, the Company has established a comprehensive product portfolio covering both front- and back-of-the eye, comprising 43 drug assets, among which 27 products have already been at the commercialization stage, five were in phase III clinical trials, one has reached the registration stage for commercialization, and another 10 drug candidates were at early development stage.

Multiple R&D milestones were successfully reached during the year:

- (i) **OT-702, Boyoujing® (aflibercept intravitreal injection):** It was approved for marketing by the NMPA for the treatment of nAMD (wet AMD) and DME in adults, marking the Company's entry into the multi-billion-yuan market of the macular degeneration field.
- (ii) **OT-202 (Syk/VEGFR-2 dual-target inhibitor):** As the first-in-class new drug self-developed by our Company for the treatment of dry eye, its Phase II clinical results have been published in a top international ophthalmology journal, highlighting our Company's capability in pioneering innovation.
- (iii) **OT-802 (pilocarpine eye drops):** The application of its phase III clinical trial was accepted by the CDE, demonstrating the robust R&D capabilities of the Group and highlighting the considerable potential in the currently underserved presbyopia treatment market.

III. KEY PROGRESS ACHIEVED IN CAPACITY EXPANSION AND SUPPLY CHAIN LOCALIZATION

To ensure stable product supply, reduce costs, and enhance quality control, our Company's Suzhou ophthalmic formulation manufacturing site is currently conducting large scale production of commercial batches. With a designed annual production capacity of 455 million doses, it has already enabled large-scale commercial production for six products. "Ocumension Manufacturing" is transitioning from blueprint to reality, with larger-scale commercial production scheduled for 2026. Localized production has not only enhanced the resilience of our supply chain but also laid a solid foundation for tapping into new revenue streams in the future.

IV. INDUSTRY OUTLOOK AND CORPORATE STRATEGY

China's ophthalmic drug market is in a golden period of structural growth. With the intensification of population aging, widespread use of electronic devices, and increasing public health awareness, demand for diagnosis and treatment continues to rise in areas such as dry eye disease, glaucoma, diabetic retinopathy, and myopia control. Meanwhile, national policies encouraging innovative drug development and import substitution have presented great potential for further growth for domestic companies like Ocumension, which possess comprehensive pipeline portfolio and robust commercialization capabilities.

Looking forward, our Company will continue to focus on the following strategic priorities:

- (i) **Deepening Global Synergies with Alcon:** Building on our strategic cooperation with Alcon and our successful integration of eight dry eye and surgical eye drop products, we will further advance channel integration and market expansion to consolidate and expand our leading market share in China's dry eye disease market.
- (ii) **Advancing the Approval and Ramp-up of Key Pipeline:** Our Company will ensure the successful launch of core products including OT-502 and rapidly capture their commercial value.

Chairman's Statement

- (iii) **Continuously improving operational efficiency:** While maintaining robust revenue growth, we are committed to further optimizing cost structures and improving working capital management. Our Company is steadily advancing toward its strategic objectives of achieving sustainable profitability and generating positive operating cash flow in the foreseeable future.
- (iv) **Expanding the frontiers of innovation:** While consolidating its competitive advantages in existing core areas, the Company will proactively explore cutting-edge ophthalmic technologies and continuously enrich its product pipeline with the aim of providing world-class integrated pharmaceutical solutions that address the unmet clinical needs of ophthalmic patients in China.

CONCLUSION

Looking back at 2025, we advanced with “Virtus et Lumen” as our conviction, overcoming challenges with steadfast determination. Looking forward, we are fully confident in the immense potential of China’s ophthalmic market and remain firmly committed to Ocumension’s strategic direction. Under the strategic guidance of the Board, the management team will, driven by innovation and collaboration, continue fulfilling their duties with diligence and dedication, leading all members of Ocumension to deliver long-term, sustainable value for our Shareholders and make China’s contribution to the global advancement of eye health.

Thank you all once again for your trust and support!

Yours faithfully,

Dr. Lian Yong CHEN

Chairman and Non-executive Director

Financial Summary

A summary of the results and of the assets and liabilities of the Group for the last five financial years is set out below:

	For the year ended December 31,				
	2025	2024	2023	2022	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Revenue	804,352	417,307	246,367	158,957	56,146
Cost of sales	(443,430)	(192,242)	(102,002)	(56,041)	(19,211)
Gross profit	360,922	225,065	144,365	102,916	36,935
Other income	10,460	46,738	23,203	35,654	27,589
Other expenses	(6,648)	(6,831)	(4,641)	(128)	(160)
Other gains and losses	367	1,430	5,430	19,901	112,403
Impairment losses under expected credit loss model, net of reversal	(653)	(651)	(349)	(683)	–
Selling and marketing expenses	(265,691)	(227,698)	(226,253)	(183,039)	(127,647)
R&D expenses	(75,081)	(113,935)	(123,768)	(184,309)	(169,055)
Administrative expenses	(179,701)	(189,212)	(196,142)	(190,748)	(126,159)
Share of results of an associate	–	–	–	–	(13,331)
Finance costs	(2,445)	(2,163)	(1,325)	(1,793)	(567)
Loss before tax	(158,470)	(267,257)	(379,480)	(402,229)	(259,992)
Income tax expense	(350)	(1,017)	(307)	(414)	–
Loss for the year attributable to:					
– Owners of the Company	(158,820)	(268,274)	(379,787)	(402,643)	(259,992)
– Non-controlling interests	–	–	–	–	–
	(158,820)	(268,274)	(379,787)	(402,643)	(259,992)
Other comprehensive income (expense):					
<i>Item that will not be reclassified to profit or loss</i>					
Fair value gain (loss) on investments in equity instruments at FVTOCI	8,449	(47,450)	407,254	(177,401)	(305)
Total comprehensive (expense) income for the year attributable to:					
– Owners of the Company	(150,371)	(315,724)	27,467	(580,044)	(260,297)
– Non-controlling interests	–	–	–	–	–
	(150,371)	(315,724)	27,467	(580,044)	(260,297)

Financial Summary

	For the year ended December 31,				
	2025 RMB'000	2024 RMB'000	2023 RMB'000	2022 RMB'000	2021 RMB'000
Loss per Share					
— Basic and diluted (RMB)	(0.20)	(0.39)	(0.59)	(0.64)	(0.43)
Loss for the year	(158,820)	(268,274)	(379,787)	(402,643)	(259,992)
<i>Add:</i>					
Impairment loss (reversed) recognised on long-lived assets	—	—	(3,179)	3,179	—
Gains related to transaction with EyePoint	—	—	—	—	(100,621)
Gains related to transaction with Alimera	—	—	—	—	(14,534)
Share-based payments	68,938	84,632	139,729	218,792	188,116
Non-IFRS measure:					
Adjusted net loss for the year ⁽¹⁾	(89,882)	(183,642)	(243,237)	(180,672)	(187,031)

Note:

- (1) The adjusted net loss for the year is defined as loss for the year adjusted by (a) adding back (i) impairment loss (reversed) recognised on long-lived assets, and (ii) share-based payments; and (b) deducting the one-time gain generated from the respective transactions with EyePoint and Alimera.

	As of December 31,				
	2025 RMB'000	2024 RMB'000	2023 RMB'000	2022 RMB'000	2021 RMB'000
Non-current assets	3,139,915	2,995,009	2,065,365	1,588,514	1,496,486
Current assets	951,039	978,795	1,205,634	1,455,160	1,834,567
Non-current liabilities	153,447	45,186	35,747	47,382	(7,026)
Current liabilities	256,760	155,001	315,284	247,653	(215,854)
Net assets	3,680,747	3,773,617	2,919,968	2,748,639	3,108,173
Equity attributable to the owners of the Company	3,680,747	3,773,617	2,919,968	2,748,639	3,108,173
Non-controlling interests	—	—	—	—	—
Total equity	3,680,747	3,773,617	2,919,968	2,748,639	3,108,173

Management Discussion and Analysis

CORPORATE PROFILE

Overview

We are a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. Our vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. We believe our ophthalmic pharmaceutical platform, which enjoys a clear first-mover advantage, will enable us to obtain and maintain our leadership position in the field of ophthalmology in China.

To date, the Company has established a complete ophthalmic drug pipeline with 43 front- and back-of-the-eye drug assets, among which, 27 products are at the commercialization stage, five drug candidates are in phase III clinical trial, one innovative drug candidate has reached the registration stage for commercialization and another 10 drug candidates are at early development stage. Our Core Product, Youshiying® (0.18mg fluocinolone intravitreal implant), was officially approved and included in the NRDL issued by the National Healthcare Security Administration (國家醫療保障局) of the PRC. ZERVATE® (innovative anti-allergic drug) and Boyoujing® (anti-VEGF drug) have also been approved for commercialization in Chinese Mainland. The following table summarizes our product portfolio and the status of each drug asset as of December 31, 2025:

Uveitis, fundus diseases									
Pipeline	MoA/Molecule	Indications	Rights	Partners	Pre	Phase I/II	Phase III/RWE	Commercialization	
OT-401	Youshiying®	Fluocinolone intravitreal implant	Chronic NIU-PS	Greater China, Korea, +11 SEA countries	EYEPOINT				Partnership
OT-702	Boyoujing (博優景®)	Aflibercept intravitreal injection	wAMD, DME	Chinese Mainland	Boan Biotech				Self-developed
OT-402	Visudyne®	Verteporfin	Choroidal neovascularisation	Chinese Mainland	CHEPLAPHARM				Partnership
OT-703	Ocusigen®	Fluocinolone intravitreal implant	DME	Greater China, Korea, +11 SEA countries	ani				Partnership
OT-701		Ranibizumab	wAMD	Greater China	SENJU				Partnership
OT-1601		Stem Cell	Retinitis pigmentosa, dAMD	Greater China	SanBio				Partnership
OT-1602		Stem Cell	Optic neuritis	Greater China	SanBio				Partnership

Refractive correction									
Pipeline	MoA/Molecule	Indications	Rights	Partners	Pre	Phase I/II	Phase III	Commercialization	
OT-101		Low-concentration atropine eye drops	Myopia	Global	Self-developed				Self-developed
OT-802		Pilocarpine Hydrochloride	Presbyopia	Global	Self-developed				Self-developed

Note: **have commercial rights

DED									
Pipeline	MoA/Molecule	Indications	Rights	Partners	Pre	Phase I/II	Phase III	Commercialization	
OT-204	Ou Qin (歐沁®)	HA	Chinese Mainland	HUONLAND					Partnership
OT-208	Bion tears®	0.4ml Dextran 70/Hydromellose	Chinese Mainland	Alcon 爱尔康					Partnership
OT-209	Tears Naturale Free®	15ml Dextran 70/Hydromellose	Chinese Mainland	Alcon 爱尔康					Partnership
OT-210	Tears Naturales Forte®	Hypromellose 2910, Dextran 70 and Glycerol	Chinese Mainland	Alcon 爱尔康					Partnership
OT-212	Systane Ultra®	polyethylene glycol 400/propylene glycol	Chinese Mainland	Alcon 爱尔康					Partnership
OT-205	Ouxiaoqing (歐小清®)	Diquafosol Sodium	Global	Self-developed					Self-developed
OT-206	Oushijie (歐世傑®)	Polyvinyl Alcohol	Global	Self-developed					Self-developed
OT-202		Spleen tyrosine kinase inhibitor	Global	Self-developed					Self-developed
OT-503	NCX 4251	Fluticasone Propionate Nanocrystals	Greater China	HICOX					Partnership
OT-211	AR-15512	TRPM8 agonist	Chinese Mainland	Alcon 爱尔康					Partnership

Notes: *approved in the U.S.; **have commercial rights

Management Discussion and Analysis

Glaucoma

■ Partnership ■ Self-developed

Pipeline	MoA/Molecule	Rights	Partners	Pre	Phase I/II	Phase III	Commercialization
OT-305 BetopticS (貝特舒)	Betaxolol hydrochloride	Chinese Mainland	NOVARTIS				
OT-306 Xalatan ® (適利達®)	Latanoprost	Chinese Mainland	VIATRIS				
OT-307 Xalacom ® (適利加®)	Latanoprost and timolol maleate	Chinese Mainland	VIATRIS				
OT-304 Outuobang (歐托邦®)	Tafuprost	Global	Self-developed				
OT-303	Brimonidine tartrate	Chinese Mainland	汇恩兰德				
OT-303-S Oudesai (歐德賽®)	Brimonidine tartrate	Global	Self-developed				
OT-301 NCX 470	Bimatoprost grenod	Greater China, Korea, 12 SEA countries	nicox				

Conjunctivitis

■ Partnership ■ Self-developed

Pipeline	MoA/Molecule	Indications	Rights	Partners	Pre	Phase I/II	Phase III	Commercialization
OT-1001 Zerviate ® (智維泰®)	Cetirizine hydrochloride	Allergic conjunctivitis	Greater China, +11 SEA countries	nicox				
OT-1004 Emadine ® (埃美丁®)	Emedastine difumarate	Allergic conjunctivitis	Chinese Mainland, Global, Technology transfer	NOVARTIS Import transfer				
OT-1005 Azep ® (愛賽平®)	Azelastine hydrochloride	Allergic conjunctivitis	Chinese Mainland	VIATRIS				
OT-606 Natacyn ®	Natamycin	Fungus disease	Greater China	HARROW				
OT-601 Kangwenjuan (康文消®)	Moxifloxacin	Bacterial conjunctivitis	Global	Self-developed				
OT-604 Kangxiaoqing (康小清®)	Levofloxacin	Bacterial conjunctivitis	Global	Self-developed				
OT-1501 Oushu (歐殊®)	Bromfenac Sodium	Anti-inflammatory	Global	Self-developed				
OT-1502 Ouran (歐然®)	Pranoprofen	Anti-inflammatory	Global	Self-developed				

Note: *Marketing application submitted, under review or pending approval

Surgery

■ Partnership ■ Self-developed

Pipeline	MoA/Molecule	Indications	Rights	Partners	Pre	Phase I/II	Phase III	Commercialization
OT-502 Dexycu ®	Dexamethasone (intraocular suspension)	Postoperative ocular inflammation	Greater China, Korea, +11 SEA countries	EYEPOINT				*
OT-1403 Cyclogyl ®	Cyclopentolate hydrochloride	Paralysis of ciliary muscle, pupil dilation	Chinese Mainland	Alcon 爱尔康				
OT-1404 Alcaine ®	Proparacaine hydrochloride	Topical ocular anesthesia	Chinese Mainland	Alcon 爱尔康				
OT-1702 Fluorescein ®	Fluorescein sodium	Used in fluorescein angiography	Chinese Mainland	Alcon 爱尔康				
OT-1402 Ougaolin (歐高林®)	Oxybuprocaine hydrochloride	Surface anesthesia of the eye	Global	Domestically first generic, Self-developed				
OT-1401 Ouzhimin (歐智敏®)	Compound Tropicamide	Mydriasis and paralysis of accommodation used for diagnostic and therapeutic purposes	Global	Self-developed				
OT-601-C	Moxifloxacin Dexamethasone Suspension	Treatment of ocular inflammation	Global	Self-developed				

Others (OTC)

Pipeline	MoA/Molecule	Indications	Rights	Partners	Commercialization
OT-903 Kangshu (康殊®)	0.02% Chlorhexidine	Eyelid and Periocular Cleansing	Chinese Mainland	Osaki	

Note: *Marketing application submitted, under review or pending approval

BUSINESS REVIEW

During the Reporting Period, we have been making significant progress with respect to our pipeline products and business operations, including the following milestones and achievements:

Overall Financial Performance

During the Reporting Period, our Company recorded revenue of RMB804.4 million, representing a year-on-year increase of 92.7%, with a comprehensive gross profit margin of approximately 44.9%. Our Company has further expanded the in-hospital market, with our key products maintaining steady sales growth. Our Core Product, Youshiying®, continues to play a pivotal role in our growth strategy. Our R&D expenses were RMB75.1 million, and we continued steadily advancing the R&D of our pipeline candidates. Notably, one of our key products, Boyoujing® (aflibercept intravitreal injection), has been approved for marketing during the Reporting Period, which is expected to serve as an additional driver of revenue growth. Our Company recorded non-IFRS adjusted EBITDA of RMB50.3 million for the Reporting Period, turning positive for the first time since inception. This was primarily attributable to the significant narrowing of our adjusted net loss for the Reporting Period compared with 2024.

Research and Development Performance

During the Reporting Period, several of our clinical R&D projects achieved important milestones, showcasing our R&D capabilities recognized domestically and internationally and attracting global attention. Among them, Boyoujing® (aflibercept intravitreal injection) has been approved for marketing by the NMPA for the treatment of nAMD (wet AMD) and DME in adults, which marks another key product of our Company in the fundus diseases segment. The phase II clinical trial results of OT-202 (Syk/VEGF), a self-developed Class 1 innovative drug for the treatment of dry eye disease, were published in the world's top ophthalmology journal *Ophthalmology*. This publication represents the first clinical trial results of a China-developed Class 1 innovative drug for dry eye published in *Ophthalmology*, highlighting our R&D capabilities and the clinical potential of OT-202. Recognition by this internationally authoritative ophthalmology journal will further encourage us to continue the R&D efforts in cutting-edge ophthalmology, striving to provide new treatment options for patients with dry eye disease worldwide. OT-802 (pilocarpine hydrochloride) has been approved to initiate phase III clinical trials. The presbyopia track, as a disease area with broad market space, currently lacks effective treatment drugs domestically, and OT-802 is expected to fully position itself in this space.

To date, we have 27 commercialized products, five drug candidates in phase III clinical trial stage and one drug candidate in the stage of registration for commercialization, comprehensively covering both front- and back-of-the-eye diseases, which demonstrates our portfolio is well-structured with a clearly tiered development pipeline. Our Company stands as one of the domestic innovative pharmaceutical companies with the largest number of drugs in phase III clinical trial and registration stage. Moreover, our Company leads the country in the number of ophthalmic drugs that have passed or are deemed to have passed the consistency evaluation, delivering robust pipeline support through continuous R&D output.

Management Discussion and Analysis

Research and Development Progress of Our Key Drug Candidates

- **OT-703 (Ocusingen[®], fluocinolone intravitreal implant)**

In May 2025, the application for the real-world study of OT-703, an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of DME, was approved by the CDE in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, the PRC. Subsequently in January 2026, it completed the enrollment of a total of 195 patients for real-world study.

We expect to move forward the real-word study of OT-703 in the first half of 2026.

- **OT-802 (pilocarpine hydrochloride)**

In June 2025, the application of the phase III clinical trial of OT-802, our self-developed product targeting the indication of presbyopia, was accepted by the CDE, demonstrating our robust R&D capabilities and highlighting the considerable potential in the currently underserved presbyopia treatment market.

We expect to commence the phase III clinical trial of OT-802 in early 2026.

- **OT-301 (NCX 470)**

In August 2025, OT-301 (NCX 470), a first-in-class, nitric oxide (NO)-donating prostaglandin analog, achieved the primary endpoint in the second phase III clinical trial (the “**Denali trial**”), meeting the efficiency requirements for NDA in China. It demonstrated a favorable safety profile and was well tolerated by patients in the Denali trial. Additionally, OT-301 demonstrated statistically superior intraocular pressure reduction from baseline compared with latanoprost in a pre-specified secondary efficacy analysis, with a p-value of less than 0.05 at three out of six timepoints.

We expect to submit NDA to CDE this year.

- **OT-702 (Aflibercept Intravitreal Injection, EYLEA[®] biosimilar)**

In November 2025, OT-702 was approved for marketing by the NMPA for the treatment of nAMD (wet AMD) and DME in adults.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND/OR MARKET OUR DRUG CANDIDATES SUCCESSFULLY.

Commercialization Performance

During the Reporting Period, we actively expanded our hospital coverage and accelerated the admission of our products into hospitals. Products such as Systane Ultra[®], Tears Naturale Forte[®] and other newly acquired pipeline products for dry eye achieved relatively rapid growth. Meanwhile, we continued maintaining a leading industry position in the anti-allergic and glaucoma fields, steadily increasing our market share. We recorded a total revenue of RMB804.4 million from our commercialized products, representing a year-on-year increase of 92.7%. We have expanded our coverage to 22,720 hospitals nationwide, including 2,858 Grade III hospitals. With a commercial team of over 334 members, our Company has established full national business network coverage.

In November 2025, at the 8th China International Import Expo (第捌屆中國國際進口博覽會) (“CIIE”), our Company entered into a strategic cooperation agreement with Shanghai Pharmaceuticals Holdings Co., Ltd (上藥控股有限公司), a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司) (stock codes: 601607.SH and 2607.HK). The scope of the cooperation covers all of our imported products, with a primary focus on product introduction, distribution and supply chain collaboration. This agreement represents another milestone in our partnership formed at the CIIE, following our cooperation in the previous year. The new cooperation aims to optimize the ophthalmic medical supply chain through resource integration, enhance the circulation efficiency of imported medical products, and support the high-quality development of ophthalmic healthcare in China.

Manufacturing Performance

During the Reporting Period, we continued carrying out commercial batch production. Supported by advanced manufacturing technologies, efficient supply chain management and a relentless commitment to excellence, “Ocumension Manufacturing” eye drop products are set to provide patients with safer and higher-quality ophthalmic medications. With production capacity steadily ramping up, the plant is well prepared to support the scaling-up of multiple commercialized products.

During the Reporting Period, the Suzhou manufacturing site completed 27 batches of commercial production. In 2026, commercial batch production is expected to achieve a significant growth, including the localization of production of Youshiying®, which will further reduce the overall cost of our commercialized products.

FUTURE DEVELOPMENT AND OUTLOOK

Building on the milestone performance breakthroughs and fundamental improvements in operational quality achieved in 2025, our Company has successfully transitioned beyond the scale expansion stage and formally entered a new development cycle characterized by continuously improving operating efficiency and steadily enhanced self-sustaining capabilities. Looking ahead, our Board and management team remain fully confident in our development prospects. We will continue firmly implementing our established strategies, committed to delivering long-term, sustainable value for our Shareholders.

1. Clear Financial Targets and Profitability Path

Our Company has set clear and achievable financial targets. Following the operational turnaround in 2025 with non-IFRS adjusted EBITDA turning positive, we expect to make further progress in 2026. This target is underpinned by the robust growth momentum of our existing businesses, anticipated contributions from soon-to-be-approved products, and the continuous optimization of our cost structure. The management team will closely monitor operational efficiency to ensure our Company stays firmly on track toward its established profitability goals.

2. Deepening Commercialization Synergies to Drive Sustained High Revenue Growth

- **Maximizing the Value of the Strategic Cooperation with Alcon:** Our Company will continue deepening comprehensive synergies with Alcon, a global leader in ophthalmology. Building on the successful integration of eight dry eye and surgical eye drop products, we will further advance channel integration and market expansion to consolidate and expand our leading market share in China’s dry eye disease market – the third-largest ophthalmic disease segment in the country.

Management Discussion and Analysis

- **Driving the Full Ramp-up of Core Product and Key Products:** Our Company will continue enhancing the market penetration of Youshiying® (OT-401) following its inclusion in the NRDL, consolidating its benchmark position in the uveitis treatment sector. We will fully promote the commercialization of Boyoujing® (OT-702), a blockbuster anti-VEGF product, and rapidly penetrate the multi-billion-RMB fundus disease market by leveraging its pricing and accessibility advantages. Meanwhile, we will accelerate market education for Zerviate® (OT-1001) in the pediatric anti-allergy segment to foster a new growth engine.
- **Expanding Diversified Revenue Sources:** Leveraging the advanced production capacity and quality control systems of our Suzhou manufacturing site, we will actively expand our ophthalmic formulation CDMO business. This will form a dual-engine drive of “product sales + CDMO services,” smoothing our product cycles and enhancing earnings stability.

3. Accelerating R&D Pipeline Advancement to Build Long-Term Competitive Barriers

Our Company will maintain its strategic focus, covering the full spectrum of ophthalmic diseases and advancing the clinical development and registration processes of our diversified product pipeline:

- **Near-Term Catalysts (2026-2027):** Our Company plans to seek NDA approval and commercially launch OT-502 (a dexamethasone implant). We also expect to complete the unblinding of the global phase III clinical trial for OT-101 (low-concentration atropine) and advance its regulatory submission. In addition, we plan to advance phase III clinical trial for AR-15512 and initiate phase III clinical trial for OT-802 for the treatment of presbyopia.
- **Mid-to-Long-Term Innovation Pipeline:** Our Company will continue advancing the phase III clinical development of OT-202, a first-in-class dry eye therapy and Syk/VEGFR-2 dual-target inhibitor, progressing the domestic regulatory filing for OT-301 (beraprost) and exploring cutting-edge technologies, including stem cell therapy, to further expand our innovation pipeline.

4. Completing Capacity Upgrades to Enhance Supply Chain Self-Sufficiency and Control

With a designed annual production capacity of 455 million doses, the facility will further strengthen our localized production capabilities for our Core Product and several in-licensed products. The full rollout of “*Ocumention Manufacturing*” will not only significantly enhance the stability and resilience of our supply chain but also substantially reduce product costs through economies of scale, improve gross profit margin, and provide a solid foundation for enhancing our market competitiveness and profitability.

5. Embracing Market Opportunities to Spearhead Ophthalmic Import Substitution

Driven by population aging, growing reliance on electronic devices, and rising health awareness, China's ophthalmic pharmaceutical market is expected to maintain robust growth. Concurrently, national policies strongly encourage innovative drug development and import substitution. As a leading platform company in China's ophthalmic innovative drug sector, equipped with the most comprehensive product pipeline and an extensive commercial network, Ocumension is at the forefront of this historic opportunity. Leveraging our comprehensive product portfolio underpinned by the "in-house R&D + global BD in-licensing" dual-engine strategy, our Company is well-positioned to accelerate import substitution across high-growth therapeutic areas, including dry eye disease, myopia control, and fundus diseases, thereby further consolidating and strengthening our market leadership.

FINANCIAL REVIEW

Overview

The revenue of our Group increased by 92.7% from RMB417.3 million for the year ended December 31, 2024 to RMB804.4 million for the year ended December 31, 2025. This substantial growth was primarily driven by (i) a significant increase in the revenue generated from the sales of our ophthalmic products, including Xalatan®, Azep® and the products acquired and in-licensed from Alcon under the Alcon Transaction; and (ii) a notable increase in the sales-based royalty income, largely driven by our successful commercialization of Boyoujing®.

Our adjusted net loss (a non-IFRS adjustment) narrowed by 51.1% to RMB89.9 million for the year ended December 31, 2025, from RMB183.6 million for the year ended December 31, 2024, primarily attributable to the significant growth in revenue and improvement in the efficiency of operation. Our Company recorded non-IFRS adjusted EBITDA of RMB50.3 million for the Reporting Period, turning positive for the first time since inception. This was primarily attributable to the significant narrowing of our adjusted net loss for the Reporting Period compared with 2024.

Management Discussion and Analysis

For the Year Ended December 31, 2025 Compared to the Year Ended December 31, 2024

	For the year ended December 31,	
	2025 RMB'000	2024 RMB'000
Revenue	804,352	417,307
Cost of sales	(443,430)	(192,242)
Gross profit	360,922	225,065
Other income	10,460	46,738
Other expenses	(6,648)	(6,831)
Other gains and losses	367	1,430
Impairment losses under expected credit loss model, net of reversal	(653)	(651)
Selling and marketing expenses	(265,691)	(227,698)
R&D expenses	(75,081)	(113,935)
Administrative expenses	(179,701)	(189,212)
Finance costs	(2,445)	(2,163)
Loss before tax	(158,470)	(267,257)
Income tax expense	(350)	(1,017)
Loss for the year	(158,820)	(268,274)
Non-IFRS measures:		
Adjusted net loss for the year	(89,882)	(183,642)
Adjusted EBITDA	50,251	(114,067)

Revenue

The revenue of our Group increased from RMB417.3 million for the year ended December 31, 2024 to RMB804.4 million for the year ended December 31, 2025, mainly attributed to (i) a significant increase in the revenue generated from the sales of our ophthalmic products, including Xalatan®, Azep® and the products acquired and in-licensed from Alcon under the Alcon Transaction; and (ii) a notable increase in the sales-based royalty income, largely driven by our successful commercialization of Boyoujing®. Revenue from our pharmaceutical products promotion services continued to decrease due to change in revenue recognition following the business model change in respect of Xalatan® and Xalacom®. The following table sets forth the components of the revenue for the years indicated:

	For the year ended December 31,	
	2025 RMB'000	2024 RMB'000
Sales of ophthalmic products	756,175	384,345
Pharmaceutical products promotion services	6,514	15,706
Sales-based royalty income	34,018	7,175
CDMO services	7,645	10,081
Total Revenue	804,352	417,307

For the sale of ophthalmic products, revenue is recognized when control of the goods is transferred, being when the goods have been delivered to the customer's specific location, i.e., when the products are delivered and titles are passed to customers upon receipt by customers. For pharmaceutical products promotion services, revenue is recognized at a point in time when we satisfy the obligation to arrange for sales and/or delivery of pharmaceutical products pursuant to the service contracts. The sales-based royalty income is based on the profit margin of each sale and is recognized at a point of time upon the customer completes its sales. The CDMO service revenue is recognized at the point in time when the deliverables are delivered to our customers.

Cost of Sales

Our cost of sales mainly consists of purchase price of goods and amortization of license rights. Our cost of sales significantly increased from RMB192.2 million for the year ended December 31, 2024 to RMB443.4 million for the year ended December 31, 2025. The increase was mainly due to the increased cost in relation to our sales of ophthalmic products and amortization of license rights for the acquisition and in-licensing of products in relation to Alcon Transaction, which was generally in line with the growth of our revenue.

Gross Profit

The gross profit of our Group significantly increased by 60.4% from RMB225.1 million for the year ended December 31, 2024 to RMB360.9 million for the year ended December 31, 2025. The increase in gross profit was generally in line with our revenue growth, partially offset by the increase in cost of sales.

Other Income

Our other income mainly consists of bank interest income arising from our bank deposit and government grant income. For the year ended December 31, 2025, our other income was RMB10.5 million, representing a decrease of approximately RMB36.2 million from RMB46.7 million for the year ended December 31, 2024, primarily due to (i) a decrease in our bank deposit and the declined deposit interest rates and (ii) the one-off compensation from Alcon recognized in the previous year did not recur during the Reporting Period, partially offset by an increase in government grant. Details of movements of our other income are set forth in Note 6 to the consolidated financial statements included in this annual report.

Other Gains and Losses

We incurred other gains of RMB0.4 million for the year ended December 31, 2025, representing a decrease of RMB1.0 million as compared to last year. This change was primarily attributable to net foreign exchange losses resulting from fluctuations in currency exchange rates, partially offset by an increase in gains from changes in fair value of other financial assets.

Selling and Marketing Expenses

Our selling and marketing expenses mainly consist of (i) salary and benefits expenses for our commercialization team; (ii) share-based payments for our commercialization team; and (iii) marketing and promotion expenses. For the year ended December 31, 2025, our selling and marketing expenses were RMB265.7 million, representing an increase of RMB38.0 million from RMB227.7 million for the year ended December 31, 2024.

Management Discussion and Analysis

The following table sets forth the components of our selling and marketing expenses for the years indicated:

	For the year ended December 31,	
	2025 RMB'000	2024 RMB'000
Salary and benefits	140,899	116,164
Share-based payments	25,318	29,758
Marketing and promotion	74,515	55,628
Others	24,959	26,148
Total selling and marketing expenses	265,691	227,698

R&D Expenses

During the Reporting Period, we recorded R&D expenses of RMB75.1 million, representing a decrease of 34.1% from RMB113.9 million for the year ended December 31, 2024. Such decrease was primarily due to (i) a decrease of RMB7.8 million in share-based payments for R&D staff during the Reporting Period and (ii) a decrease of RMB20.4 million in third-party contracting costs, as compared to 2024.

The following table sets forth the components of our R&D expenses for the years indicated:

	For the year ended December 31,	
	2025 RMB'000	2024 RMB'000
Third-party contracting costs	18,079	38,522
Staff costs	42,565	52,660
Depreciation and amortization	8,723	10,253
Others	5,714	12,500
Total R&D expenses	75,081	113,935

Administrative Expenses

Our administrative expenses consist of (i) salaries and other expenses such as benefits, travel and share-based payments; (ii) professional service fee; (iii) depreciation and amortization of the property for the purpose of administrative use and right-of-use assets; and (iv) rental and related expenses.

For the year ended December 31, 2025, our administrative expenses were RMB179.7 million, representing a slight decrease of RMB9.5 million from RMB189.2 million for the year ended December 31, 2024, which was primarily due to a decrease in staff cost and share-based payments for administrative staff.

Income Tax Expense

Our income tax expense mainly represents the profit tax in relation to the revenue incurred in markets inside and outside the PRC. For the year ended December 31, 2025, income tax expense was RMB0.4 million, representing a decrease of RMB0.6 million from RMB1.0 million for the year ended December 31, 2024, which was primarily due to a decrease in taxable income outside PRC.

Loss for the Year

As a result of the above factors, our loss narrowed by 40.8% to RMB158.8 million for the year ended December 31, 2025, from RMB268.3 million for the year ended December 31, 2024, representing a reduction of RMB109.5 million. This was primarily attributable to an increase of RMB135.9 million in gross profit, a decrease of RMB38.9 million in R&D expenses and a decrease of RMB9.5 million in administrative expenses, partially offset by an increase of RMB38.0 million in selling and marketing expenses, as compared to 2024.

Non-IFRS Measures

To supplement our consolidated financial statements which are presented in accordance with IFRS, we also use non-IFRS measures, including adjusted net loss for the year and the adjusted EBITDA to present our operating performance. Adjusted net loss for the year and non-IFRS adjusted EBITDA, as additional financial measures, are not required by, or presented in accordance with IFRS. We believe that such non-IFRS measures facilitate comparisons of our operating performance from year to year by eliminating impacts of non-cash items (such as share-based payments, one-time expenses, one-time impairment losses and etc.) that our management considers to be not indicative of our operating performance, and provide useful information to Shareholders and investors in evaluating our operating results in the same manner as our management does. However, our presentation of the adjusted net loss for the year and non-IFRS adjusted EBITDA may not be comparable to similarly titled measures presented by other companies. The use of such non-IFRS measures has limitations as an analytical tool, and you should not consider them in isolation, or as substitute for analysis of, our results of operations or financial position as reported under IFRS.

For the Reporting Period, we define adjusted net loss for the year as loss for the year adjusted by adding back, where applicable, share-based payments. The following table reconciles our non-IFRS adjusted net loss for the year with our loss for the year:

	For the year ended December 31,	
	2025	2024
	RMB'000	RMB'000
Loss for the year	(158,820)	(268,274)
<i>Add:</i>		
Share-based payments	68,938	84,632
Non-IFRS adjusted net loss for the year	(89,882)	(183,642)

Management Discussion and Analysis

We defined non-IFRS adjusted EBITDA as non-IFRS adjusted net loss for the year plus, where applicable, (i) income tax, (ii) depreciation and amortization, (iii) finance cost and (iv) bank interest income. The following table reconciles the Company's profit for the year, prepared and presented in accordance with IFRS, to non-IFRS adjusted EBITDA for the years indicated:

	For the year ended December 31,	
	2025 RMB'000	2024 RMB'000
Loss for the year	(158,820)	(268,274)
<i>Add:</i>		
Share-based payments	68,938	84,632
Non-IFRS adjusted net loss for the year	(89,882)	(183,642)
<i>Add:</i>		
Income tax	350	1,017
Depreciation and amortization	143,734	88,614
Finance costs	2,445	2,163
Bank interest income	(6,396)	(22,219)
Non-IFRS adjusted EBITDA	50,251	(114,067)

Selected Data from Consolidated Statement of Financial Position

	As of December 31,	
	2025 RMB'000	2024 RMB'000
Total current assets	951,039	978,795
Total non-current assets	3,139,915	2,995,009
Total assets	4,090,954	3,973,804
Total current liabilities	256,760	155,001
Total non-current liabilities	153,447	45,186
Total liabilities	410,207	200,187
Net assets	3,680,747	3,773,617

Trade Receivables

We allow an average credit period of 30 to 90 days to our trade customers, and the credit terms of certain trade customers are based on the timing of their actual sales.

A majority of the trade receivables aged less than 90 days based on invoice date.

The increase in our trade receivables as of December 31, 2025 is generally in line with our revenue growth.

Trade Payables

A majority of the trade payables aged less than 60 days based on invoice date.

Working Capital and Source of Capital

Our primary uses of cash related to (i) expenses and costs for our daily operation and sales and marketing activities; (ii) R&D expenses in relation to the clinical trials for our drugs and/or drug candidates; and (iii) payments in relation to the maintenance, refinement and upgrade of the production equipment at our Suzhou manufacturing site, as well as operational costs and fees incurred for the on-site trial production. During the Reporting Period, we primarily funded our working capital needs through equity financing and cash generated from (i) the sales of ophthalmic products, including, among others, Xalatan®, Azep® and the products acquired and in-licensed from Alcon under the Alcon Transaction; (ii) the pharmaceutical products promotion services; (iii) sales-based royalty income; and (iv) the CDMO services. We monitor and maintain a level of cash and cash equivalents deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. As of December 31, 2025, our cash and cash equivalents amounted to RMB377.5 million (December 31, 2024: RMB729.2 million). The decrease in cash and cash equivalents was primarily due to cash outflows for operating activities and R&D expenditures during the Reporting Period, and the allocation of a portion of cash to purchase wealth management products. Currently, we follow a set of funding and treasury policies to manage our capital resources and mitigate potential risks involved. These policies are designed to optimize the use of our financial resources, maintain adequate liquidity for our operational and development needs, and preserve capital while seeking reasonable returns on surplus cash. We regularly review our capital structure and funding requirements to ensure sufficient financial flexibility to support our business growth.

Borrowings

As of December 31, 2025, we recorded a loan of RMB158.2 million (December 31, 2024: RMB16.5 million). The increase in loan was primarily for the purpose of supplementing our working capital, optimizing our funding structure and enhancing liquidity management. During the Reporting Period, we entered into loan agreements with banks. The borrowings bear interest at either fixed rate of one-year Loan Prime Rate (“LPR”) minus 0.35% or a floating rate based on one-year LPR minus 0.76% or 0.10%, with the floating rates reset every 12 months (2024: one-year LPR minus 0.35%). All such borrowings are guaranteed by other entities within the Group.

Capital Commitment

As of December 31, 2025, we have a capital commitment of RMB0.6 million for the contracts in relation to acquisition of property, plant and equipment (December 31, 2024: RMB5.0 million).

Contingent Liabilities

As of December 31, 2025, we did not have any material contingent liabilities, guarantees or any litigation against us (December 31, 2024: nil).

Management Discussion and Analysis

Pledge of Assets

As of December 31, 2025, we did not have any pledged assets (December 31, 2024: nil).

Gearing Ratio

Gearing ratio is calculated as interest-bearing borrowings less cash and cash equivalents and term deposits with initial term of over three months, divided by total equity and multiplied by 100%. As of December 31, 2025, we were in a net cash position and therefore the gearing ratio was not applicable.

Significant Investments, Material Acquisitions and Disposals

Our Group did not hold any investment (including any investment in an investee company) which on a standalone basis carried a value of 5% or more of our total assets as of December 31, 2025. Our Company did not make any material acquisition or disposal of subsidiaries, associates and joint ventures during the year ended December 31, 2025.

Future Plans for Material Investments or Capital Assets

As of the date of this annual report, we did not have any concrete future plans for material capital expenditure, investments or capital assets. We will make further announcements in accordance with the Listing Rules, where applicable, if any investments and acquisition opportunities materialize.

Foreign Exchange

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Certain of our bank balances and cash, trade and other receivables and trade and other payables are denominated in foreign currencies and are exposed to foreign currency risk. Our Group currently implements foreign currency hedging measures under our funding and treasury policies. In addition, we will continue to manage the foreign exchange risk by closely monitoring our foreign exchange exposure and will consider implementing more detailed measures as needed to hedge significant foreign currency exposure thus to prevent significant net foreign exchange losses in the future.

Employees and Remuneration

As of December 31, 2025, we had a total of 552 employees (December 31, 2024: 489). For the year ended December 31, 2025, we incurred total employee remuneration cost (including share-based payments) of RMB301.2 million (December 31, 2024: RMB318.2 million). The following table sets forth a breakdown of our employees by function as of December 31, 2025:

Function	Number	% of total
Commercial	334	60.5%
R&D	55	10.0%
Manufacturing	118	21.4%
Management and administrative	45	8.1%
Total	552	100%

We provide formal and comprehensive company-level and department-level training to our new employees, followed by on-the-job training. We also provide training and development programs to our employees from time to time to ensure their awareness and compliance with our various policies and procedures. Some of the training is conducted jointly by departments serving different functions but working with or supporting each other in our day-to-day operations.

Our employee remuneration comprises salaries, bonuses, employees' provident fund, share-based payments, social security contributions and other welfare payments, which is determined based on their responsibilities, qualifications, positions and seniority. We regularly review and determine the remuneration and compensation package of the employees with reference to, among other things, their performance, qualifications, respective responsibilities and market levels of salaries paid by comparable companies. In accordance with applicable laws and regulations, we made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees.

We have also adopted the ESOP, the RSU Scheme, the 2021 Share Option Scheme, the 2021 Share Award Scheme and the 2024 Share Award Scheme to provide incentives for our employees.

Profiles of Directors and Senior Management

DIRECTORS

Executive Directors

- **Mr. Ye LIU**, aged 54, joined our Group as CEO on August 1, 2018. He has been our executive Director since November 23, 2018. Mr. Liu is responsible for overall strategic planning, business direction and daily management of the Company.

Mr. Liu has over 25 years of experience in the pharmaceutical industry. Prior to joining our Group, he served as the chairman and general manager in Santen Pharmaceutical (China) Co., Ltd. (參天製藥(中國)有限公司) from October 2014 to July 2018. From February 2009 to September 2014, Mr. Liu served as the head of pharmaceutical affair division and later became the general manager of Eisai (China) Inc. (衛材(中國)藥業有限公司), responsible for the management of pharmaceutical affairs and development, and the overall corporate operation, respectively. Mr. Liu served as a director of EyePoint from January 2021 to June 2024.

Mr. Liu obtained his Master of Science in pharmacology from Dalhousie University in Canada in August 2003. He graduated with a Bachelor of Science in pharmaceutical chemistry from Shanghai Medical University (上海醫科大學) in Shanghai, China in July 1993.

- **Dr. Zhaopeng HU**, aged 53, joined our Group on September 3, 2018 as the vice president of registration affairs. He has been our executive Director since April 24, 2020, and our chief development officer since June 1, 2020. Dr. Hu is primarily responsible for participating in strategic planning and management of CMC and registration affairs.

Dr. Hu has around 25 years of experience in pharmaceutical industry. From July 2006 to August 2018, he held positions including plant technique and registration group manager, registration and pharmaceutical department director, clinical development department director and internal audit department director in Santen Pharmaceutical (China) Co., Ltd., mainly responsible for clinical development compliance and other drug-related regulations and compliance.

Dr. Hu obtained his doctorate degree in pharmacokinetics in March 2002 and his master's degree in pharmaceutics in March 1999 from Kyoto Pharmaceutical University in Japan. He obtained his bachelor's degree in pharmacy in Shenyang Pharmaceutical University (瀋陽藥科大學) in China in July 1996.

Non-executive Directors

- **Dr. Lian Yong CHEN**, aged 63, has been the Chairman of the Board and a Director since May 23, 2018. He was appointed as a non-executive Director on May 23, 2018, re-designated as an executive Director on April 28, 2020 and re-designated as a non-executive Director on July 20, 2021.

Dr. Chen has over 29 years of experience in the life sciences industry. He is currently the founding managing partner and CEO of 6 Dimensions Capital. He has been the founder and managing partner at Suzhou Frontline II since 2012.

Dr. Chen has been a non-executive director of Cutia Therapeutics (科笛集團), a company whose shares are listed on the Stock Exchange (stock code: 2487) and Xikang Cloud Hospital Holdings Inc. (熙康雲醫院控股有限公司), the shares of which are listed on the Stock Exchange (stock code: 9686), since August 2019 and December 2019, respectively. He has been a director of 111, Inc. (111集團), a company whose shares are listed on NASDAQ (ticker symbol: YI), since May 2019. From January 2015 to March 16, 2022, he served as a non-executive director of Hua Medicine (華領醫藥), a company whose shares are listed on the Stock Exchange (stock code: 2552). From October 29, 2018 to July 9, 2021, he served as a non-executive director at CStone Pharmaceuticals (基石藥業), a company whose shares are listed on the Stock Exchange (stock code: 2616). From December 2014 to May 24, 2021, he served as a director of Shanghai Hile Bio-Technology Co. Ltd. (上海海利生物技術股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 603718). From May 2008 to March 2014, Dr. Chen served as a partner at FIL Capital Management (Hong Kong) Limited in Asia.

Dr. Chen conducted postdoctoral research in chemistry at the Massachusetts Institute of Technology in the United States from August 1991 to December 1992 after obtaining his Ph.D. in chemistry (with top honor) from the University of Louvain, located in Louvain-la-Neuve, Belgium, in June 1991. He graduated from Peking University (北京大學) majoring in chemistry in Beijing, China in July 1984.

- **Mr. Yanling CAO**, aged 42, has been a non-executive Director since June 18, 2019.

Mr. Cao has over 16 years of experience in private equity investment and management. He served as an investment professional of General Atlantic LLC, a company primarily engaged in private equity and venture capital investment, and was responsible for private equity and venture capital investment from December 2007 to January 2011. He is one of the founding members of Boyu Capital Group Management Ltd. since March 2011 and is currently serving as a partner, mainly responsible for investments in the healthcare industry. Mr. Cao served as a director of CStone Pharmaceuticals from April 2016 to March 2017 and a non-executive director from May 2019 to January 2023. From October 2016 to March 2021, Mr. Cao served as a non-executive director of Hygeia Healthcare Holdings Co., Limited (海吉亞醫療控股有限公司), a company whose shares are listed on the Stock Exchange (stock code: 6078). From April 2019 to March 2021, he served as a director of Gan & Lee Pharmaceuticals Co., Ltd., a company whose shares are listed on the Shanghai Stock Exchange (stock code: 603087). He served as a non-executive director of Antengene Corporation Limited (德琪醫藥有限公司), a company whose shares are listed on the Stock Exchange (stock code: 6996) from February 2019 to December 2021. From May 2020 to December 2021, he also served as an independent non-executive director of JW (Cayman) Therapeutics Co. Ltd (藥明巨諾(開曼)有限公司), a company whose shares are listed on the Stock Exchange (stock code: 2126). He has been a non-executive director of Wuxi Biologics (Cayman) Inc. (藥明生物技術有限公司), a company whose shares are listed on the Stock Exchange (stock code: 2269), since May 2016, and a non-executive director of Viela Bio, Inc., a company whose shares were listed on NASDAQ (ticker symbol: VIE) until March 2021, since February 2018.

Mr. Cao obtained a bachelor's degree in economics and mathematics from Middlebury College in the United States in May 2006.

Profiles of Directors and Senior Management

- **Dr. Qin XIE**, aged 45, has been appointed as a non-executive Director since January 2025. She previously served as our advisor from February 2018 to December 2020.

Dr. Xie has more than 11 years of extensive experience in pharmaceuticals-related industry. Since September 2017, Dr. Xie has been working in Frontline BioVentures (Shanghai) Limited (崇凱創業投資諮詢(上海)有限公司) (the management company of Suzhou Frontline II and Suzhou 6 Dimensions, each a controlling Shareholder of the Company), where she currently serves as a managing partner, primarily responsible for overseeing the overall strategic development. From January 2016 to August 2017, she worked at 6 Dimensions Venture Consultant (Shanghai) Co., Ltd. (毓承投資諮詢(上海)有限公司). From September 2013 to December 2015, she had served as a business development manager in Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. (輝正(上海)醫藥科技有限公司), a subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. (浙江海正藥業股份有限公司), which is a pharmaceutical company listed on the Shanghai Stock Exchange (stock code: 600267). From November 2010 to December 2012, Dr. Xie served as a senior investment manager in Shanghai Pharmaceuticals Holding Co. Ltd. (上海醫藥集團股份有限公司), a company primarily engaged in the pharmaceutical industry with its shares listed on both the Shanghai Stock Exchange (stock code: 601607) and the Stock Exchange (stock code: 2607).

Dr. Xie served as a director from August 2019 to November 2022 and was redesignated as a non-executive director in November 2022 of Cutia Therapeutics (科笛集團), a biotech company whose shares are listed on the Stock Exchange (stock code: 2487).

Dr. Xie obtained her bachelor's degree in clinical medicine from the Xi'an Jiaotong University (西安交通大學) in the PRC in July 2003. She then received her master's degree in pharmacology and doctorate degree in pharmacology from University of Oxford in the United Kingdom in September 2004 and April 2011, respectively.

Independent Non-executive Directors

- **Mr. Ting Yuk Anthony WU**, aged 71, has been an independent non-executive Director of the Company since June 23, 2020.

Mr. Wu is a leader in the healthcare industry and has extensive management experience in medical system. He is the longest-serving chairman of the Hospital Authority. He had led the team of the Hospital Authority to manage all public hospitals and public clinics in Hong Kong and implement the public health policy of the Hong Kong Government. Mr. Wu had also actively promoted a number of public and private medical co-operation projects during his tenure. Mr. Wu is currently an advisor to the Public Policy Advisory Committee of the National Health Commission, the principal advisor for international cooperation to the State Administration of Traditional Chinese Medicine of the PRC and a member of the Chinese Medicine Reform and Development Advisory Committee. Mr. Wu was a member of the State Council's Medical Reform Leadership Advisory Committee.

Mr. Wu was a member of the General Committee of the Hong Kong General Chamber of Commerce from 2000 to 2017, served as its chairman from 2010 to 2012, and is currently a member of its Council. Mr. Wu was a director of the Fidelity Funds from 2011 to 2014 and was the chairman of Bauhinia Foundation Research Centre from 2007 to 2012.

Mr. Wu has directorships in certain listed companies. He is the chairman and non-executive director of Clarity Medical Group Holding Limited (清晰醫療集團控股有限公司), a company whose shares are listed on the Stock Exchange (stock code: 1406), the chairman and an independent non-executive director of Venus Medtech (Hangzhou) Inc. (杭州啓明醫療器械股份有限公司), a company whose shares are listed on the Stock Exchange (stock code: 2500), an independent non-executive director of Power Assets Holdings Limited (電能實業有限公司), a company whose shares are listed on the Stock Exchange (stock code: 0006), China Taiping Insurance Holdings Company Limited (中國太平保險控股有限公司) Limited, a company whose shares are listed on the Stock Exchange (stock code: 0966), China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), a company whose shares are listed on the Stock Exchange (stock code: 1515), CStone Pharmaceuticals (基石藥業), a company whose shares are listed on the Stock Exchange (stock code: 2616), Sing Tao News Corporation Limited (星島新聞集團有限公司), a company whose shares are listed on the Stock Exchange (stock code: 1105) and Hui Xian Real Estate Investment Trust (匯賢產業信託), a collective investment scheme authorized by the SFC under section 104 of the SFO and regulated by the provisions of Appendix C of the Code on Real Estate Investment Trusts whose units are listed on the Stock Exchange (stock code: 87001).

Mr. Wu confirmed that he is able to devote sufficient time to act as our independent non-executive Director.

Mr. Wu completed a foundation course in accountancy at the then Teesside Polytechnic in the United Kingdom in July 1975. Mr. Wu is a fellow of Hong Kong Institute of Certified Public Accountants and the Institute of Chartered Accountants in England and Wales, and the honorary chairman of the Institute of Certified Management Accountants (Australia) Hong Kong Branch.

Profiles of Directors and Senior Management

- **Mr. Yiran HUANG**, aged 71, has been an independent non-executive Director of the Company since June 23, 2020.

Mr. Huang is currently a professor of urology, chief physician and doctoral supervisor of Renji Hospital (上海交通大學醫學院附屬仁濟醫院). He is also a leading committee member of the committee of urology of Shanghai Association of Social Medical Institutions (上海市社會醫療機構協會), a standing committee member of the urology branch of Chinese Medical Association (中華醫學會), and the founder of Yiran Education Foundation (翼然教育基金會). From May 2016 to December 2019, Mr. Huang was the chairman of Shanghai International Medical Center (上海國際醫學中心). From June 2009 to January 2015, Mr. Huang served as a vice chairman of the Renji Hospital.

Mr. Huang obtained his master's degree in urology from Shanghai Second Medical University (上海第二醫科大學) in July 1989. He graduated with a Bachelor of Medicine from Jiangxi Medical College (江西醫學院) in December 1982.

- **Mr. Zhenyu ZHANG**, aged 50, has more than 24 years of experience in legal and corporate compliance practice. He currently serves as the vice president responsible for legal, compliance and governmental affairs of Greater China region for The a2 Milk Company Limited, a public company dual listed on the New Zealand's Exchange (stock code: ATM) and the Australian Securities Exchange (stock code: A2M), respectively. From October 2012 to February 2019, Mr. Zhang served as the vice president responsible for legal, compliance and governmental affairs, and the general counsel as well as the chief compliance officer of APAC region for Thermo Fisher Scientific Inc., a company whose securities are listed on the New York Stock Exchange (ticker symbol: TMO). From March 2011 to October 2012, he served as the senior legal counsel of merger and acquisition of APAC region for United Technologies Corporation. From April 2008 to March 2011, Mr. Zhang served as a legal counsel and the chief compliance officer of Great China region for Sandoz AG, a company incorporated in Switzerland and a global research-based pharmaceutical and nutrition group. Prior to serving at Sandoz AG, Mr. Zhang has consecutively acted as an in-house legal counsel for TOM Group Limited, Sony Music Entertainment China Ltd. and Shanghai Huahong (Group) Co., Ltd. (上海華虹(集團)有限公司). Mr. Zhang has been an independent non-executive director of Shanghai XNG Holdings Limited (上海小南國控股有限公司) (formerly known as TANSI Global Food Group Co., Ltd (國際天食集團有限公司), a company whose shares are listed on the Stock Exchange (stock code: 3666), since May 2019 until March 3, 2026.

Mr. Zhang obtained a bachelor's degree in law from East China University of Political Science and Law (華東政法大學) in 1998 and was awarded with a diploma in Beijing International MBA from Peking University in 2010.

Proposed Independent Non-executive Director

- **Ms. Beibei ZHUANG**, aged 45, has over 15 years of experience in auditing and financial services. From August 2006 to May 2025, she worked at PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) where her last position was an audit partner. In June 2025, she joined BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所(特殊普通合夥)) as an audit partner. Ms. Zhuang possesses in-depth professional knowledge and extensive practical experience in the field of auditing, with a thorough and comprehensive understanding of Chinese Accounting Standards for Business Enterprises, International Financial Reporting Standards, and relevant regulatory requirements. She has led audit engagements for numerous companies and is well-positioned to contribute to the Group's financial reporting, internal controls and compliance matters.

Ms. Zhuang graduated from Nanjing Audit University (南京審計大學) in June 2003 with a bachelor's degree in financial management. She also obtained the Certified Internal Auditor (CIA) qualification in November 2005, the China Certified Public Accountant (CPA) qualification certificate in June 2008, and the CPA practicing certificate in May 2010.

Ms. Zhuang will be proposed for appointment as an independent non-executive Director at the AGM.

SENIOR MANAGEMENT

- **Mr. Ye LIU**, aged 54, has been our CEO since August 1, 2018. For further details, please see “– Directors – Executive Directors” in this section.
- **Dr. Zhaopeng HU**, aged 53, has been our chief development officer since June 1, 2020. For further details, please see “– Directors – Executive Directors” in this section.
- **Mr. Qinglei ZUO**, aged 42, has been our chief commercial officer since January 1, 2021, responsible for product commercialization.

Mr. Zuo served as our vice president of commercialization from September 2018 to January 2021. Prior to joining our Group, Mr. Zuo held positions including manager of business development department, director of business development department and head of sales of the pharmaceutical department of Santen Pharmaceutical (China) Co., Ltd. from April 2015 to August 2018. From October 2010 to March 2015, he successively served as associate product manager and district sales manager of gastrointestinal and liver diseases department in Eisai (China) Inc., where he was responsible for sales of drugs. From June 2009 to September 2010, he served as a preclinical project manager of R&D department in Shanghai Hengrui Pharmaceutical Co., Ltd. (上海恒瑞醫藥有限公司).

Mr. Zuo obtained his master’s degree in pharmacology in Shanghai Institute of Pharmaceutical Industry (上海醫藥工業研究院) in May 2009. He graduated with bachelor’s degree in pharmacy from Yantai University (煙台大學) in June 2006.

- **Mr. Tim RUAN**, aged 40, has been our chief financial officer since January 12, 2023, responsible for financial management and investor relations of the Group.

Mr. Ruan has extensive experience of financial management. Prior to joining our Group, he served as an executive director of the investment banking division of Goldman Sachs (Asia) L.L.C. from November 2020 to January 2023, primarily responsible for affairs in debt and equity capital markets and M&A. From January 2018 to November 2020, he served as a vice president of the investment banking division of Morgan Stanley Asia Limited. From February 2016 to January 2018, he acted as an associate within the investment banking division of Nomura International (Hong Kong) Limited. From September 2013 to January 2016, he served as associate at Sullivan & Cromwell LLP.

Mr. Ruan graduated from The Hong Kong University of Science and Technology in November 2021 with a master’s degree of science, majoring in biotechnology. He graduated from The University of New South Wales in December 2009 with bachelor’s degree of laws and bachelor’s degree of commerce majoring in finance.

Profiles of Directors and Senior Management

- **Ms. Hongying LIU**, aged 48, has been our chief manufacturing officer and head of manufacture since January 2023, responsible for construction and operation of our Suzhou manufacturing site, as well as the production of drugs locally manufactured and Good Manufacturing Practice (GMP) management of our Group and was appointed as chief internal audit officer on rotation with effect from February 2025. Ms. Liu has extensive experience in pharmaceutical products production and quality management. Ms. Liu successively served as our production director, head of manufacture, and vice president of manufacturing from August 2019 to January 2023. Prior to joining our Group, Ms. Liu served as a drug GMP inspector of CDE Shanghai Branch (上海藥品審評核查中心) from March 2017 to August 2019, responsible for GMP inspection for drugs. From July 2000 to March 2017, she successively served as a Quality Assurance (QA) inspector, workshop officer, deputy general manager of production, chairwoman of labour union and general manager of a subsidiary within Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司), the shares of which are listed on the Shanghai Stock Exchange (stock code: 601607) and the Stock Exchange (stock code: 2607).

Ms. Liu graduated from Shenyang Pharmaceutical University (瀋陽藥科大學) in July 2000 with a bachelor's degree in engineering, majoring in pharmacy.

- **Dr. Yang SHEN**, aged 43, has been our chief medical officer since January 2024, responsible for leading the clinical development of our Group. Dr. Shen served as our vice president of clinical R&D from May 2023 to December 2023, vice president of regulatory affairs from October 2022 to May 2023, and medical director from April 2019 to October 2022. Prior to joining our group, Dr. Shen served as a medical information section manager of Santen Pharmaceutical (China) Co., Ltd. (參天製藥(中國)有限公司) from September 2015 to March 2019. From August 2013 to September 2015, she served as an associate manager of medical information in Roche China.

Dr. Shen obtained her bachelor's degree in pharmacy from the Medical School of Zhengzhou University (鄭州大學醫學院) in June 2005 and her doctorate of pharmacology from China Pharmaceutical University (中國藥科大學) in June 2010, respectively. She also served as a post-doctoral fellow at the Chinese Academy of Sciences (中國科學院) from July 2010 to July 2012.

JOINT COMPANY SECRETARIES

- **Mr. Tim RUAN**, aged 40, was appointed as the one of authorized representatives and one of the joint company secretaries of the Company on September 30, 2023. For further details of his biography, please see “– Senior Management” in this section.
- **Ms. Tingchan CHEN**, aged 31, was appointed as the secretary of the Board and one of the joint company secretaries of the Company on September 30, 2023. She joined the Company on July 1, 2021.

Ms. Chen has several years of experience in corporate governance and company secretarial practice. Prior to joining our Group, Ms. Chen served as the senior manager of capital markets and investor relations at Shanghai Fosun High Technology (Group) Co. Ltd. (上海復星高科技(集團)有限公司), a subsidiary of Fosun International Limited (復星國際有限公司), a company whose shares are listed on the Stock Exchange (stock code: 656), from September 2020 to June 2021. From April 2017 to September 2020, she served as the supervisor of the secretariat to the board at Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (廣州白雲山醫藥集團股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 600332) and the Stock Exchange (stock code: 874).

Ms. Chen obtained her bachelor's degree in business administration from The Chinese University of Hong Kong in November 2016 and her master's degree in corporate governance from Hong Kong Metropolitan University in March 2023. She has been an associate member of The Hong Kong Chartered Governance Institute since July 2023.

CHANGES TO DIRECTORS' INFORMATION

The changes in the information of Directors or chief executive of the Company during the Reporting Period and as of the date of this annual report are set out below:

1. Dr. Wei LI ceased to be our non-executive Director on January 16, 2025.
2. Dr. Qin XIE has been appointed as our non-executive Director on January 16, 2025.
3. Mr. Zhenyu ZHANG resigned as an independent non-executive director at Shanghai XNG Holdings Limited (上海小南國控股有限公司), the shares of which are listed on the Stock Exchange (stock code: 3666) on March 3, 2026.
4. Ms. Beibei ZHUANG was proposed to be an independent non-executive Director on March 26, 2026 subject to the approval from Shareholders at the forthcoming AGM to be held in June 2026.

Save as disclosed above, during the Reporting Period and up to the date of this annual report, there was no change in the information of the Directors or chief executive of the Company which shall be disclosed pursuant to Rule 13.51 B(1) of the Listing Rules.

Corporate Governance Report

The Board is pleased to present this corporate governance report in the annual report of the Company for the Reporting Period.

CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code. The Board believes that the Company has fully complied with the code provisions of the CG Code during the Reporting Period. The Company will continue to review and enhance its corporate governance practices to ensure compliance with the CG Code.

COMPANY'S CULTURE

The Board believes that corporate culture underpins the long-term business, economic success and sustainable growth of the Group. A strong culture enables the Company to deliver long-term sustainable performance and fulfill its role as a responsible corporate citizen.

Our vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Our mission is to provide Chinese ophthalmic patients with excellent and comprehensive treatment solutions through continuous scientific research and innovation. We take on such vision and mission with courage and assume responsibilities to bring light to patients and ophthalmic industries. Therefore, the Company's slogan was officially designated as "*Virtus et Lumen*" ("Courage and Light" in Chinese) in July 2020. To achieve our vision, the Company has been carrying on our in-width and in-depth expansion of product line, constructing a leading manufacture base for ophthalmic drugs in China and building up a competitive commercial team. Meanwhile, the Company has always been committed to fostering a culture of integrity and compliance. All new joiners are required to complete onboarding training related to the Company's regulations within one month upon joining the Company so that they could better understand our corporate culture, structure and policies, learn relevant laws and regulations, and raise their compliance awareness.

The Board always ensures that the objectives, values and strategies set are consistent with the corporate culture, while all directors take the lead to act and are committed to promoting the corporate culture. For details of the Company's achievements during the Reporting Period, please see "Management Discussion and Analysis" on pages 9 to 23 of this annual report. The Board believes that the Company's existing business model is in line with the Company's objective and long-term strategy of becoming the world's leading ophthalmic pharmaceutical enterprise.

THE BOARD

(1) Responsibilities

The Board is responsible for the overall leadership of the Group, oversees the Group's strategic decisions and monitors business and performance. The Board has delegated the authority and responsibility for day-to-day management and operation of the Group to the senior management of the Group. To oversee particular aspects of the Company's affairs, the Board has established three Board committees including the Audit Committee, the Remuneration Committee and the Nomination Committee. The Board has delegated to the Board committees responsibilities as set out in their respective terms of reference. All Board committees are provided with sufficient resources to perform their duties.

All Directors shall ensure that they carry out duties in good faith, in compliance with applicable laws and regulations, and in the interests of the Company and the Shareholders at all times.

(2) Directors' and Senior Management's Liability Insurance and Indemnity

The Company has arranged appropriate liability insurance to indemnify the Directors and senior management of the Company for their liabilities arising out of corporate activities. The insurance coverage will be reviewed on an annual basis.

(3) Board Composition

As of the date of this annual report, the Board comprises two executive Directors, three non-executive Directors and three independent non-executive Directors.

Executive Directors

Mr. Ye LIU (*Chief Executive Officer*)

Dr. Zhaopeng HU

Non-executive Directors

Dr. Lian Yong CHEN (*Chairman of the Board*)

Dr. Wei LI (*resigned on January 16, 2025*)

Mr. Yanling CAO

Dr. Qin XIE (*appointed on January 16, 2025*)

Independent Non-executive Directors

Mr. Ting Yuk Anthony WU

Mr. Yiran HUANG

Mr. Zhenyu ZHANG

There is not any relationship (including financial, business, family or other material/relevant relationship(s)) between the Board members and the senior management members.

As of the date of this annual report, the Board at all times met the requirements of Rules 3.10(1), 3.10(2) and 3.10A of the Listing Rules relating to the appointment of at least three independent non-executive Directors with at least one independent non-executive Director possessing appropriate professional qualifications or accounting or related financial management expertise and the appointment of independent non-executive Directors representing at least one-third of the Board. Among the three independent non-executive Directors, Mr. Ting Yuk Anthony WU has appropriate professional qualifications or accounting or related financial management expertise as required by Rule 3.10(2) of the Listing Rules.

Reference is made to Company's announcement dated March 26, 2026 in relation to the retirement of Mr. Ting Yuk Anthony WU at the forthcoming AGM in 2026 and the proposed appointment of Ms. Beibei ZHUANG as an independent non-executive Director which is subject to the approval from the Shareholders from the forthcoming AGM in 2026. Once such resolution is approved, Ms. Beibei ZHUANG will be the Director holding appropriate professional qualifications or accounting or related financial management expertise as required by Rule 3.10(2) of the Listing Rules.

(4) Board Diversity Policy

Pursuant to Rule 13.92 of the Listing Rules, the nomination committee (or the board) shall have a policy concerning diversity of board members, and shall disclose the policy on diversity or a summary of the policy in the corporate governance report.


The Company has adopted the board diversity policy (the “**Board Diversity Policy**”) in accordance with the CG Code which sets out the objective and approach to achieve and maintain diversity of the Board and all levels of the employees in order to enhance the effectiveness of the Board. Pursuant to the Board Diversity Policy, the appointment of Directors will be based on meritocracy, and candidates will be evaluated against objective criteria, having due regard for the benefits of diversity of the Board. Selection of candidates will be based on a range of diversity perspectives, including but not limited to gender, age, ethnicity, language, cultural and educational background, industry and professional experience. The Directors have a balanced mix of knowledge and skills, including knowledge and experience in the areas of pharmaceutical and medical industry, business management, investment, finance, legal profession, auditing and accounting. They obtained degrees in various majors including pharmaceuticals, chemistry, economics and law. Furthermore, the Board has a wide range of age, ranging from 42 years old to 71 years old.

The composition of the Board will be disclosed in the Corporate Governance Report every year and the Nomination Committee will supervise the implementation of the Board Diversity Policy and review the effectiveness of the Board Diversity Policy annually as appropriate, discuss any revisions that may be required, and recommend any such revisions to the Board for consideration and approval.

As of the date of this annual report, the diversity of the Board is illustrated as below. Further details on the biographies and experience of the Directors are set out on pages 24 to 28 of this annual report.

The Nomination Committee has reviewed the membership, structure and composition of the Board, and is of the opinion that the structure of the Board is reasonable, and the experiences and skills of the Directors in various aspects and fields can enable the Company to maintain high standard of operation.

The Board aims to maintain at least the current level of female representation.



(5) Measurable Objectives

The Company aims to maintain an appropriate balance of diverse perspectives that are relevant to the Company's business growth. The Company is also committed to ensuring that recruitment and selection practices at all levels (from the Board downwards) are appropriately structured so that a diverse range of candidates are considered. The Nomination Committee will discuss periodically and when necessary, agree on the measurable objectives for achieving diversity, including gender diversity, on the Board and recommend them to the Board for adoption. In particular, the Nomination Committee will identify and make recommendations to the Board to implement programs that will assist in the development of a broader and more diverse pool of skilled and experienced employees that, in time, will prepare them for Board positions.

The Company has also taken, and will continue to take steps to promote gender diversity at all levels of the Company, including but without limitation at the Board and the management levels.

At present, the Board considers an appropriate balance of diversity perspectives of the Board is maintained and has not set any other measurable objectives. At the management level, the chief medical officer, chief internal audit officer and one of the joint company secretaries of the Company are female. The Board has also assessed the Group's diversity profile annually of all levels of employees and apply the diversity policy to attract, retain and motivate employees from the widest possible pool of available talent. As of December 31, 2025, the Group had 552 full-time employees, of whom the number of female employees accounted for approximately 47% and the Group has achieved the objective of maintaining a relatively balanced gender ratio. Based on the Board's review, there was no mitigating factor or circumstance which makes achieving gender diversity across the workforce (including senior management) more challenging or less relevant.

(6) Board Independence

The Company recognizes that Board independence is key to good corporate governance. The Company has in place effective mechanisms that underpin an independent Board and those independent views. The current composition of the Board, comprising 37.5% of the independent non-executive Directors and the fact that all members of the Audit Committee are independent non-executive Directors, exceed the independence requirements under the Listing Rules. The Remuneration Committee and Audit Committee are all chaired by independent non-executive Directors. The remuneration of independent non-executive Directors is subject to a regular review to maintain competitiveness and commensurate with their responsibilities and workload. The independence of each independent non-executive Director is assessed upon his appointment and annually.

Directors are requested to declare their direct or indirect interests, if any, in proposals or transactions to be considered by the Board at the Board meetings and abstain from voting, where appropriate. External independent professional advice is available to all Directors, including independent non-executive Directors, whenever deemed necessary. The independent non-executive Directors have consistently demonstrated strong commitment and the ability to devote sufficient time to discharge their responsibilities at the Board.

The Company has also established channels through formal and informal means whereby independent non-executive Directors can express their views in an open manner, and in a confidential manner, should circumstances require.

(7) Confirmation of Independence by the Independent Non-executive Directors

The Company has received from each of the independent non-executive Directors an annual confirmation in writing of his independence pursuant to Rule 3.13 of the Listing Rules. The Company considers that, as of the date of this annual report, all of the independent non-executive Directors are independent.

(8) Induction and Continuous Professional Development

All Directors should participate in continuous professional development to develop and refresh their knowledge and skills to ensure their contribution to the Board remains informed and relevant pursuant to the Listing Rules. The joint company secretaries update and provide written materials on the latest developments of applicable laws, corporate governance issues, rules and regulations to the Directors from time to time.

Every newly appointed Director should receive formal, comprehensive and tailored induction on the first occasion of his/her appointment to ensure appropriate understanding of the business and operations of the Company and full awareness of Director's responsibilities and obligations under the Listing Rules and relevant statutory requirements.

During the year ended December 31, 2025, all Directors had participated in appropriate continuous professional development activities by ways of attending trainings and/or reading materials relating to the latest development of Listing Rules and other regulatory requirements relevant to the Group, general business or directors' duties and responsibilities, etc. All Directors are encouraged to attend relevant training courses at the Company's expense.

(9) Chairman and Chief Executive Officer

Under the code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and performed by different individuals. As of the date of this annual report, Dr. Lian Yong CHEN ("**Dr. Chen**") acted as the chairman of the Board and Mr. Ye LIU acted as the chief executive officer of the Company. Dr. Chen's responsibilities are more focused on strategic management and planning, while Mr. Liu's responsibilities are more focused on business direction and daily management. Their respective responsibilities and division of labor have been set out in writing. The chairman of the Board and the chief executive officer of the Company do not have any relationships (including financial, business, family or other material or connected relationship).

Under the code provision C.2.7 of the CG Code, the chairman should at least annually hold meeting with the independent non-executive directors without the presence of other directors. During the year under review, Dr. Chen, the chairman of the Board, held the meeting with the independent non-executive Directors without the presence of other Directors.

Dr. Chen is also responsible for the duties as specified in code provisions C.2.2 to C.2.9 of the CG Code.

The Board and the senior management, which comprises experienced and high-caliber individuals can ensure the balance of power and authority.

(10) Appointment and Re-Election of Directors

Save as disclosed in the section headed “Report of Directors – Service Contracts of the Directors” in this annual report, none of the Directors has or is proposed to have entered into any service agreement or letter of appointment with any member of the Group (excluding agreements expiring or determinable by any member of the Group within one year without payment of compensation other than statutory compensation).

Code provision B.2.2 of the CG Code states that every director, including those appointed for a specific term, should be subject to retirement by rotation at least once every three years. In accordance with the Articles of Association, all Directors are subject to retirement by rotation at least once every three years and any new Director appointed to fill a casual vacancy shall submit himself/herself for election by Shareholders at the first general meeting of the Company after appointment and any new Director appointed as an addition to the Board shall submit himself/herself for re-election by the Shareholders at the next following annual general meeting after appointment.

The Board appointed Dr. Qin XIE as a non-executive Director on January 16, 2025. Dr. Qin XIE confirms that she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on December 27, 2024 prior to her appointment, and (ii) understands her obligations as a director of a listed issuer under the Listing Rules.

During the Reporting Period, the Directors, being Mr. Ye LIU, Dr. Zhaopeng HU and Mr. Yiran HUANG being eligible, have been re-elected as their respective role in the Board, at the annual general meeting held in 2025. Mr. Zhenyu ZHANG should have been but was not re-elected at the annual general meeting held in 2025 due to inadvertent oversight. To rectify the non-compliance with the CG Code, the Board has confirmed the appointment of Mr. Zhang as a Director at the Board meeting held on March 26, 2026 (with Mr. Zhang abstaining from voting), and Mr. Zhang will be subject to re-election at the AGM. Notwithstanding that Mr. Zhang was not re-elected at the annual general meeting held in 2025, his biography and emolument details were set out in the 2025 annual report of the Company for Shareholders’ information. Considering that the reelection of Mr. Zhang will be considered at the forthcoming AGM, the Board believes that such deviation does not have a material impact on the operation of the Company as a whole. Mr. Zhang will be put forward for retirement and re-election at the forthcoming AGM.

The Board proposed to appoint Ms. Beibei ZHUANG as an independent non-executive Director on March 26, 2026 which is subject to the approval by the Shareholders at the forthcoming AGM.

The procedures and process of appointment, re-election and removal of Directors are set out in the Articles of Association. The Nomination Committee is responsible for reviewing the Board composition, monitoring and making recommendations to the Board on the appointment, re-election and succession planning of Directors, in particular the chairman of the Board and the chief executive officer of the Company.

(11) Board Meetings and Committee Meetings

The Company adopts the practice of holding Board meetings regularly, at least four times a year, and at approximately quarterly intervals. Both the Nomination Committee and the Remuneration Committee shall meet at least once every year and the Audit Committee shall meet at least twice a year. Notices of not less than fourteen days are given for all regular Board meetings to provide all Directors with an opportunity to attend and include matters in the agenda for a regular meeting. For other Board and committee meetings, reasonable notice is generally given. The agenda and accompanying board papers are dispatched to the Directors or committee members at least three days before the intended date of the meeting to ensure that they have sufficient time to review the papers and be adequately prepared for the meeting. When Directors or committee members are unable to attend a meeting, they will be advised of the matters to be discussed and given an opportunity to make their views known to the chairman of the Board or the committee members prior to the meeting. Minutes of meetings are kept by the joint company secretaries of the Company with copies circulated to relevant Board or the committees for comments and records.

Minutes of the Board meetings and committee meetings are recorded in sufficient detail the matters considered by the Board and the committees and the decisions reached, including any concerns raised by the Board or committee members and dissenting views expressed. Draft minutes of each Board meeting and committee meeting are sent to the relevant Board or committee members for comments within a reasonable time after the date on which the meeting is held. The minutes of the Board meetings are open for inspection by Directors.

During the year ended December 31, 2025, five Board meetings, two Audit Committee meetings, three Remuneration Committee meetings and three Nomination Committee meetings were held.

A summary of the attendance record of the Directors at Board meetings, committee meetings and general meetings during the year ended December 31, 2025 is set out in the following table below:

Name of Director	Number of meeting(s) attended/number of meeting(s) held during the year ended December 31, 2025				
	Board meeting	Audit Committee meeting	Remuneration Committee meeting	Nomination Committee meeting	General meeting
Executive Directors:					
Mr. Ye LIU	5/5	N/A	N/A	N/A	1/1
Dr. Zhaopeng HU	5/5	N/A	N/A	N/A	1/1
Non-executive Directors:					
Dr. Lian Yong CHEN	5/5	N/A	N/A	3/3	1/1
Mr. Yanling CAO	5/5	N/A	N/A	N/A	1/1
Dr. Qin XIE ⁽¹⁾	4/4	N/A	N/A	N/A	1/1
Independent Non-executive Directors:					
Mr. Ting Yuk Anthony WU ⁽¹⁾	5/5	2/2	3/3	N/A	1/1
Mr. Yiran HUANG	5/5	2/2	3/3	3/3	1/1
Mr. Zhenyu ZHANG	5/5	2/2	3/3	3/3	1/1

Note:

(1) Each of Dr. Qin XIE and Mr. Ting Yuk Anthony WU was appointed as a member of the Nomination Committee on June 30, 2025.

(12) Model Code for Securities Transactions

The Company has adopted the Written Guidelines on no less exacting terms than the Model Code as its own code of conduct regarding securities transactions by the Directors and relevant employees. All Directors and relevant employees have confirmed, following specific inquiry by the Company, that they have complied with the Model Code during the year ended December 31, 2025.

(13) Delegation by the Board

The Board reserves for its decision on all major matters of the Company, including approval and monitoring of all policy matters, overall strategies and budgets, internal control and risk management systems, material transactions (in particular those that may involve conflict of interests), financial information, appointment of Directors and other significant financial and operational matters. All Directors are encouraged to openly share their views on the Company's affairs and issues and they are entitled to have access to the management who will respond to queries raised by the Directors as promptly and fully as possible. Directors could have recourse to seek independent professional advice in performing their duties at the Company's expense for ensuring that board procedures and all applicable rules and regulations are followed.

The daily management, administration and operation of the Group are delegated to the senior management. The delegated functions and responsibilities are periodically reviewed by the Board to ensure that they remain appropriate to the Company's needs. Approval has to be obtained from the Board prior to any significant transactions entered into by the management on the Company's behalf.

(14) Corporate Governance Function

The Board recognizes that corporate governance should be the collective responsibility of Directors and has delegated the corporate governance duties to the Audit Committee which include:

- (a) to develop and review the Group's policies and practices on corporate governance and make recommendations to the Board;
- (b) to review and monitor the training and continuous professional development of Directors and senior management of the Group;
- (c) to review and monitor the Group's policies and practices on compliance with legal and regulatory requirements;
- (d) to develop, review and monitor the code of conduct and compliance manual (if any) applicable to employees and Directors of the Group; and
- (e) to review the Group's compliance with the CG Code from time to time adopted by the Group and the disclosure in the Corporate Governance Report to be contained in the Company's annual reports.

BOARD COMMITTEES

(1) Nomination Committee

We established a Nomination Committee on June 23, 2020 with its written terms of reference in compliance with the Listing Rules. As of the date of this annual report, the Nomination Committee currently comprises five members, including two Non-executive Directors, namely, Dr. Lian Yong CHEN and Dr. Qin XIE, and three independent non-executive Directors, namely, Mr. Ting Yuk Anthony Wu, Mr. Yiran HUANG and Mr. Zhenyu ZHANG. Dr. Lian Yong CHEN is the chairman of the Nomination Committee.

The primary duties of the Nomination Committee are to make recommendations to the Board on the appointment of Directors and management of Board succession. The written terms of reference of the Nomination Committee are available on the respective website of the Stock Exchange and the Company. The details of the policies in assessing the candidates or incumbent will be set out in the section headed "Nomination Policy".

Three Nomination Committee meetings were held during the year ended December 31, 2025. The following is a summary of work performed by the Nomination Committee during the Reporting Period:

- assess the independence of the independent non-executive Directors;
- considered and/or made recommendations to the Board on the appointment and re-election of Directors; and
- reviewed the structure, size and composition of the Board.

Nomination Policy

The Company has adopted a director nomination policy (the "**Director Nomination Policy**") in accordance with the CG Code. The Director Nomination Policy sets out the selection criteria and process and the Board succession planning considerations in relation to nomination and appointment of Directors of the Company and aims to ensure that the Board has a balance of skills, experience and diversity of perspectives appropriate to the requirements of the Company's business.

The Nomination Committee shall identify, consider and recommend to the Board appropriate candidates to serve as Directors and to make recommendations to the Shareholders. The ultimate responsibility for selection and appointment of Directors rests with the entire Board.

The Nomination Committee will recommend to the Board for the nomination, appointment of new Directors in accordance with the following procedures and process: (a) the Nomination Committee shall first review and assess factors relating to the diversity of the Board, including but not limited to professional experience, skill, knowledge and length of service, gender, age, cultural and education background, and give consideration to the candidate's willingness to devote adequate time to the Board and independence of each independent non-executive Director based on the requirements of the Listing Rules as amended from time to time; and (b) the Nomination Committee shall then nominate suitable candidates to the Board based on the then-current and anticipated future leadership needs of the Company, with a view to achieving a sustainable and balanced development of the Company.

For the re-election of Directors at the general meeting, the Nomination Committee shall review the overall contribution and service to the Company of the retiring Directors, including its attendance at Board meetings, Board committee meetings and general meetings (if applicable), and his/her level of participation and performance on the Board. The Nominating Committee shall require the nominee to submit updated biographical information and the consent to be re-elected as a Director; and should review and determine whether retiring Directors still meet the criteria for Director selection. The Nominating Committee shall then make recommendations to the Board on the re-election of Directors.

The Nomination Committee shall also monitor and review the implementation of the nomination policy, as appropriate from time to time, and will report to the Board annually.

(2) Remuneration Committee

We established a Remuneration Committee on June 23, 2020 with its written terms of reference in compliance with the Listing Rules. As of the date of this annual report, the Remuneration Committee currently comprises three members and all are independent non-executive Directors, namely Mr. Zhenyu ZHANG, Mr. Ting Yuk Anthony WU and Mr. Yiran HUANG. Mr. Zhenyu ZHANG is the chairman of the Remuneration Committee. The Remuneration Committee confirms that sufficient resources are available to perform its duties.

The primary duties of the Remuneration Committee are to determine a policy and structure for the Directors' and senior management's remunerations, establish a formal and transparent procedure for formulating related remuneration policies, evaluate the performance of Directors and senior management, approve the terms of Directors' service contracts and review and/or approve matters relating to share schemes under Chapter 17 of the Listing Rules, and recommend the remuneration packages for all Directors and senior management. The written terms of reference of the Remuneration Committee are available on the respective website of the Stock Exchange and the Company.

The Remuneration Committee reviewed and approved management's compensation proposals in response to the Company's overall operating performance indicators and the respective annual performance goals of senior management approved by the Board of Directors to be effective, and has adopted the second model described in code provision E.1.2(c) under the CG Code (i.e. making recommendations to the Board on the remuneration packages of individual executive Directors and senior management), and made recommendations to the Board on the remuneration of non-executive Directors. The Remuneration Committee has consulted the chairman and/or chief executive about their remuneration proposals for other executive Directors. The Remuneration Committee should have access to independent professional advice if necessary. The Remuneration Committee has considered the remuneration paid by similar companies, the time commitment and responsibilities required and the conditions of employment of other positions within the Group, and ensured that no Director or any of his/her associates is involved in deciding his or her own remuneration.

The Remuneration Committee reviews and approves the compensations payable to executive Directors and senior management for loss or termination of their office or appointment to ensure that it is consistent with contractual terms and is otherwise fair and reasonable and not excessive; reviews and approves compensation arrangements relating to dismissal or removal of Directors for misconduct to ensure that they are consistent with contractual terms and are otherwise reasonable and appropriate. During the Reporting Period, there was no compensation arising from the above matters.

Corporate Governance Report

During the year ended December 31, 2025, three Remuneration Committee meetings were held. The following is a summary of work performed by the Remuneration and Assessment Committee during the Reporting Period:

- reviewed and made recommendations to the Board on the remuneration package of the Directors and senior management;
- reviewed and made recommendations to the Board on the Company's policy and structure for the remuneration of the Directors and senior management; and
- reviewed and made recommendations to the Board on the details of the vesting of options and awards.

The Board granted options and awards to the executive Directors under the 2021 Share Award Scheme and 2021 Share Option Scheme as part of the Company's remuneration policy, the purpose of which is to closely align the interests and benefits of the Company, the Board and the management of the Group in order to maximize the motivation of the executive Directors and senior management. Such grants aim to provide sufficient incentive to retain and motivate our executive Directors to participate in the formulation of strategy and long-term development of the Company and to recognize their contribution to the growth of the Company. Retaining executive Directors is highly beneficial for the Group's development and expansion, and can avoid potential disruption to the operation of the Group resulting from the lack of continuity of leadership.

The vesting of the options and awards granted to the executive Directors was in accordance with the proportion of achievement of the performance targets as set out in the Company's circular dated November 4, 2022. Partial achievement of the performance targets will result in proportionate vesting, and the unvested award shares shall lapse and become return shares. In addition, in the event of any occurrence of misconduct or breach of employment contract, or any other conduct which as the Board or its delegates determines in good faith would justify the termination of the employment contract, any unvested outstanding options or awards shall not be vested and shall be immediately forfeited, and for options and awards already transferred to the grantee, the Company may require such grantee to return the equivalent value of the shares underlying the options or awards. The Board and the Remuneration Committee has reviewed and confirmed that the performance targets of the executive Directors in 2025 have been fully achieved and therefore, their options and awards will be fully vested according to the proportion agreed in the offer letters.

Details of the Directors' remuneration for the year ended December 31, 2025 are set out in Note 11 to the consolidated financial statements in this annual report.

Remuneration by band of the senior management (including two Directors) of the Group for the year ended December 31, 2025 is set out below:

Remuneration band (HK\$)	Number of senior management
0-10,000,000	4
20,000,000 - 30,000,000	1

Note: The remunerations above also include share-based payments in the consolidated statement of profit or loss and other comprehensive income, details of which are set out in Note 11 to the consolidated financial statements in this annual report.

(3) Audit Committee

We established an Audit Committee on June 23, 2020 with its written terms of reference in compliance with the Listing Rules. As of the date of this annual report, the Audit Committee currently comprises three members and all are independent non-executive Directors, namely Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG. Mr. Ting Yuk Anthony WU is the chairman of the Audit Committee.

The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, risk management and internal control system of the Group, maintaining an appropriate relationship with the auditors and monitoring the relationship between the Group and the auditors, overseeing the audit process and performing other duties and responsibilities as assigned by the Board. The written terms of reference of the Audit Committee are available on the respective website of the Stock Exchange and the Company.

Two Audit Committee meetings were held during the year ended December 31, 2025. The following is a summary of work performed by the Audit Committee during the Reporting Period:

- reviewed the annual and interim results and reports, the Group's financial and accounting policies and practices and the scope of audit and appointment of auditors;
- reviewed the risk management, internal control and compliance systems and the effectiveness of internal audit function and discussed with the management and internal audit on their findings;
- discussed matters with respect to the accounting policies and practices adopted by the Company and internal control with senior management members of the Company; and
- performed corporate governance related duties such as reporting to the Board on the matters in the CG Code.

The Audit Committee also met Deloitte Touche Tohmatsu, the external auditors of the Company twice for the year ended December 31, 2025. There are proper arrangements for employees, in confidence, to raise concerns about possible improprieties in financial reporting, internal control and other matters.

DIRECTORS' RESPONSIBILITIES FOR FINANCIAL REPORTING IN RESPECT OF FINANCIAL STATEMENTS

The Directors acknowledge their responsibility for preparing the consolidated financial statements of the Company for the year ended December 31, 2025 which give a true and fair view of the affairs of the Company and the Group and of the Group's results and cash flows.

The management of the Company has provided to the Board such explanation and information as are necessary to enable the Board to carry out an informed assessment of the Company's financial statements, which are put to the Board for approval. The Company provides all members of the Board with monthly updates on Company's performance, positions and prospects.

The Directors were not aware of any material uncertainties relating to events or conditions which may cast significant doubt upon the Group's ability to continue as a going concern.

Corporate Governance Report

The statement by the external auditor of the Company regarding their reporting responsibilities on the consolidated financial statements of the Company is set out in the section headed “Independent Auditor’s Report” in this annual report.

RISK MANAGEMENT AND INTERNAL CONTROL

The Board acknowledges it is responsible for the Company’s risk management and internal control systems and reviewing their effectiveness. The risk management and internal control measures are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss. During the Reporting Period, the Board had conducted a review of the effectiveness of the risk management internal control system of the Company and considered the system effective and adequate.

The Group has established an internal audit department and designated staff to be responsible for identifying and supervising the Group’s risk and internal control issues and reporting directly to the Board of any findings and follow-up actions. The internal audit department supervised and reviewed corporate daily business to ensure that the Company’s business continues to meet the requirements of the Company’s system and external supervision.

The Group has established a risk management manual, a compliance manual and an internal control manual, which are designed to enable the company to maintain the highest standards of corporate governance and to identify and reduce any potential risks.

The Group also provides employees with revised staff manual and various management systems from time to time. Our Company has set up employee induction training and assessment and provide employees with compliance training on a regular basis to enhance compliance awareness.

The Group has established a risk management manual, which clarifies the division of responsibility and authority of risk management corresponding to each relevant department and standardizes the basic process of risk management. All departments will (i) systematically and regularly identify internal and external risks; (ii) assess the possibility and impact of risks; (iii) determine risk response strategies and implement response plans; (iv) regularly manage the risk and test the situation and response capabilities; (v) evaluate the overall effectiveness of the design and implementation of risk response strategies; and (vi) regularly and systematically report the risks and risk management information.

Pursuant to the compliance manual of Ocumension, the Company has established a compliance window for all the employees of the Company to submit their compliance inquiries and compliance reports. During the Reporting Period, the Company set up an external reporting channel and policies, allowing stakeholders (such as suppliers, customers, etc.) to report any inappropriate matters that may be related to the Company secretly and anonymously. This reporting channel regularly reviews and reports the reported matters to the Audit Committee. The Company reviewed and enhanced its internal control system regularly by revising and improving its internal control matrix and internal control manual once a year. The Company’s existing system, operating procedures and control measures were adjusted in accordance with the needs of the Company’s business management and external regulatory requirements. The Company carried out an internal control assessment at least once a year to ensure that each of its departments has properly complied with its internal control system as well as any recommendation for rectification on any defects in its internal control identified when its self-assessment could be provided after internal communication and determination.

The Group has formulated an information disclosure management system to clarify the relevant obligations of insiders, reporting procedures and information disclosure responsibilities of relevant personnel, and arrange self-inspection in a timely manner. The Group monitors possible inside information and organizes intermediary agencies to determine whether the information is inside information or whether it needs to be disclosed.

The Group has set out in writing the prohibition of bribery, fraud and corruption in the compliance manual. The legal department (as the relevant functional department) will review, supervise the behaviors of all employees, investigate violations and make recommendations on discipline. We have established a compliance committee led by the Group's CEO, which is responsible for directing, supervising and coordinating the compliance management work of the Group, and strengthening the compliance awareness of all employees through training and examinations in daily work.

Our Company review risk management and internal control systems once a year. Our Group's internal control and risk management reports for the year ended December 31, 2025 were submitted to the Audit Committee and the Board for review in March 2026. The Board has reviewed and believes that the risk management and internal control systems of the Group for the year ended December 31, 2025 are complete, and are fully and effectively operated in all material controls, including financial, operational and compliance controls, which are sufficient to protect the interests of all stakeholders of the Group. The Board also confirmed that the resources, staff qualifications and experience, training programs and budget of the Company's accounting, internal audit, financial reporting functions, as well as those relating to the ESG performance and reporting are adequate.

AUDITOR'S REMUNERATION

The Company appointed Deloitte Touche Tohmatsu as the external auditor for the year ended December 31, 2025, and details of the fees paid/payable in respect of the audit and non-audit services provided by Deloitte Touche Tohmatsu for the year ended December 31, 2025 are set out in the table below:

Services rendered for the Company	Total Fees paid and payable RMB'000
Audit services:	
Annual audit services	2,970
Non-audit services:	
Tax advisory services	388
Review of interim results	880
Total	4,238

JOINT COMPANY SECRETARIES

In compliance with Rule 3.29 of the Listing Rules, Mr. Tim RUAN and Ms. Tingchan CHEN both undertook not less than 15 hours of relevant professional training to update their skills and knowledge during the Reporting Period. All members of the Board can have access to the joint company secretaries' advice and services.

The appointment and removal of the company secretary will be subject to Board's approval.

GENERAL MEETING

During the year ended December 31, 2025, one general meeting was held.

COMMUNICATION WITH SHAREHOLDERS AND INVESTOR RELATIONS

The Company considers that effective communication with Shareholders is essential for enhancing investor relations and understanding of the Shareholders and potential investors on the Group's business, performance and strategies. The Company also recognizes the importance of timely and non-selective disclosure of information, which will enable Shareholders and investors to make the informed investment decisions.

The general meetings provide opportunity for Shareholders to communicate directly with the Directors. The chairman of the Board, the chairpersons of the Board Committees will attend the general meetings to answer Shareholders' questions. The external auditors of the Company will also attend the annual general meeting to answer questions about the conduct of the audit, the preparation and content of the auditor's report and auditor independence.

To promote effective communication, the Company adopts a Shareholders' communication policy which aims at establishing a two-way relationship and established a range of communication channels between the Company, its Shareholders, investors and other stakeholders. These include (i) the publication of interim and annual reports and/or dispatching circulars, notices, and other announcements; (ii) the annual general meeting or extraordinary general meeting providing a forum for Shareholders to raise comments and exchanging views with the Board; (iii) updated and key information of the Group available on the Company's website and the Stock Exchange's website; (iv) the Company's website offering communication channel between the Company and its stakeholders; (v) the Company's share registrar in Hong Kong serving the Shareholders in respect of all share registration matters; and (vi) convening investor meeting and/or analyst briefings, which led by our executive Directors and investor relations team with existing and potential investors.

Having considered the multiple channels of communication and shareholders engagement in the general meetings held during the year, the Board is satisfied that the shareholders communication policy has been properly implemented during 2025 and is effective.

SHAREHOLDERS' RIGHTS

To safeguard Shareholders' interests and rights, a separate resolution will be proposed by the chairperson of that meeting for each substantially separate issue at Shareholder meetings, including nomination and election of individual Directors.

All resolutions put forward at Shareholder meetings will be voted on by poll pursuant to the Listing Rules and poll results will be posted on the websites of the Company and the Stock Exchange in a timely manner after each Shareholder meeting in accordance with the Listing Rules.

(1) Procedures for Shareholders to convene an extraordinary general meeting

In accordance with Article 12.3 of the Articles of Association, the Board may, whenever it thinks fit, convene an extraordinary general meeting. Extraordinary general meetings shall also be convened on the written requisition of any one or more members holding together, as of the date of deposit of the requisition, shares representing not less than one-tenth of the paid-up capital of the Company which carry the right of voting at general meetings of the Company. The written requisition shall be deposited at the principal office of the Company in Hong Kong or, in the event the Company ceases to have such a principal office, the registered office of the Company, specifying the objects of the meeting and signed by the requisitionist(s). If the Board does not within 21 days from the date of deposit of the requisition proceed duly to convene the meeting to be held within a further 21 days, the requisitionist(s) themselves or any of them representing more than one-half of the total voting rights of all of them, may convene the general meeting in the same manner, as nearly as possible, as that in which meetings may be convened by the Board provided that any meeting so convened shall not be held after the expiration of three months from the date of deposit of the requisition, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to them by the Company.

(2) Procedures for putting forward proposals at general meeting

There are no provisions allowing Shareholders to propose new resolutions at the general meetings under the Companies Law of the Cayman Islands. However, Shareholders who wish to propose resolutions may follow Article 12.3 of the Articles of Association for requisitioning an extraordinary general meeting and including a resolution at such meeting. The requirements and procedures of Article 12.3 are set out above.

As regards proposing a person for election as a Director, the procedures are available on the website of the Company.

(3) Inquiries to the Board

Shareholders and investors may send written inquiries or requests to the Company as follows:

Address: 56F, One Museum Place, 669 Xin Zha Road, Jing'an District, Shanghai, the PRC
Email: ir@ocumension.com

DIVIDEND POLICY

The Company is a company incorporated in the Cayman Islands. We have never declared or paid any dividends on our ordinary Shares or preferred shares. We may need dividends and other distributions on equity from our PRC subsidiaries to satisfy our liquidity requirements. Current PRC regulations permit our PRC subsidiaries to pay dividends to us only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, our PRC subsidiaries are required to set aside at least 10% of their respective accumulated profits each year, if any, to fund certain reserve funds until the total amount set aside reaches 50% of their respective registered capital. Our PRC subsidiaries may also allocate a portion of its after-tax profits based on PRC accounting standards to employee welfare and bonus funds at their discretion. These reserves are not distributable as cash dividends. Furthermore, if our PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments to us. In addition, the PRC tax authorities may require us to adjust our taxable income under the contractual arrangements we currently have in place in a manner that would materially and adversely affect our PRC subsidiaries' ability to pay dividends and other distributions to us.

Corporate Governance Report

The Company currently intends to retain all available funds and any future earnings, if any, to fund the R&D of our drug candidates and we do not anticipate paying any cash dividends in the foreseeable future. Any declaration and payment as well as the amount of dividends will be subject to our constitutional documents and the Cayman Companies Law. The declaration and payment of any dividends in the future will be determined by our Board, in its discretion, and will depend on a number of factors, including our earnings, capital requirements, overall financial conditions and contractual restrictions. Our Shareholders in a general meeting may approve any declaration of dividends, which must not exceed the amount recommended by our Board. As advised by our Cayman Islands counsel, under the Cayman Islands law a company may declare and pay a dividend out of either profits or share premium account, provided that in no circumstances may a dividend be declared or paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Investors should not purchase our Shares with the expectation of receiving cash dividends.

If we pay dividends in the future, in order for us to distribute dividends to our Shareholders, we will rely to some extent on any dividends distributed by our PRC subsidiaries. Any dividend distributions from our PRC subsidiaries to us will be subject to PRC withholding tax. In addition, regulations in the PRC currently permit payment of dividends of a PRC company only out of accumulated distributable after-tax profits as determined in accordance with its articles of association and the accounting standards and regulations in China. For details, please refer to “Risk Factors – Risks Relating to Doing Business in China – We may rely on dividends and other distributions on equity paid by our subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business” of the Prospectus.

CONSTITUTIONAL DOCUMENTS

The Company has adopted the seventh amended and restated memorandum and articles of association pursuant to the approval from the Shareholders in the AGM held in 2025. For details of the relevant amendments, please refer to the Company’s announcement dated March 31, 2025 and the circular dated April 29, 2025.

Save as disclosed above, there is no other change in constitutional documents of the Company for the year ended December 31, 2025 and up to the date of this annual report.

The Board of the Company is pleased to present this Report of Directors together with the consolidated financial statements of the Group for the year ended December 31, 2025.

BOARD OF DIRECTORS

The Board currently comprises two executive Directors, three non-executive Directors and three independent non-executive Directors.

The Directors during the year ended December 31, 2025 and up to the date of this annual report were:

Executive Directors

Mr. Ye LIU (*Chief Executive Officer*)
Dr. Zhaopeng HU

Non-executive Directors

Dr. Lian Yong CHEN (*Chairman of the Board*)
Dr. Wei LI (*resigned on January 16, 2025*)
Mr. Yanling CAO
Dr. Qin XIE (*appointed on January 16, 2025*)

Independent Non-executive Directors

Mr. Ting Yuk Anthony WU
Mr. Yiran HUANG
Mr. Zhenyu ZHANG

GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on February 27, 2018, as an exempted limited liability company under the laws of the Cayman Islands. The Company's Shares were listed on the Main Board of the Stock Exchange on July 10, 2020.

PRINCIPAL ACTIVITIES

We are a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. Our vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China.

BUSINESS REVIEW

A review of the business of the Group during the year as required by Schedule 5 to the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), including a discussion and analysis on the Group's future business development and the financial and operational key performance indicators employed by the Directors in measuring the performance of the Group's business is set out in "Management Discussion and Analysis" on pages 9 to 23 of this annual report. These discussions form part of this Report of Directors. Events affecting the Company that have occurred since the end of the financial year is set out in "Events After Reporting Period" in this Report of Directors on page 81 of this annual report.

PRINCIPAL RISKS AND UNCERTAINTIES

The following list is a summary of certain principal risks and uncertainties faced by the Group, some of which are beyond its control:

- We may need to raise additional capital to meet our operating cash requirements, and financing may not be available on terms acceptable to us, or at all;
- We may not be able to in-license new drug candidates with high potential;
- We may be unable to successfully complete clinical trials, obtain regulatory approval and commercialize our drug candidates, or experience significant delays in doing so;
- We may not be able to discover new drug candidates;
- The R&D of our drug candidates involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. You may lose all or part of your investments in us if our R&D fails;
- We expect to rely on third parties (including our licensing partners) to supply drug candidates or raw materials for manufacturing our future approved drugs, and our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices;
- We may rely on third parties (including our licensing partners) to manufacture or import our clinical and commercial drug supplies, and our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices;
- Our approved drugs will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements;
- Our rights to develop and commercialize our drug candidates are subject, in part, to the terms and conditions of licenses granted to us by licensing partners; and
- Our in-licensed patents and other intellectual property may be subject to further priority disputes or to inventorship disputes and similar proceedings.

However, the above is not an exhaustive list. Investors are advised to make their own judgment or consult their own investment advisors before making any investment in the Shares.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Group is committed to fulfilling social responsibility, promoting employee benefits and development, protecting the environment and giving back to community and achieving sustainable growth. Based on our environmental policies and goals set, the Company spares no efforts to minimize the relative environmental impact through resources management and emissions management. On top of that, the Group also pays attention to the performance of suppliers in terms of environmental protection and social responsibility with a closed-loop management mechanism established.

The Company's Environmental, Social and Governance Report are prepared separately from this annual report and will be published on the same date as the publication of this annual report.

COMPLIANCE WITH RELEVANT LAWS AND REGULATIONS

As far as the Board and management are aware, the Group has complied in all material aspects with the relevant laws and regulations that have a significant impact on the business and operation of the Group. During the year ended December 31, 2025, there was no material breach of, or non-compliance with, applicable laws and regulations by the Group.

EMPLOYEES AND REMUNERATION POLICIES

A review of the employees and remuneration policies of the Group for the Reporting Period is set out in “Management Discussion and Analysis” on pages 22 to 23 of this annual report.

RETIREMENT BENEFITS SCHEME

The Group does not have any employee who is required to participate in the Mandatory Provident Fund in Hong Kong. The employees of the Group’s subsidiary in the PRC are members of the state-sponsored retirement benefit scheme organized by the relevant local government authority in the PRC. The subsidiary is required to contribute, based on a certain percentage of the payroll costs of its employees, to the retirement benefit scheme and has no further obligations for the actual payment of pensions or post-retirement benefits beyond the annual contributions.

The only obligation of the Group with respect to this retirement benefits scheme is to make the required contributions under the scheme. During the Reporting Period, there were no forfeited contributions under the Group’s retirement benefits scheme, and there were no forfeited contributions that may be used by the Group to reduce the existing level of contribution.

Details of the pension contributions of the Company are set out in Note 29 to the consolidated financial statements in this annual report.

MAJOR SUPPLIERS

For the year ended December 31, 2025, the Group’s suppliers primarily consisted of (i) product suppliers; (ii) licensors from which we obtained intellectual property rights in respect of our in-licensed drug candidates; (iii) contract research organizations (CROs), who provide third-party contracting services for R&D; and (iv) suppliers of other materials for R&D activities, machines and equipment. The Group selects its suppliers by considering their product quality, industry reputation and compliance with relevant regulations and industry standards.

For the year ended December 31, 2025, purchases from the Group’s five largest suppliers in the aggregate amounted to RMB386.7 million (2024: RMB269.1 million), accounted for 52.8% (2024: 44.6%) of the Group’s total purchases for the same year. Purchases from the Group’s largest supplier for the year ended December 31, 2025 amounted to RMB192.7 million (2024: RMB97.9 million), accounting for approximately 26.3% (2024: 16.2%) of the Group’s total purchase amount for the same year.

None of the Directors, their respective close associates, or any Shareholder of the Company who, to the knowledge of the Directors, owning more than 5% of the Company’s issued capital, has any interest in any of the Group’s five largest suppliers.

During the year ended December 31, 2025, the Group did not experience any significant disputes with its suppliers.

MAJOR CUSTOMERS

During the Reporting Period, the Group continued the commercialization of its ophthalmic products. For the year ended December 31, 2025, sales from the Group's five largest customers in the aggregate amounted to RMB763.2 million (2024: RMB376.8 million), accounted for 94.9% (2024: 90.3%) of the Group's total sales for the same year. Sales from the Group's largest customer for the year ended December 31, 2025 amounted to RMB652.9 million (2024: RMB305.0 million), accounting for approximately 81.2% (2024: 73.1%) of the Group's total sales amount for the same year.

None of the Directors, their respective close associates, or any Shareholder of the Company who, to the knowledge of the Directors, owning more than 5% of the Company's issued capital, has any interest in any of the Group's five largest customers.

During the year ended December 31, 2025, the Group did not experience any significant disputes with its customers.

KEY RELATIONSHIP WITH STAKEHOLDERS

The Group recognizes that various stakeholders including suppliers, employees, Shareholders, customers and other business associates are key to Group's success. The Group strives to achieve corporate sustainability through engaging, collaborating, and cultivating strong relationship with them.

Relationship with Our Employees

We endeavor to cultivate talented and loyal employees by treating our employees with dignity, respect and fairness. We conduct new employee training, as well as professional and compliance training programs for employees. We enter into employment contracts with our employees to cover matters such as wages, benefits and grounds for termination. The remuneration package of our employees usually includes salary, bonus and share incentives, which are generally determined by their qualifications, industry experience, position and performance. We make contributions to social insurance and housing provident funds as required by the PRC laws and regulations.

Relationship with Our Shareholders

We recognize the importance of protecting the interests of the Shareholders and of having effective communication with them. We believe communication with the Shareholders is a two-way process and have thrived to ensure the quality and effectiveness of information disclosure, maintain regular dialog with the Shareholders and listen carefully to the views and feedback from the Shareholders. This has been done through general meetings, corporate communications, annual reports and results announcements.

BIOGRAPHIES OF THE DIRECTORS AND SENIOR MANAGEMENT

The biographical details of the Directors and the senior management of the Company during the Reporting Period are set out in "Profiles of Directors and Senior Management" on pages 24 to 31 of this annual report.

SERVICE CONTRACTS OF THE DIRECTORS

Each of the executive Directors has entered into a service agreement with the Company. The initial term of their respective service agreements shall commence from the Listing Date and continue for a period of three years and be always subject to re-election as and when required under the Articles of Association, until terminated in accordance with the terms and conditions of the service agreement or by either party giving to the other not less than 30 days' prior notice in writing.

Dr. Lian Yong CHEN, being the non-executive Director, which has been re-designated from an executive Director to a non-executive Director with effect from July 20, 2024, has entered into an appointment letter with the Company in relation to his appointment as a non-executive Director. Mr. Yanling CAO being a non-executive Director and Mr. Ting Yuk Anthony WU and Mr. Yiran HUANG, being the independent non-executive Directors, have entered into an appointment letter with the Company respectively. Their respective appointment letters shall commence from the July 10, 2023 and continue for a period of three years subject always to re-election as and when required under the Articles of Association, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing.

Mr. Zhenyu ZHANG, being an independent non-executive Director, has entered into a service agreement with the Company on April 8, 2025. The initial term of his service agreement shall commence from the date of appointment and continue for a period of three years subject to retirement by rotation and re-election as and when required under the Articles of Association or vacation from office pursuant to any applicable laws from time to time.

Dr. Qin XIE, being a non-executive Director, has entered into a service agreement with the Company with effect from January 16, 2025. The initial term for her service agreement shall commence from the date of appointment and continue for a period of three years subject to retirement by rotation and re-election as and when required under the Articles of Association or vacation from office pursuant to any applicable laws from time to time.

Ms. Beibei ZHUANG, a proposed independent non-executive Director, will enter into a letter of appointment with the Company for a term of three years commencing from the date of the AGM subject to the approval for her appointment at the forthcoming AGM and will be subject to retirement by rotation and re-election at least once every three years in accordance with the Articles of Association.

In accordance with the Articles of Association, all Directors are subject to retirement by rotation at least once every three years and any new Director appointed to fill a casual vacancy shall submit himself/herself for re-election by Shareholders at the first general meeting of the Company after appointment and any new Director appointed as an addition to the Board shall submit himself/herself for re-election by the Shareholders at the next following annual general meeting after appointment. Each of Mr. Ye LIU and Dr. Zhaopeng HU, being eligible, has been re-elected as an executive Director, and Mr. Yiran HUANG, being eligible, has been re-elected as an independent non-executive Director, respectively, at the annual general meeting held on June 20, 2025.

None of the Directors proposed for re-election at the forthcoming annual general meeting has a service contract with the Company or any member of the Group which is not determinable by the employer within one year without payment of compensation (other than statutory compensation).

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in this annual report, at no time during the year ended December 31, 2025 was the Company or any of its subsidiaries a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of Shares in, or debentures of, the Company or any other body corporate; and none of the Directors, or any of their spouse or children under the age of 18, had any right to subscribe for equity or debt securities of the Company or any other body corporate, or had exercised any such right.

REMUNERATION OF THE DIRECTORS AND FIVE HIGHEST PAID INDIVIDUALS

In compliance with Rule 3.25 of the Listing Rules and the CG Code, the Company has established the Remuneration Committee to formulate remuneration policies. The remuneration is determined and recommended based on each Director's and senior management personnel's qualification, position and seniority. As for the independent non-executive Directors, their remuneration is determined by the Board upon recommendation from the Remuneration Committee. The Directors and the senior management personnel are eligible participants of the ESOP, the RSU Scheme, the 2021 Share Option Scheme, the 2021 Share Award Scheme and the 2024 Share Award Scheme.

Details of the remuneration of the Directors, chief executive officer and the five highest paid individuals for the Reporting Period are set out in Note 11 to the consolidated financial statements in this annual report. During the Reporting Period, there was no emoluments paid by the Group to any of the Directors, chief executive officer or the five highest paid individuals as an inducement to join, or upon joining the Group, or as compensation for loss of office.

DIRECTORS' INTERESTS IN TRANSACTIONS, ARRANGEMENTS OR CONTRACT OF SIGNIFICANCE

Save as disclosed in this annual report, none of the Directors nor any entity connected with the Directors had a material interest, either directly or indirectly, in any transaction, arrangement or contract of significance, whether for the provision of services or otherwise, to the Group to which the Company, its holding company, or any of its subsidiaries or fellow subsidiaries was a party subsisting during or at the end of the year ended December 31, 2025.

CONTROLLING SHAREHOLDERS' INTERESTS IN CONTRACT OF SIGNIFICANCE

Save as disclosed in this annual report, no controlling Shareholders or their subsidiaries had a material interest, either directly or indirectly, in any contract of significance, whether for the provision of services or otherwise, to the Group to which the Company or any of its subsidiaries or fellow subsidiaries was a party subsisting during or as of the end of the year ended December 31, 2025.

DIRECTORS INTERESTS IN COMPETING BUSINESS

Save as disclosed in the Prospectus and save for their respective interests in the Group, none of the Directors and the controlling Shareholders was interested in any business which competes or is likely to compete, directly or indirectly, with the businesses of the Group for the year ended December 31, 2025.

From time to time our non-executive Directors may serve on the boards of both private and public companies within the broader healthcare and biopharmaceutical industries. However, as these non-executive Directors are neither our controlling Shareholders nor members of our executive management team, we do not believe that their interests in such companies as directors would render us incapable of carrying on our business independently from the other companies in which they may hold directorships from time to time.

MANAGEMENT CONTRACTS

No contract concerning the management and administration of the whole or any substantial part of the business of the Company was entered or existed during the year ended December 31, 2025.

INVESTMENT POLICY AND PORTFOLIO

Investment Policy and Portfolio

The Company's investment policy aims to preserve capital, enhance the value of its assets, and support its corporate strategy and principal business operations as a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first – or best-in-class ophthalmic therapies. The purpose of these investments is to generate long-term value, maintain sufficient liquidity for operational needs including research and development activities, selling and marketing activities, and manufacturing operations, and foster potential synergies with the Company's drug development pipeline and commercialization business to support future sustainable growth.

The Company's investments activities may include, without limitation, equity investments, acquisitions of assets or businesses, the establishment of subsidiaries or joint ventures, investments in securities and funds, subscription of wealth management products, and other investment activities as may be permitted under applicable laws and regulations and the Company's constitutional documents and internal policies.

While the above categories represent the primary focus of the Company's investment activities, the Company retains the flexibility to explore investments strategic acquisitions in the ophthalmology sector, such as the acquisition of drug assets or in-licensing of pharmaceutical products, each of which will undergo independent due diligence and is subject to the approval procedures described below. The Company does not engage in speculative investment activities and generally prohibits investments in high-risk or highly leveraged financial products.

The investment strategy is closely aligned with the Company's corporate strategy, combining long-term strategic investments — such as investments in listed equity securities of international ophthalmic companies held for long-term purposes and strategic value, and investments in drug assets and licenses that support the Company's product pipeline and market position — with short-term investments, including bank term deposits and principal-protected financial products issued by banks, which aim to maintain liquidity and enhance yields on available cash.

Investment decisions are subject to a tiered approval mechanism based on transaction size. Significant investments are subject to audit or valuation requirements where applicable. The Board and relevant committees shall oversee the investment strategy and risk management. The Company shall also ensure compliance with applicable disclosure obligations under the Listing Rules in respect of the investment activities.

The Company monitors its investment portfolio on an ongoing basis. As of December 31, 2025, we did not hold any single investment that accounted for 5% or more of our total assets. As of December 31, 2025, our investment portfolio primarily consisted of short-term structured deposits utilized for liquidity management purposes, supplemented by selected long-term strategic investments. These strategic holdings principally include listed equity securities and contingent value rights associated with our industry partners. For further details regarding our equity investments, please refer to Note 17 to the consolidated financial statements in this annual report.

Report of Directors

Risk Management, Control Measures, and Oversight Mechanisms

The Company has established comprehensive internal controls and risk management measures over its investment activities through its treasury management policies and procedures. These measures include:

- **Budget Plans:** The Company monitors and maintains a level of cash and cash equivalents deemed adequate to finance its operations and mitigate the effects of fluctuations in cash flows, and manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximizing the return to investors through the optimization of the debt and equity balance.
- **Approval Processes:** Proposed investments undergo preliminary review and analysis (including background searches, due diligence, and compliance analysis), followed by final review and approval by the appropriate level of the Company's management. Material investment decisions, including significant acquisitions and disposals, remain subject to the Board's oversight and approval as appropriate, and will be announced in accordance with the Listing Rules where applicable.
- **Ongoing Monitoring:** The Company continuously monitors all investment projects, assessing market risks (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk. The Company's finance team is responsible for determination of credit limits, credit approvals, and monitoring of the credit risk gradings of counterparties. The management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

The Board and the Audit Committee are responsible for overall risk management and internal controls. The Board acknowledges it is responsible for the Company's risk management and internal control systems and reviewing their effectiveness. The Group has established an internal audit department and designated staff to be responsible for identifying and supervising the Group's risk and internal control issues and reporting directly to the Board of any findings and follow-up actions. Material investment decisions remain subject to the Board's oversight and approval as appropriate.

RELATED PARTY TRANSACTIONS AND CONNECTED TRANSACTIONS

Details on related party transactions for the year ended December 31, 2025 are set out in Note 31 to the consolidated financial statements in this annual report.

Continuing Connected Transactions in Relation to the Alcon Transaction

On August 12, 2024, we entered into the Alcon Transaction with Alcon Group. Following the Alcon Consideration Issue, Alcon Pharma became our substantial Shareholder, holding approximately 16.99% of the total issued share capital of the Company (excluding the treasury Shares) as enlarged by the Alcon Consideration Issue. Each of Alcon Research and Alcon Pharma is a wholly owned subsidiary of Alcon. Therefore, Alcon Research became an associate of a connected person of our Company. As such, purchase arrangements contemplated under the Manufacture and Supply Agreement, the royalty payments contemplated under the Asset Purchase Agreement and royalty payments and milestone payments contemplated under the License Agreement constitute continuing connected transactions of the Company and are subject to the requirements under Chapter 14A of the Listing Rules. The details of the Alcon Transaction are set forth in the Company's announcement dated August 12, 2024 and the circular dated September 30, 2024.

Purchase Arrangements under the Manufacture and Supply Agreement

As the Group could only commence the manufacture of the Transferred Products after becoming the market authorization holder of the Transferred Products in the PRC pursuant to a domestic drug license, the Group agreed to purchase the Transferred Products from Alcon Pharma during the transition period for commercialization of such products in the PRC. As the manufacture of the Commercial Product has been and continues to be conducted outside the PRC, the Group agreed to purchase the Commercial Product from Alcon Pharma for commercialization throughout the term of the parties' relationship. Subject to the R&D progress of the Pipeline Product, Ocumension HK may also need to purchase the Pipeline Product from Alcon Pharma for the purpose of conducting a pivotal study in the PRC. For the aforesaid purposes, on August 12, 2024, Ocumension HK and Alcon Pharma entered into the Manufacture and Supply Agreement, pursuant to which, Ocumension HK agreed to purchase from Alcon Pharma, and Alcon Pharma or its subcontractors agreed to manufacture and supply to Ocumension HK the Transferred Products, Commercial Product, and the Pipeline Product during the periods as agreed by the parties. Such purchase arrangements under the Manufacture and Supply Agreement constitute continuing connected transactions of the Company after the completion of the Alcon Consideration Issue.

Subject to the terms of the Manufacture and Supply Agreement and unless terminated earlier by the parties as agreed in the agreement, Ocumension HK has agreed and will continue to purchase from Alcon Pharma, among others, the Commercial Product for so long as it remains commercialized in the PRC. Furthermore, the one-time purchase of the Pipeline Product does not have a fixed term as the purchase of Pipeline Product for pivotal study is subject to the progress and needs of the R&D of the Pipeline Product. Therefore, the Manufacture and Supply Agreement does not have a fixed term and will continue in force for so long as the purchase arrangements of the Commercial Product and the Pipeline Product remain in place. The Company has obtained from the Stock Exchange a waiver from strict compliance with Rule 14A.52 of the Listing Rules such that the Manufacture and Supply Agreement and the purchase arrangements in respect of the Commercial Product and the Pipeline Product can be of an indefinite term.

The annual cap for purchase arrangements contemplated under the Manufacture and Supply Agreement for the year ended December 31, 2025 is HK\$199.7 million. The aggregate transaction amount incurred in accordance with the Manufacture and Supply Agreement for the year ended December 31, 2025 was HK\$158.5 million.

For further details of the purchase arrangements under the Manufacture and Supply Agreement, please refer to the Company's announcement dated August 12, 2024 and the circular dated September 30, 2024.

Royalty Payments under the Asset Purchase Agreement and the License Agreement

On August 12, 2024, Ocumension HK (as the purchaser) entered into the Asset Purchase Agreement with Alcon Research (as the seller), a wholly owned subsidiary of Alcon, pursuant to which Ocumension HK agreed to acquire from Alcon Research certain transferred assets for the purpose of manufacture and commercializing the Transferred Products in the PRC.

In connection with the commercialization of the Transferred Products under the Asset Purchase Agreement and the Commercial Product under the License Agreement, Ocumension HK agreed to pay Alcon or its designee royalty payments based on net sales of the Transferred Products and the Commercial Product sold in the PRC, by or on behalf of Ocumension HK or its (sub) licensees during the royalty term. Such royalty payments constitute continuing connected transactions of the Company after the completion of the Alcon Consideration Issue.

Report of Directors

As the royalty payments in respect of the Transferred Products under the Asset Purchase Agreement commenced from the first commercial sale and will continue until the expiration of the 15-year period in respect of each relevant Transferred Product (unless terminated earlier as agreed by the parties), the term of the Asset Purchase Agreement and the royalty payments in respect of the Transferred Products thereunder are fixed at the time of entering into the Asset Purchase Agreement. The royalty payments in respect of the Commercial Product under the License Agreement commenced from the first commercial sale and will continue until the expiration of the 15-year period. However, since the License Agreement includes in-licensing of both the Commercial Product and the Pipeline Product, and the term of the License Agreement commenced from the closing date of the Alcon Transaction and will end on the date on which the royalty term expires for the final Licensed Product (unless terminated earlier), the License Agreement remained and will remain in force until 15 years after the first commercial sale of the Pipeline Product, which is subject to the successful R&D and commercialization of the Pipeline Product. Therefore, the term of the License Agreement and the royalty payments thereunder could not be fixed at the time of entering into the License Agreement. The commercial reasonableness justified a fixed term longer than three years of the royalty payments under the Assets Purchase Agreement and the License Agreements.

The annual cap for the royalty payments contemplated under the Asset Purchase Agreement for the year ended December 31, 2025 is HK\$39.2 million. The aggregate transaction amount incurred in accordance with the Asset Purchase Agreement for the year ended December 31, 2025 was HK\$35.9 million.

For further details of the royalty payments under the Asset Purchase Agreement, please refer to the Company's announcement dated August 12, 2024 and the circular dated September 30, 2024.

Royalty and Milestone Payments under the License Agreement

As Alcon possesses proprietary technology and know-how related to the Pipeline Product, Ocumension HK obtained from Alcon Pharma, and Alcon Pharma granted Ocumension HK, an exclusive license for Ocumension HK to develop, manufacture, and commercialize the Pipeline Product for dry eye uses in the PRC under the License Agreement entered into between Ocumension HK and Alcon Pharma on August 12, 2024.

The term of the License Agreement commenced from the closing date of the Alcon Transaction and will continue until the date on which the royalty term expires for the final Licensed Products, unless terminated earlier. The royalty term of the Pipeline Product is 15 years commencing from the first commercial sale of the Pipeline Product. As the Pipeline Product remains in the R&D process, and the first commercial sale of the Pipeline Product is subject to its successful R&D and approval by the NMPA, the term of the in-licensing of the Pipeline Product for R&D and commercialization cannot be fixed at the time of entering into the License Agreement. Accordingly, the License Agreement does not have a fixed term. The Company has obtained from the Stock Exchange a waiver from strict compliance with Rule 14A.52 of the Listing Rules such that the License Agreement and the in-licensing of the Pipeline Product thereunder can be of an indefinite term.

The annual cap for the royalty and milestone payments contemplated under the License Agreement is expressed in a formula form. The Company has obtained from the Stock Exchange a waiver from strict compliance with Rule 14A.53 of the Listing Rules for not setting any monetary annual cap for the transaction amounts in respect of the royalty payments and sales milestone payments with respect to the Pipeline Product under the License Agreement. During the Reporting Period, the aggregate transaction amount incurred in accordance with the License Agreement was nil.

For further details of the royalty and milestone payments under the License Agreement, please refer to the Company's announcement dated August 12, 2024 and the circular dated September 30, 2024.

Confirmations from the Auditors and Independent Non-Executive Directors

In the view of our independent non-executive Directors, the continuing connected transactions under the Alcon Transaction have been entered into (i) in the ordinary and usual course of business of our Group, (ii) according to the agreement governing them on terms (including the pricing policy therein) that are fair and reasonable and on normal commercial terms or better; and (iii) according to the agreement governing them on terms (including the pricing policy therein) that are fair and reasonable and in the interest of our Company and our Shareholders as a whole.

The auditors of the Company were engaged to report on the above continuing connected transactions under the Alcon Transaction which were conducted during the Reporting Period and provided the Board with a letter in accordance with Rule 14A.56 of the Listing Rules confirming that nothing has come to their attention that causes them to believe that the continuing connected transactions (i) have not been approved by the Board; (ii) were not, in all material respects, in accordance with the pricing policies of the Group; (iii) were not entered into, in all material respects, in accordance with the agreement governing them; and (iv) have exceeded the annual cap.

Save as disclosed in this annual report, (i) none of the related party transactions constitute a connected transaction or continuing connected transaction which is subject to the Shareholders' approval, annual review and all disclosure requirements under Chapter 14A of the Listing Rules; and (ii) there was no connected transaction nor continuing connected transaction of the Group which has to be disclosed in accordance with the Chapter 14A of the Listing Rules during the Reporting Period.

DIRECTORS AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS

As of December 31, 2025, the interests and short positions of the Directors or chief executive of our Company in any of the Shares, underlying Shares and debentures of our Company or its associated corporation (within the meaning of Part XV of the SFO), which have been notified to the Company and the Stock Exchange pursuant to Division 7 and 8 of Part XV of SFO (including any interest or short positions which they are taken or deemed to have under such provisions of the SFO) or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

Interests in Shares or underlying Shares of the Company

Name of Director	Nature of interest	Number of Shares/ underlying Shares	Approximate percentage of shareholding interest ⁽³⁾
Mr. Ye LIU	Beneficial owner	84,251,340 ⁽¹⁾	10.07%
Dr. Zhaopeng HU	Beneficial owner	4,238,552 ⁽²⁾	0.51%

Report of Directors

Notes:

- (1) Including (i) a total of 40,918,730 Shares directly held by him; (ii) 13,216,210 options that have been granted yet unexercised under the ESOP; (iii) RSUs representing 11,150,050 Shares upon vesting that have been granted yet unsettled under the RSU Scheme; (iv) 18,152,515 options that have been granted yet unexercised under the 2021 Share Option Scheme; and (v) 813,835 awards that have been granted yet unvested under the 2021 Share Award Scheme.
- (2) Including (i) a total of 3,828,452 Shares directly held by him; (ii) 342,000 options that have been granted yet unexercised under the 2021 Share Option Scheme; and (iii) 68,100 awards that have been granted yet unvested under the 2021 Share Award Scheme.
- (3) The calculation is based on the total number of 836,331,914 Shares in issue as of December 31, 2025.

Save as disclosed above, as of December 31, 2025, so far as it was known to the Directors or chief executive of the Company, none of the Directors or chief executive of the Company had interests or short positions in the Shares, underlying Shares and debentures of the Company or its associated corporations as recorded in the register required to be kept, pursuant to Section 352 of the SFO; or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

As of December 31, 2025, so far as the Directors are aware, the following persons (other than the Directors or chief executive of the Company) had or were deemed or taken to have interests or short positions in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company and the Stock Exchange under the provision of Divisions 2 and 3 of Part XV of the SFO or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Interests in the Shares or underlying Shares of the Company

Name of Shareholders	Nature of interest	Total number of Shares/ underlying Shares	Approximate percentage in shareholding ⁽⁶⁾
6 Dimensions Capital (Note 1)	Beneficial interest	119,890,000	14.34%
6 Dimensions Affiliates (Note 1)	Beneficial interest	6,310,000	0.75%
6 Dimensions Capital GP, LLC (Note 1)	Interest in controlled corporation	126,200,000	15.09%
Suzhou Frontline II (Note 2)	Beneficial interest	62,440,000	7.47%
Suzhou Fuyan Venture Capital Management Partnership (Limited Partnership) (蘇州富沿創業投資管理合夥企業(有限合夥)) (Note 2)	Interest in controlled corporation	62,440,000	7.47%
Suzhou 6 Dimensions (Note 2)	Beneficial interest	26,760,000	3.20%
Suzhou Tongyu Investment Management Partnership (Limited Partnership) (蘇州通毓投資管理合夥企業(有限合夥)) (Note 2)	Interest in controlled corporation	26,760,000	3.20%
Suzhou Yunchang Investment Consulting Co., Ltd. (蘇州蘊長投資諮詢有限公司) (Note 2)	Interest in controlled corporation	89,200,000	10.67%

Name of Shareholders	Nature of interest	Total number of Shares/ underlying Shares	Approximate percentage in shareholding ⁽⁶⁾
Qiping ZHANG (張綺蘋) (Note 2)	Interest in controlled corporation	89,200,000	10.67%
Alcon Pharma (Note 3)	Beneficial interest	139,159,664	16.64%
Alcon (Note 3)	Interest in controlled corporation	139,159,664	16.64%
Summer Iris Limited (Note 4)	Beneficial interest	78,214,230	9.35%
Boyu Capital Fund IV, L.P. (Note 4)	Interest in controlled corporation	78,214,230	9.35%
Boyu Capital General Partner IV, Ltd. (Note 4)	Interest in controlled corporation	78,214,230	9.35%
Boyu Capital Group Holdings Ltd. (Note 4) (Note 5)	Interest in controlled corporation	85,903,230	10.27%

Notes:

- (1) For the purpose of the SFO, 6 Dimensions Capital GP, LLC, as the general partner of each of 6 Dimensions Capital and 6 Dimensions Affiliates, is deemed to have an interest in the Shares held by each of 6 Dimensions Capital and 6 Dimensions Affiliates.
- (2) Suzhou Fuyan Venture Capital Management Partnership (Limited Partnership) (蘇州富沿創業投資管理合夥企業(有限合夥)) is the general partner of Suzhou Frontline II. Suzhou Tongyu Investment Management Partnership (Limited Partnership) (蘇州通毓投資管理合夥企業(有限合夥)) is the general partner of Suzhou 6 Dimensions. Suzhou Yunchang Investment Consulting Co., Ltd. (蘇州蘊長投資諮詢有限公司) is the general partner of each of Suzhou Fuyan Venture Capital Management Partnership (Limited Partnership) (蘇州富沿創業投資管理合夥企業(有限合夥)) and Suzhou Tongyu Investment Management Partnership (Limited Partnership) (蘇州通毓投資管理合夥企業(有限合夥)), and is wholly held by Qiping ZHANG (張綺蘋). Qiping ZHANG (張綺蘋) is the mother-in-law of Dr. Lian Yong CHEN, the Chairman and non-executive Director of our Company.
- For the purpose of the SFO, (i) Suzhou Fuyan Venture Capital Management Partnership (Limited Partnership) (蘇州富沿創業投資管理合夥企業(有限合夥)) is deemed to have an interest in the Shares held by Suzhou Frontline II; (ii) Suzhou Tongyu Investment Management Partnership (Limited Partnership) (蘇州通毓投資管理合夥企業(有限合夥)) is deemed to have an interest in the Shares held by Suzhou 6 Dimensions; and (iii) Qiping ZHANG (張綺蘋) and Suzhou Yunchang Investment Consulting Co., Ltd. (蘇州蘊長投資諮詢有限公司) are deemed to have an interest in the Shares held by each of Suzhou Frontline II and Suzhou 6 Dimensions.
- (3) For the purpose of the SFO, Alcon is deemed to have an interest in the Shares held by its wholly-owned subsidiary, Alcon Pharma.
- (4) For the purpose of the SFO, each of Boyu Capital Fund IV, L.P. (as the sole shareholder of Summer Iris Limited), Boyu Capital General Partner IV, Ltd. (as the general partner of Boyu Capital Fund IV, L.P.) and Boyu Capital Group Holdings Ltd. (as the sole shareholder of Boyu Capital General Partner IV, Ltd.) is deemed to have an interest in the 78,214,230 Shares held by Summer Iris Limited.
- (5) For the purpose of the SFO, Boyu Capital Group Holdings Ltd. is deemed to have an interest in the 7,689,000 Shares held by Boyu Capital Opportunities Master Fund, as Boyu Capital Opportunities Master Fund is managed by Boyu Capital Investment Management Limited, which in turn is ultimately controlled by Boyu Capital Group Holdings Ltd.
- (6) The calculation is based on the total number of 836,331,914 Shares in issue as of December 31, 2025.

Save as disclosed above, as of December 31, 2025, the Company has not been notified of any other relevant interests or short positions in the issued share capital of the Company, other than the Directors and chief executive of the Company, which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

Report of Directors

SHARE SCHEMES

During the year ended December 31, 2025 and up to the date of this annual report, we have five share schemes in effect which were required to be disclosed under the requirements of Chapter 17 of the Listing Rules.

ESOP

The ESOP was adopted by the Company on May 23, 2018 and amended from time to time. Subject to the terms of the ESOP, the Board may at its discretion specify any conditions which must be satisfied before the option(s) under the ESOP may be exercised. Further details of the ESOP are set out in the Prospectus and Note 28(a) to the consolidated financial statements in this annual report.

Principal Terms of the ESOP

Below is a summary of the terms of the ESOP:

Purpose

The purpose of the ESOP is to recognize the contributions of the Directors and employees and to incentivize them to further promote the development of the Group by providing a means through which the Company may grant options to attract, motivate, retain and reward certain eligible employees.

Participants

Any employee, officer, Director, contractor, advisor or consultant of the Group who is notified by the Board that he or she is an eligible employee by reason of their contribution to the Group is entitled to be offered and granted options.

Maximum number of Shares available for issue

The maximum number of Shares in respect of which options may be granted under this plan shall not, subject to reorganization of capital structuring and other corporate events provisions under the plan, exceed 60,328,890 Shares in the aggregate, representing approximately 7.40% of the total issued Shares of the Company (excluding treasury shares) as of the date of this annual report, being 815,382,414 Shares.

Maximum entitlement of each participant

No employee shall be granted an option which, if exercised in full, would result in such employee becoming entitled to subscribe for such number of Shares as, when aggregated with the total number of Shares already issued under all the options previously granted to him which have been exercised, and, issuable under all the options previously granted to him which are for the time being subsisting and unexercised, would exceed ten percent of the aggregate number of Shares for the time being issued and issuable under this plan.

Option period

An option may be exercised in accordance with the offer letter and the rules under the ESOP at any time during the option period as specified by the Board in relation to each such option in its terms of grant.

Vesting period

Unless otherwise approved by the Board and set forth in an offer letter, the vesting schedule shall be a 60-month vesting schedule consisting of a cliff vesting of twenty percent (20%) after twelve (12) months from the vesting commencement date and, thereafter, quarterly vesting of equal instalments over the remaining sixteen (16) quarters. In case of a listing, the vesting schedule of the unvested option shall be accelerated by 50%.

Subscription price

The subscription price shall be approved by the Board and shall be set out in the offer letter. A grantee is not required to pay for the grant of any option.

Basis of determining the exercise price of options

No basis of determining the exercise price of options granted was specified in the terms of the ESOP.

Remaining life

The ESOP shall be valid and effective for a period of 10 years commencing on the adoption date, after which period no further options will be granted, but the provisions of the ESOP shall in all other respects remain in full force and effect and the grantees may exercise the options in accordance with the terms upon which the options are granted. The Company shall not grant any options under the ESOP after the Listing. The remaining life of the ESOP is until May 22, 2028.

Movements in the Options under the ESOP

Details of the options granted under the ESOP and their movements during the year ended December 31, 2025 are as follows :

Name of grantee	Date of grant	Vesting period	Exercise period	Exercise price (US\$ per Share)	Number of Shares underlying options as of January 1, 2025	Number of options exercised during the Reporting Period	Number of options canceled/ forfeited/ lapsed during the Reporting Period	Number of Shares underlying options as of December 31, 2025
Directors								
Mr. Ye LIU	Between August 28, 2018 to January 22, 2020	(Note 1)	Until May 23, 2028	Between 0.001 to 0.188	16,714,710	3,498,500 ⁽²⁾	0	13,216,210
Other grantees in aggregate⁽⁵⁾	Between August 28, 2018 to January 22, 2020	(Note 3)	(Note 3)	Between 0.001 to 0.201	101,606	0	0	101,606
Total					16,816,316	3,498,500	0⁽⁴⁾	13,317,816

Report of Directors

Notes:

- (1) All the options granted to Mr. Liu under the ESOP have been vested to him. The options vested to Mr. Liu are exercisable before May 23, 2028.
- (2) During the Reporting Period, Mr. Liu exercised 3,498,500 options under the ESOP for the subscription of 3,498,500 Shares, among which nil Share was subsequently sold. The weighted average closing price of such Shares immediately before the dates on which these options were exercised during the Reporting Period was HK\$7.02 per Share.
- (3) The vesting schedule shall be a 60-month vesting schedule consisting of a cliff vesting of twenty percent (20%) after twelve (12) months from the vesting commencement date and, thereafter, quarterly vesting of equal instalments over the remaining sixteen (16) quarters. In case of a listing, the vesting schedule of the unvested option shall be accelerated by 50%. The options are exercisable until the later of (i) second anniversary of the Listing Date; or (ii) three months following the options are fully-vested in accordance with the vesting schedule.
- (4) During the Reporting Period, nil option had been forfeited, subsequently lapsed or canceled. Since the Listing and as of December 31, 2025, a total of 633,844 options under the ESOP had been forfeited.
- (5) Other grantees are all employees of the Company (other than the Directors) who entered into valid employment contracts with the Company.

Save as disclosed above, no option had been granted or agreed to be granted, exercised, canceled or lapsed under the ESOP throughout the year ended December 31, 2025.

RSU Scheme

The RSU Scheme was approved by the Shareholders on April 28, 2020. Subject to the terms of the RSU Scheme, the Board may at its discretion specify any terms and conditions of the grant of RSUs to eligible participants. Further details of the RSU Scheme are set out in the Prospectus.

Principal Terms of the RSU Scheme

Below is a summary of the terms of the RSU Scheme:

Purpose

The purpose of the RSU Scheme is to recognize the contributions of the Directors, employees and any consultant or adviser of the Group and to incentivize them to further promote the development of the Group.

Participants

Any employee, officer, director, contractor, advisor or consultant of the Group who is notified by the Board that he or she is an eligible participant by reason of their contribution to the Group.

Maximum number of Shares available for issue

Pursuant to the RSU Scheme, an aggregate of 24,000,000 underlying Shares were issued to Coral Incentivization Limited, representing an aggregate of 2.94% of the total issued Shares of the Company (excluding treasury shares) as of the date of this annual report. The maximum number of Shares in respect of which RSUs may be granted under the plan shall not exceed 24,000,000 Shares in the aggregate. As of the date of this annual report, the number of Share available for issue under the RSU Scheme was nil. The Company will not make any further grant under the RSU Scheme in the future. The RSU Scheme will be further terminated upon the Board's approval in due course.

Maximum entitlement of each participant

Subject to the maximum number of Shares in respect of which RSUs may be granted under the plan as set out above, the RSU Scheme contains no provisions on the maximum entitlement of each participant.

Vesting period

Unless otherwise approved by the Board and set forth in an offer letter, the vesting schedule shall be a 60-month vesting schedule consisting of a cliff vesting of twenty percent (20%) after twelve (12) months from the vesting commencement date and, thereafter, quarterly vesting of equal instalments over the remaining sixteen (16) quarters. The vesting schedule for RSUs for the grantee shall be set forth in the offer letter to such grantee for such RSUs.

Subscription price

The consideration payable by the grantee for RSUs shall be set forth in the offer letter to such grantee for such RSUs.

Basis of determining the purchase price of RSUs

At the time of grant of RSUs, the Board will determine the consideration, if any, to be paid by the Grantee upon delivery of each Share subject to the RSUs. The consideration to be paid (if any) by the grantee for each Share subject to an RSU shall be set forth in the offer letter for such RSUs and may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. RSUs may be awarded for nil consideration if permitted under applicable law.

Remaining life

The RSU Scheme shall be valid and effective for a period of 10 years commencing on the adoption date, after which period no further RSUs will be granted, but the provisions of the RSU Scheme shall in all other respects remain in full force and effect and the RSUs shall be settled in accordance with the terms upon which the RSUs are granted. The remaining life of the RSU Scheme is until April 27, 2030.

Movements in the RSUs under the RSU Scheme

Details of the RSUs granted under the RSU Scheme and their movements during the year ended December 31, 2025 are as follows:

Category and name of grantee	Date of grant	Vesting period	Purchase price (US\$ per share)	Number of Shares underlying unvested RSUs as of January 1, 2025	Number of Shares underlying RSUs granted during the Reporting Period	Number of Shares underlying RSUs vested during the Reporting Period	Number of RSUs canceled/ forfeited during the Reporting Period	Number of Shares underlying unvested RSUs as of December 31, 2025
Directors								
Mr. Ye LIU	April 30, 2020	(Note 1)	0.188	11,150,050	N/A	0	0	11,150,050
External consultant of the Group	September 9, 2022	(Note 2)	0.188	300,000	N/A	0	0	300,000
Other grantees in aggregate⁽⁵⁾	April 30, 2020 and June 15, 2020	(Note 1)	Between 0.188 to 0.201	290,471	N/A	7,000 ⁽³⁾	0	283,471
Total				11,740,521	0	7,000	0⁽⁴⁾	11,733,521

Report of Directors

Notes:

- (1) The vesting schedule is a 60-month vesting schedule consisting of a cliff vesting of 20 percent after 12 months from the vesting commencement date and, thereafter, quarterly vesting of equal instalments over the remaining 16 quarters.
- (2) The vesting schedule is a 60-month vesting schedule consisting of a cliff vesting of 20 percent after 12 months from the vesting commencement date and, thereafter, quarterly vesting of equal instalments over the remaining 16 quarters, subject generally to the grantee continuing to be a consultant of the Group through each such date.
- (3) The weighted average closing price of the Shares immediately before the date on which the RSUs were vested to other grantees in aggregate during the Reporting Period was HK\$7.32 per Share.
- (4) During the Reporting Period, nil RSU under the RSU Scheme had been forfeited and subsequently lapsed due to resignation of the relevant employee and nil RSUs had been canceled. The Company had granted RSUs representing 23,166,920 Shares upon vesting under the RSU Scheme, among which RSUs representing 1,181,321 Shares upon vesting have been forfeited as of December 31, 2025.
- (5) Other grantees are all employees of the Company (other than the Directors) who entered into valid employment contracts with the Company.

Save as disclosed above, no RSU has been granted under the RSU Scheme throughout the year ended December 31, 2025.

Details of the basis for fair value measurement and information on whether and how the features of the RSUs are incorporated into the measurement of fair value are set out in Note 28(b) to the consolidated financial statements in this annual report.

2021 Share Option Scheme

The 2021 Share Option Scheme was adopted by the Company on August 31, 2021 and amended from time to time, the latest amendments of which were effective on June 20, 2024. Subject to the terms of the 2021 Share Option Scheme, the Board may at its discretion specify any conditions which must be satisfied before the option(s) under the 2021 Share Option Scheme may be exercised. Further details of the 2021 Share Option Scheme are set out in the circular of the Company dated May 23, 2024 and Note 28(c) to the consolidated financial statements in this annual report.

Principal Terms of the 2021 Share Option Scheme

Below is a summary of the terms of the 2021 Share Option Scheme:

Purpose

The purpose of the 2021 Share Option Scheme is to provide incentive or reward to the eligible persons for their contribution to, and continuing efforts to promote the interests of, the Group, and to incentivize them to remain with the Group, as well as for such other purposes as the Board may approve from time to time.

Participants

The eligible persons of 2021 Share Option Scheme include: (i) any director (including executive, non-executive and independent non-executive directors) of the Group; (ii) any employee (whether full-time or part-time) of the Group; and (iii) any person(s) who provide services to the Group on a continuing or recurring basis in its ordinary and usual course of business which are material to the long-term growth of the Group. The basis of eligibility of any of the above classes of eligible persons of 2021 Share Option Scheme to the grant of any options shall be determined by the Board from time to time on the basis of their individual performance, time commitment, responsibilities or employment conditions according to the prevailing market practice and industry standard, the length of employment or engagement with the Group, contribution and/or future contribution to the development and growth of the Group.

Maximum number of Shares available for issue

The 2021 Share Option Scheme is subject to the Scheme Mandate Limit and Service Provider Sublimit as refreshed by the Company by ordinary resolution of the Shareholders in general meeting, from time to time. As of the date of this annual report, 15,758,923 issued Shares are available for grant to the eligible person(s) under the 2021 Share Option Scheme, representing approximately 1.93% of the issued Shares of the Company (excluding treasury Shares) as of the same date, subject to the Scheme Mandate Limit as below.

Maximum entitlement of each participant

Unless approved by the Shareholders or upon the other conditions set out in the scheme rules of the 2021 Share Option Scheme, subject to the Listing Rules:

- (i) no option shall be granted to any eligible person if, at the relevant time of grant, the number of relevant Shares issued and to be issued (including any sale or transfer of treasury Shares out of treasury) in respect of all options and awards granted to the him/her (excluding any options and awards lapsed in accordance with the terms of relevant scheme of the Company) would exceed 1% of the total number of Shares in issue (excluding treasury Shares) at such time within any 12-month period; or
- (ii) no option shall be granted to an independent non-executive Director or substantial Shareholder of the Company, or any of their respective associates if, at the relevant time of grant, the number of relevant Shares issued and to be issued (including any sale or transfer of treasury Shares out of treasury) in respect of all options and awards granted to the him/her (excluding any options and awards lapsed in accordance with the terms of relevant scheme of the Company) would exceed 0.1% of the total number of Shares in issue (excluding treasury Shares) at such time within any 12-month period.

Option period

The option shall be exercised in any event not later than the last day of the 10-year period after the date of grant of the option (subject to early termination due to the occurrences stipulated in relevant provisions in the 2021 Share Option Scheme, including, among others, (a) termination, expiry or no renewal of the grantee's employment contract; (b) retirement, death or becoming seriously ill or injured of the grantee which renders him/her unfit to continue performing the duties under the employment contract; and (c) conducting any act of grave misconduct or willful default or willful neglect in the discharge of his/her duties, carrying out fraudulent activity, appropriating assets of the Group, or seriously violating the agreements with the Group). Subject to the above, in all other respects, in particular, in respect of options remaining outstanding on the expiration of the 10 year period, the provisions of the 2021 Share Option Scheme shall remain in full force and effect.

Vesting period

Subject to the rules of the 2021 Share Option Scheme, the Listing Rules and any applicable law and regulations, the Board and the committee of the Board or person(s) to which the Board has delegated its authority shall have the power from time to time to decide the vesting schedule of the option. While the vesting period in respect of any option shall be not less than twelve (12) months (or such other period as the Listing Rules may prescribe or permit), save for certain circumstances set forth in the scheme rules of the 2021 Share Option Scheme, in which a shorter vesting period may be imposed by the Board at its absolute discretion only in relation to the grant of options to directors or employees of the Group.

Report of Directors

Subscription price

The Board shall specify in the offer letter that no amount shall be payable on application or acceptance of the option and the period within which payments or calls must or may be made or loans for such purposes must be repaid.

Basis of determining the exercise price of options

The price at which each Share subject to an option may be subscribed for on the exercise of that option shall be a price solely determined by the Board and notified to an eligible person of the 2021 Share Option Scheme and shall be at least the highest of: (a) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the offer date, which must be a business day; and (b) the average of the closing price of the Shares as stated in the Stock Exchange's daily quotations sheets for the five Business Days immediately preceding the date of grant.

Remaining life

The 2021 Share Option Scheme shall be valid and effective for a period of ten (10) years commencing on August 31, 2021, being the adoption date, after which period no further options shall be granted, but the provisions of the 2021 Share Option Scheme shall in all other respects remain in full force and effect and the grantees may exercise the options in accordance with the terms upon which the options are granted. The remaining life of the 2021 Share Option Scheme is until August 30, 2031.

Movements in Options under the 2021 Share Option Scheme

Details of the options granted under the 2021 Share Option Scheme and their movements during the year ended December 31, 2025 are as follows:

Name of grantee	Date of grant	Vesting period	Exercise period	Exercise price (HK\$ per share)	Number of Shares underlying outstanding options as of January 1, 2025	Number of options granted during the Reporting Period	Number of options exercised during the Reporting Period	Number of options canceled/ forfeited/ lapsed during the Reporting Period	Number of Shares underlying outstanding options as of December 31, 2025
Directors									
Mr. Ye LIU	July 2, 2021	(Note 1)	(Note 1)	HK\$27.43	8,668,000	N/A	0	0	8,668,000
	September 9, 2022	(Note 1)	(Note 1)	HK\$11.41	2,160,000	N/A	0	0	2,160,000
	June 24, 2025	(Note 1)	(Note 1)	HK\$10.98	N/A	7,324,515 ⁽⁶⁾	0	0	7,324,515
Dr. Zhaopeng HU	September 30, 2021	(Note 2)	(Note 2)	HK\$19.07	150,000	N/A	0	150,000 ⁽⁷⁾	0
	September 9, 2022	(Note 2)	(Note 2)	HK\$11.41	137,000	N/A	0	0	137,000
	June 24, 2025	(Note 3)	(Note 3)	HK\$10.98	N/A	105,000 ⁽⁶⁾⁽⁷⁾	0	0	105,000
	June 24, 2025	(Note 2)	(Note 2)	HK\$10.98	N/A	100,000 ⁽⁶⁾	0	0	100,000
Other grantees in aggregate⁽⁵⁾	September 30, 2021	(Note 4)	(Note 4)	HK\$19.07	4,132,153	N/A	0	3,857,183 ⁽⁷⁾	274,970
	September 9, 2022	(Note 4)	(Note 4)	HK\$11.41	9,126,050	N/A	16,500 ⁽³⁾	601,400	8,508,150
	June 24, 2025	(Note 3)	(Note 3)	HK\$10.98	N/A	2,515,090 ⁽⁶⁾⁽⁷⁾	2,400 ⁽³⁾	3,000	2,509,690
	June 24, 2025	(Note 4)	(Note 4)	HK\$10.98	N/A	8,038,350 ⁽⁶⁾	0	106,549	7,931,801
Total					24,373,203	18,082,955⁽⁷⁾	18,900⁽⁶⁾	4,718,132⁽⁸⁾	37,719,126

Notes:

- (1) The options granted to Mr. Liu on July 2, 2021 shall vest as follows: (a) 25% of the options shall vest on the first anniversary of the date of grant; (b) 25% of the options shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the first anniversary of the date of grant to the second anniversary of the date of grant; (c) 25% of the options shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the second anniversary of the date of grant to the third anniversary of the date of grant; and (d) 25% of the options shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the third anniversary of the date of grant to the fourth anniversary of the date of grant. The exercise of such options granted to Mr. Liu is not subject to any performance targets.

The options granted to Mr. Liu on September 9, 2022 shall vest as follows: (a) 25% of the options shall vest immediately on the date of grant; (b) 25% of the options shall vest on the first anniversary of the date of grant; (c) 25% of the options shall vest on the second anniversary of the date of grant; and (d) 25% of the options shall vest on the third anniversary of the date of grant.

The options granted to Mr. Liu on June 24, 2025 shall vest as follows: (a) 25% of the options shall vest on the first anniversary of the date of grant; (b) 25% of the Options shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the first anniversary of the date of grant to the second anniversary of the date of grant; (c) 25% of the Options shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the second anniversary of the date of grant to the third anniversary of the date of grant; and (d) 25% of the Options shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the third anniversary of the date of grant to the fourth anniversary of the date of grant.

The exercise of the options granted to Mr. Liu on September 9, 2022 and June 24, 2025 is conditional upon the achievement of certain performance targets relating to the overall performance of the Company as set out in the respective grant letter entered into between Mr. Liu and the Company, including R&D and registration progress of drug candidates, marketing and sales of commercialized products, and daily operation and management of the Group.

Subject to the above, an option may be exercised by Mr. Liu (or his personal representatives) at any time during the respective option period, which is in any event not later than the last day of the 10-year period after the dates of grant of the option in 2021 and 2022 and 5-year period after the date of grant of the option in 2025.

- (2) The options granted to Dr. Hu on September 30, 2021, September 9, 2022 and June 24, 2025 (excluding the Replacement Options as defined below) shall vest as follows: (a) 10% of the options shall vest on the first anniversary of the date of grant; (b) 20% of the options shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the first anniversary of the date of grant to the second anniversary of the date of grant; (c) 30% of the options shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the second anniversary of the date of grant to the third anniversary of the date of grant; and (d) 40% of the options shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the third anniversary of the date of grant to the fourth anniversary of the date of grant. Such exercise of options is conditional upon the completion of the performance targets as set out in the respective grant letter entered into between Dr. Hu and the Company.

Subject to the above, an option may be exercised by Dr. Hu (or his personal representatives) at any time during the respective option period, which is in any event not later than the last day of the 10-year period after the dates of grant of the option in 2021 and 2022 and 5-year period after the date of grant of the option in 2025.

- (3) On June 24, 2025, the Board resolved to (a) cancel 4,018,842 options which were previously granted to existing grantees on September 30, 2021 (the “**Canceled Options**”) and (b) as replacement for and in consideration of such cancellation, re-grant 2,813,189 options (the “**Replacement Options**”) to such grantees, subject to the consent of the existing grantees (the “**Cancellation and Re-grant Consent(s)**”), the details of which are set forth in the Company’s announcement dated the same date.

The vesting of Replacement Options shall vest as follow: (a) 85.7% of the Replacement Options shall immediately vest on the date of grant; and (b) 14.3% of the Replacement Options shall vest on the first anniversary of the date of grant. The exercise of the Replacement Options is not subject to any performance targets.

Subject to the above, a Replacement Options may be exercised by Dr. Hu and the grantee (or his or her personal representatives) at any time during the option period, which is in any event not later than the last day of the 5-year period after the date of grant of the Replacement Options.

Report of Directors

- (4) The vesting period and exercise period for the grant of options (excluding the Replacement Options) to other grantees under the 2021 Share Option Scheme is the same as those of Dr. Hu's as set out in note (2) above. Such vesting of options is conditional upon the completion of the performance targets as set out in the respective grant letter entered into between the grantees and the Company.

Subject to the above, an option may be exercised by the grantee (or his or her personal representatives) at any time during the respective option period, which is in any event not later than the last day of the 10-year period after the dates of grant of the option in 2021 and 2022 and 5-year period after the date of grant of the option in 2025.

- (5) Other grantees are all employees of the Company (other than the Directors) who entered into valid employment contracts with the Company.
- (6) The closing price of the Shares immediately before the date of grant as quoted on the Stock Exchange was HK\$10.98 per Share. Details of the fair value of the options at the date of grant and the accounting standard and policy adopted are set out in Note 28(c) to the Consolidated Financial Statements in this annual report.
- (7) As of December 31, 2025, 3,770,624 Canceled Options have been canceled and 2,620,090 Replacement Options have been correspondingly regranted according to the Cancellation and Re-grant Consents.
- (8) During the Reporting Period, 947,508 options under the 2021 Share Option Scheme had been forfeited and subsequently lapsed due to resignation of the relevant employees. During the Reporting Period, 710,949 Shares underlying options that had lapsed became available again for future grants under the Scheme Mandate Limit.
- (9) The weighted average prices for the Shares immediately before the dates on which the options granted to other grantees on September 9, 2022 and June 24, 2025 were vested during the Reporting Period were HK\$11.46 per Share and HK\$11.97 per Share, respectively.

Save as disclosed above, no option had been granted or agreed to be granted, exercised, canceled or lapsed under the 2021 Share Option Scheme throughout the year ended December 31, 2025.

Details of the basis for fair value measurement and information on whether and how the features of the options are incorporated into the measurement of fair value are set out in Note 28(c) to the consolidated financial statements in this annual report.

2021 Share Award Scheme

The 2021 Share Award Scheme was approved by the Company on July 2, 2021 and amended from time to time, the latest amendments of which were effective on June 20, 2024. Further details of the 2021 Share Award Scheme are set out in the circular of the Company dated May 23, 2024 and Note 28(d) to the consolidated financial statements in this annual report.

Principal Terms of the 2021 Share Award Scheme

Below is a summary of the terms of the 2021 Share Award Scheme:

Purpose

The purpose of the 2021 Share Award Scheme is to align the interests of eligible persons with those of the Group through ownership of Shares, dividends and other distributions paid on Shares and/or the increase in value of the Shares and to encourage and retain eligible persons to make contributions to the long-term growth and profits of the Group.

Participants

The eligible persons under the 2021 Share Award Scheme include: (a) any director (including executive, non-executive and independent non-executive directors) of the Group; (b) any employee (whether full-time or part-time) of the Group; and (c) any person(s) who provide services to the Group on a continuing or recurring basis in its ordinary and usual course of business which are material to the long-term growth of the Group. The basis of eligibility of any of the above classes of eligible persons to the grant of any awards shall be determined by the Board from time to time on the basis of their individual performance, time commitment, responsibilities or employment conditions according to the prevailing market practice and industry standard, the length of employment or engagement with the Group, contribution and/or future contribution to the development and growth of the Group.

Maximum number of Shares available for issue

The 2021 Share Award Scheme is subject to the Scheme Mandate Limit and Service Provider Sublimit as refreshed by the Company by ordinary resolution of the Shareholders in general meeting, from time to time. As of the date of this annual report, 15,758,923 issued Shares are available for grant to the eligible person(s) under the 2021 Share Award Scheme, representing approximately 1.93% of the issued Shares of the Company as of the same date, subject to the Scheme Mandate Limit as below.

Maximum entitlement of each participant

Unless approved by the Shareholders or upon the other conditions set out in the scheme rules of the 2021 Share Award Scheme, subject to the Listing Rules:

- (i) no award shall be granted to any eligible person if, at the relevant time of grant, the number of relevant Shares issued and to be issued (including any sale or transfer of treasury Shares out of treasury) in respect of all options and awards granted to the him/her (excluding any options and awards lapsed in accordance with the terms of relevant scheme of the Company) would exceed 1% of the total number of Shares in issue (excluding treasury Shares) at such time within any 12-month period;
- (ii) no award shall be granted to an independent non-executive Director or substantial Shareholder of the Company, or any of their respective associates if, at the relevant time of grant, the number of relevant Shares issued and to be issued (including any sale or transfer of treasury Shares out of treasury) in respect of all options and awards granted to the him/her (excluding any options and awards lapsed in accordance with the terms of relevant scheme of the Company) would exceed 0.1% of the total number of Shares in issue (excluding treasury Shares) at such time within any 12-month period; or
- (iii) no award shall be granted to a Director (other than an independent non-executive) or chief executive of the Company, or any of their respective associates if, at the relevant time of grant, the number of relevant Shares issued and to be issued (including any sale or transfer of treasury Shares out of treasury) in respect of all awards granted to the him/her (excluding any awards lapsed in accordance with the terms of relevant scheme of the Company) would exceed 0.1% of the total number of Shares in issue (excluding treasury Shares) at such time within any 12-month period.

Vesting period

The Board or the committee of the Board or person(s) to which the Board delegated its authority may from time to time while the 2021 Share Award Scheme is in force and subject to all applicable laws, determine such vesting criteria and conditions or periods for the award to be vested thereunder, provided however that the vesting period for awards shall not be less than twelve (12) months, except that any awards granted to an employee participant may be subject to a shorter vesting period under the circumstances as stated in the scheme rules of the 2021 Share Award Scheme.

Subscription price and its basis

Unless the Board determines otherwise at its absolute discretion, no purchase price is payable in relation to awards granted under the 2021 Share Award Scheme, and the amount payable on acceptance of such awards for the eligible persons shall be nil.

Report of Directors

Remaining life

Unless terminated earlier by the Board in accordance with the Scheme Rules, the 2021 Share Award Scheme is valid and effective for a period of ten (10) years commencing on the Adoption Date (after which no further awards will be granted under the 2021 Share Award Scheme), and thereafter for so long as there are any non-vested award Shares granted hereunder prior to the expiration of the 2021 Share Award Scheme, in order to give effect to the vesting of such award Shares or otherwise as may be required in accordance with the provisions of the rules of the 2021 Share Award Scheme.

Movements in the awards under the 2021 Share Award Scheme

Details of the awards granted under the 2021 Share Award Scheme and their movements during the year ended December 31, 2025 are as follows:

Name of grantee	Date of grant	Vesting period	Purchase price (HK\$ per share)	Number of Shares underlying unvested awards as of January 1, 2025	Number of Share awards granted during the Reporting Period	Number of Shares underlying awards vested during the Reporting Period ⁽⁹⁾	Number of awards canceled/ forfeited/ lapsed during the Reporting Period	Number of Share awards underlying awards as of December 31, 2025
Directors								
Mr. Ye LIU	July 2, 2021	<i>(Note 1)</i>	0	2,437,875	N/A	2,437,875 ⁽⁴⁾	0	0
	September 9, 2022	<i>(Note 1)</i>	0	1,080,000	N/A	1,080,000 ⁽⁴⁾	0	0
	June 24, 2025	<i>(Note 1)</i>	0	N/A	813,835 ⁽¹⁰⁾	0	0	813,835
Dr. Zhaopeng HU	July 2, 2021	<i>(Note 2)</i>	0	45,000	N/A	45,000 ⁽⁵⁾	0	0
	September 9, 2022	<i>(Note 2)</i>	0	85,625	N/A	44,525 ⁽⁵⁾	0	41,100
	June 24, 2025	<i>(Note 2)</i>	0	N/A	27,000 ⁽¹⁰⁾	0	0	27,000
Other grantees in aggregate⁽⁷⁾	September 30, 2021	<i>(Note 3)</i>	0	1,246,051	N/A	1,181,725 ⁽⁶⁾	38,653	25,673
	September 9, 2022	<i>(Note 3)</i>	0	5,659,424	N/A	2,832,700 ⁽⁶⁾	278,602 ⁽⁸⁾	2,548,122
	June 24, 2025	<i>(Note 3)</i>	0	N/A	8,111,350 ⁽¹⁰⁾	0	106,549 ⁽⁸⁾	8,004,801
Total			0	10,553,975	8,952,185	7,621,825	423,804⁽⁸⁾	11,460,531

Notes:

- (1) The awards granted to Mr. Liu on July 2, 2021 and on June 24, 2025 shall vest as follows: (a) 25% of the awards shall vest on the first anniversary of the date of grant; (b) 25% of the awards shall vest in four equal installments during the period from the first anniversary of the date of grant to the second anniversary of the date of grant; (c) 25% of the awards shall vest in four equal installments during the period from the second anniversary of the date of grant to the third anniversary of the date of grant; and (d) 25% of the awards shall vest in four equal installments during the period from the third anniversary of the date of grant to the fourth anniversary of the date of grant.

The awards granted to Mr. Liu on September 9, 2022 shall vest as follows: (a) 25% of the awards shall vest immediately on the date of grant; (b) 25% of the awards shall vest on the first anniversary of the date of grant; (c) 25% of the awards shall vest on the second anniversary of the date of grant; and (d) 25% of the awards shall vest on the third anniversary of the date of grant.

The vesting of such awards granted to Mr. Liu is conditional upon the achievement of certain performance targets relating to the overall performance of the Company as set out in the respective grant letter entered into between Mr. Liu and the Company, including R&D and registration progress of drug candidates, marketing and sales of commercialized products, and daily operation and management of the Group.

- (2) The awards granted to Dr. Hu on September 30, 2021 shall vest as follows: (a) 10% of the awards shall vest on the first anniversary of the date of grant; (b) 20% of the awards shall vest in four equal installments during the period from the first anniversary of the date of grant to the second anniversary of the date of grant; (c) 30% of the awards shall vest in four equal installments during the period from the second anniversary of the date of grant to the third anniversary of the date of grant; and (d) 40% of the awards shall vest in four equal installments during the period from the third anniversary of the date of grant to the fourth anniversary of the date of grant. The vesting of the awards is conditional upon the completion of the performance targets as set out in the respective grant letter entered into between the Dr. Hu and the Company.

The awards granted to Dr. Hu on September 9, 2022 and June 24, 2025 shall vest as follows: (a) 10% of the awards shall vest on the first anniversary of the date of grant; (b) 20% of the awards shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the first anniversary of the date of grant to the second anniversary of the date of grant; (c) 30% of the awards shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the second anniversary of the date of grant to the third anniversary of the date of grant; and (d) 40% of the awards shall vest in four equal installments (with each installment vesting at the end of each quarter) during the period from the third anniversary of the date of grant to the fourth anniversary of the date of grant.

The vesting of the awards granted to Dr. Hu is conditional upon the achievement of the performance targets by Dr. Hu set out in the respective grant letter entered into between him and the Company, which include targets relating to R&D and registration progress of in-licensed and in-house developed drug candidates, chemistry, manufacturing and controls (CMC) management and regulatory affairs management.

- (3) The vesting schedule for other grantees to whom are granted awards on September 30, 2021, September 9, 2022 and June 24, 2025 under the 2021 Share Award Scheme is the same as those of Dr. Hu's as set out in note (2) above. The vesting of such awards is conditional upon the completion of the performance targets as set out in the respective grant letter entered into between the grantees and the Company.
- (4) The weighted average closing price of the Shares immediately before the dates on which the awards granted to Mr. Liu on July 2, 2021 and September 9, 2022 were vested to him during the Reporting Period were HK\$6.81 per Share and HK\$10.45 per Share, respectively.
- (5) The weighted average closing price of the Shares immediately before the dates on which the awards granted to Dr. Hu on July 2, 2021 and September 9, 2022 were vested to him during the Reporting Period were HK\$6.81 per Share and HK\$7.89 per Share, respectively.
- (6) The weighted average closing price of the Shares immediately before the dates on which the awards granted to other grantees on September 30, 2021 and September 9, 2022 were vested to them during the Reporting Period were HK\$7.89 per Share and HK\$7.81 per Share, respectively.
- (7) Other grantees are all employees of the Company (other than the Directors) who entered into valid employment contracts.
- (8) During the Reporting Period, 423,804 awards under the 2021 Share Award Scheme had been forfeited due to resignation of the relevant employees. During the Reporting Period, 385,151 Shares underlying awards that had lapsed became available again for future grants under the Scheme Mandate Limit.
- (9) The numbers of awards vested are calculated in accordance with the respective vesting schedules of the grants under the 2021 Share Award Scheme. There might be discrepancies between the awards vested during the Reporting Period and those actually settled as the settlement process could take several days, particularly when the vesting date fell on a non-business day.
- (10) The closing price of the Shares immediately before the date of grant as quoted on the Stock Exchange was HK\$10.98 per Share. Details of the fair value of the awards at the date of grant and the accounting standard and policy adopted are set out in Note 28(d) to the Consolidated Financial Statements in this annual report.

Save as disclosed above, no award has been granted or agreed to be granted, vested, canceled or lapsed under the 2021 Share Award Scheme throughout the year ended December 31, 2025.

Report of Directors

Details of the basis for fair value measurement and information on whether and how the features of the awards are incorporated into the measurement of fair value are set out in Note 28(d) to the consolidated financial statements in this annual report.

2024 Share Award Scheme

On March 21, 2024, the Board resolved to adopt the 2024 Share Award Scheme, which is funded by the existing Shares primarily from on-market purchase by the trustee. Further details of the 2024 Share Award Scheme are set out in the Company's 2024 interim report. The 2024 Share Award Scheme was adopted to be funded solely by the existing Shares purchased on the Stock Exchange and therefore constitutes a share scheme involving existing share instead of the issue of new shares under Chapter 17 of the Listing Rules.

Principal Terms of the 2024 Share Award Scheme

Below is a summary of the terms of the 2024 Share Award Scheme:

Purposes

The purposes of the 2024 Share Award Scheme are: (i) to recognize the contributions by certain eligible participants and to provide them with incentives in order to retain them for the continual operation and development of the Group; and (ii) to attract suitable personnel for further development of the Group.

Participants

The eligible persons under the 2024 Share Award Scheme include any individual, being an employee, a director, a consultant or an advisor of any member of the Group who the Board considers, at its sole discretion, to have contributed or will contribute to the Group.

Maximum number of Shares available for issue

The Company shall not make any further awards which will result in the aggregate number of Shares underlying all grants made pursuant to the 2024 Share Award Scheme to exceed 10% of the total number of Shares in issue as of the adoption date of the 2024 Share Award Scheme, being 69,561,485 Shares. As of the date of this annual report, 4,249,514 issued Shares are available for grant to the Directors, employees and any consultant or adviser of the Group under the 2024 Share Award Scheme, representing approximately 0.52% of the issued Shares of the Company as of the same date, subject to the Scheme Mandate Limit as below.

Maximum entitlement of each participant

The maximum number of Shares which may be granted to a single selected participant under the 2024 Share Award Scheme shall not exceed one (1) per cent of the issued share capital of the Company from time to time in any 12-month period, save and except approved by the Shareholders in a general meeting.

The aforesaid limits shall always be subject to the compliance with the Listing Rules that are in force from time to time, including the requirement on maintaining a minimum public float.

Vesting period

The Board or the committee of the Board or person(s) to which the Board delegated its authority may from time to time while the 2024 Share Award Scheme is in force and subject to all applicable laws, determine such vesting criteria and conditions or periods for the award to be vested thereunder.

Subscription price and its basis

The consideration payable by the grantee for award Shares shall be determined by the Board and set forth in the award letter to such grantee for award Shares.

Remaining life

Unless terminated earlier by the Board in accordance with the scheme rules, the 2024 Share Award Scheme is valid and effective for a period of ten (10) years commencing on the adoption date (after which no further awards will be granted under the 2024 Share Award Scheme), and thereafter for so long as there are any non-vested award Shares granted hereunder prior to the expiration of the 2024 Share Award Scheme, in order to give effect to the vesting of such award Shares or otherwise as may be required in accordance with the provisions of the scheme rules of the 2024 Share Award Scheme. The remaining life of the 2024 Share Award Scheme is until March 20, 2034.

Movements in the awards under the 2024 Share Award Scheme

During the Reporting Period, nil award has been granted to any eligible participants.

Share Incentives Available for Grant and Shares May Be Issued Underlying All Share Incentive Granted

	Scheme Mandate Limit		Service Provider Sublimit	
	Available for grant as of January 1, 2025	Available for grant as of December 31, 2025	Available for grant as of January 1, 2025	Available for grant as of December 31, 2025
Options and awards	41,391,491	15,452,451	5,342,000	5,342,000

The calculation of the Scheme Mandate Limit and Service Provider Sublimit does not take into account: (i) options and awards granted prior to September 9, 2022 and the refreshment of the Scheme Mandate Limit on November 25, 2022 that subsequently lapsed; or (ii) Shares available for grant under the 2024 Share Award Scheme, which is funded solely by existing Shares (the “**Calculation Methodology**”).

During the Reporting Period and based on the Calculation Methodology, options and awards in respect of 27,035,140 Shares were granted, utilizing the Scheme Mandate Limit, while options and awards in respect of 1,096,100 Shares were lapsed, which were returned to the Scheme Mandate Limit. The aforementioned grants are subject to the Cancellation and Re-grant Consents as of December 31, 2025.

Based on the Calculation Methodology and to provide a comprehensive and clear illustration of the Scheme Mandate Limit and Service Provider Sublimit since the refreshment date of November 25, 2022 and up to December 31, 2025, taking into account grants made in 2022, the movements in the Scheme Mandate Limit are set forth in the table below. The Service Provider Sublimit remained unchanged at 5,342,000 Shares.

	November 25, 2022	December 31, 2022	As of		June 30, 2024	December 31, 2024	June 30, 2025	December 31, 2025
			June 30, 2023	December 31, 2023				
Scheme Mandate Limit	38,204,000	38,486,000	39,451,000	40,632,100	40,951,850	41,391,491	14,890,639	15,452,451

The number of Shares that may be issued in respect of options, awards and RSUs granted under all effective incentive schemes of the Company during the Reporting Period is 27,035,140, which is subject to the Cancellation and Re-grant Consents as of December 31, 2025, representing 3.32% the weighted average number of Shares in issue (excluding treasury Shares) for the Reporting Period (i.e. 815,382,414 Shares).

EQUITY-LINKED AGREEMENTS

Share Incentive Schemes

Details of the ESOP, the RSU Scheme, the 2021 Share Option Scheme, the 2021 Share Award Scheme and the 2024 Share Award Scheme are set out above in this section on pages 62 to 75 of this annual report.

Issue of Warrants under the Warrant Subscription Agreement

On April 14, 2021, the Company and Alimera entered into an exclusive license agreement, a share purchase agreement and a warrant subscription agreement, pursuant to which Alimera agreed to grant the Group the licensed rights in relation to the licensed product in certain territories and to issue and sell 1,144,945 shares of Alimera for a total consideration of US\$10 million. In consideration thereof, the Group agreed to pay US\$10 million (equivalent to approximately RMB65,297,000) and issue 1,000,000 non-transferable warrants which would entitle Alimera to subscribe for up to 1,000,000 fully paid ordinary Shares at the exercise price of HK\$23.88 per Share.

On August 13, 2021, in accordance with the terms and conditions of the warrant subscription agreement dated April 14, 2021, the Company issued 1,000,000 warrants at a nominal consideration of HK\$1.00 to Alimera, conferring it rights to subscribe for an aggregate of 1,000,000 warrant Shares at the subscription price of HK\$23.88 per Share during the period of 48 months commencing from the date of issue of the warrants. For further details of the warrants issue, please refer to the Company's announcements dated April 14, 2021 and August 13, 2021, respectively. There was no exercise of warrants during the Reporting Period.

Save as disclosed in this annual report, no equity-linked agreements that will or may result in the Company issuing Shares or that require the Company to enter into any agreements that will or may result in the Company issuing Shares were entered into by the Group, or existed during the year ended December 31, 2025.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration during the year ended December 31, 2025. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the year ended December 31, 2025.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

During the Reporting Period, the Company repurchased a total of 3,863,500 Shares on the Stock Exchange for an aggregate consideration of HK\$17,697,268 before expenses. The repurchased 3,863,500 Shares have not yet been cancelled as of the date of this annual report. The repurchase was effectuated by the Board for the enhancement of shareholder value in the long term. Details of the Shares repurchased are as follows:

Month of purchase in 2025	Share repurchased No. of Shares purchased	Purchase consideration per Share		Aggregate consideration Paid (HKD)
		Highest price paid (HKD)	Lowest price paid (HKD)	
January 2025	534,000	4.63	3.71	2,174,693
February 2025	745,500	4.61	3.97	3,155,375
April 2025	2,174,000	5.42	4.09	10,217,680
May 2025	410,000	5.41	5.17	2,149,520
Total	3,863,500			17,697,268

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares) during the Reporting Period. As of December 31, 2025, 20,949,500 Shares were purchased and held in treasury by the Company. The Company intends to use the treasury Shares for potential financing, as incentives for eligible participant(s) under the effective share incentive plans of the Company and/or for other purposes in compliance with the Company's constitutional documents, the Listing Rules and any other applicable laws, rules and regulations.

SHARE CAPITAL AND SHARES ISSUED

Details of movements in the share capital of the Company for the year ended December 31, 2025 and details of the Shares issued during the year ended December 31, 2025 are set out in Note 25 to the consolidated financial statements in this annual report.

DEBENTURE ISSUED

The Group did not issue any debenture during the year ended December 31, 2025. (2024: nil)

BANK LOANS AND OTHER BORROWINGS

As of December 31, 2025, we recorded a loan of RMB158.2 million (December 31, 2024: RMB16.5 million). During the Reporting Period, we entered into loan agreements with banks. The borrowings bear interest at either a fixed rate of one-year Loan Prime Rate ("LPR") minus 0.35% or a floating rate based on one-year LPR minus 0.76% or 0.10%, with the floating rates reset every 12 months (2024: one-year LPR minus 0.35%). All such borrowings are guaranteed by other entities within the Group.

CONVERTIBLE BONDS

As of the date of this annual report, the Company has not issued any convertible bonds (December 31, 2024: nil).

LOAN AGREEMENT WITH COVENANTS RELATING TO SPECIFIC PERFORMANCE OF THE CONTROLLING SHAREHOLDERS

As of the date of this annual report, the Company has not entered into any loan agreement which contains covenants requiring specific performance of the controlling Shareholders.

DIVIDENDS

The Board does not recommend the distribution of a final dividend for the year ended December 31, 2025 (2024: nil).

Report of Directors

PERMITTED INDEMNITY

Pursuant to the Articles of Association and subject to the applicable laws and regulations, every Director shall be indemnified and secured harmless out of the assets and profits of the Company against all actions, costs, charges, losses, damages and expenses which they or any of them may incur or sustain in or about the execution of their duty in their offices.

The Company has arranged appropriate liability insurance to indemnify the Directors and senior management of the Company for their liabilities arising out of corporate activities. The insurance coverage will be reviewed on an annual basis.

DISTRIBUTABLE RESERVES

The Company may pay dividends out of the share premium account, retained earnings and any other reserves provided that immediately following the payment of such dividends, the Company will be in a position to pay off its debts as and when they fall due in the ordinary course of business.

As of December 31, 2025, the Company had distributable reserves of RMB3,680.7 million.

Details of movements in the reserves of the Group and the Company during the year ended December 31, 2025 are set out in the consolidated statement of changes in equity on page 89 and Note 36 to the consolidated financial statements in this annual report.

CHARITABLE DONATIONS

During the year ended December 31, 2025, the Group did not make any charitable donations (2024: nil).

PROPERTY, PLANT AND EQUIPMENT

Details of the movements in the property, plant and equipment of the Group during the Reporting Period are set out in Note 14 to the consolidated financial statements in this annual report.

USE OF PROCEEDS FROM LISTING AND PLACING

Use of Proceeds from the Listing

The Company was listed on the Main Board of the Stock Exchange on July 10, 2020. The total net proceeds raised from the Listing (after full exercise of over-allotment option and deducting the underwriting fees and related Listing expenses) amounted to approximately HK\$1,646.41 million. On September 11, 2020, the Company further announced to change the intended uses of the net proceeds. As of December 31, 2025, such net proceeds were utilized as follows in accordance with the intended uses:

Use of proceeds from Listing	Amount of net proceeds for planned applications (HK\$ million)	Percentage of total net proceed (%)	Unutilized net proceeds as of December 31, 2024 (HK\$ million)	Utilized net proceeds during the Reporting Period (HK\$ million)	Utilized net proceeds as of December 31, 2025 (HK\$ million)	Unutilized net proceeds as of December 31, 2025 (HK\$ million)	Expected time frame for unutilized amount
For the Core Product							
1. For funding the costs and expenses in connection with R&D personnel as well as the continuing R&D activities of OT-401	197.57	12.00%	99.27	8.42	106.72	90.85	by the end of 2028 ⁽¹⁾
2. For milestone payments of OT-401	49.39	3.00%	15.49	–	33.90	15.49	– ⁽²⁾
3. For the commercialization of OT-401	246.96	15.00%	–	–	246.96	–	–
For the other drug candidates, including OT-101, OT-301, OT-1001, OT-502, OT-202, OT-503 and OT-701							
1. For the continuing R&D activities of other drug candidates, including OT-101, OT-301, OT-1001, OT-502, OT-202, OT-503 and OT-701	562.42	34.16%	–	–	562.42	–	–
2. For milestone payments of our other in-licensed drug candidates	96.15	5.84%	22.47	–	73.68	22.47	by the end of 2027
3. For the further expansion of our sales and marketing team	164.64	10.00%	–	–	164.64	–	–
For the acquisition of 100% equity interest in Suzhou Xiaxiang	164.64	10.00%	–	–	164.64	–	–
For our working capital and other general corporate purposes	164.64	10.00%	–	–	164.64	–	–
Total	1,646.41	100.00%	137.23	8.42	1,517.60	128.81	

Notes:

- (1) As of the date of this annual report, there has been a delay in the expected timeline for certain uses of proceeds compared to the implementation plan as disclosed in our annual report for the year ended December 31, 2024. Such delay is not material and primarily relates to the continuing R&D activities of OT-401, as its phase IV post-marketing studies are expected to be conducted over a longer period and conclude by the end of 2028.
- (2) The remaining balance of RMB15.49 million was due to a reduction in milestone payments agreed by the parties.

As of December 31, 2025, all the unused net proceeds are held by the Company in short-term deposits with licensed banks or authorized financial institutions.

Report of Directors

Use of Proceeds from the Placing

In January 2021, 28,000,000 Shares of our Company have been placed to not less than six Independent Third Party places at a placing price of HK\$28.35 per Share. For details of the placing and subscription, please refer to the Company's announcements dated January 13, 2021 and January 22, 2021, respectively.

The net proceeds arising from the placing and subscription amounted approximately HK\$781.7 million, of which the intended uses were set out in the announcement of the Company dated January 22, 2021. The placing and subscription was undertaken to strengthen the Group's financial position and for the long term funding of its business, expansion and growth plan. As of December 31, 2025, the net proceeds from the placing and subscription were utilized as follows in accordance with the intended uses:

Use of proceeds from placing and subscription	Amount of net proceeds for planned applications (HK\$ million)	Percentage of total net proceeds (%)	Unutilized net proceeds as of December 31, 2024 (HK\$ million)	Utilized net proceeds during the Reporting Period (HK\$ million)	Utilized net proceeds as of December 31, 2025 (HK\$ million)	Unutilized proceeds as of December 31, 2025 (HK\$ million)	Expected time frame for unutilized amount
Expansion of the Company's commercial team in view of the proposed launch of its new therapies	234.51	30.00%	109.10	109.10	234.51	-	-
Funding of international multi-center clinical trials of the Company's therapies	273.60	35.00%	21.77	2.40	254.23	19.37	— ⁽¹⁾
OT-702 (Eylea biosimilar)	99.66	12.75%	-	-	99.66	-	-
OT-301 (NCX-470)	50.03	6.40%	-	-	50.03	-	-
OT-101 (low-concentration atropine)	43.78	5.60%	-	-	43.78	-	-
OT-1001 (Zerviate)	30.10	3.85%	21.77	2.40 ⁽¹⁾	10.73	19.37	— ⁽¹⁾
OT-202 (TKI)	50.03	6.40%	-	-	50.03	-	-
Building and development of new manufacturing facilities and equipment of Suzhou Xiixiang and active pharmaceutical ingredients manufacturing facilities	195.43	25.00%	-	-	195.43	-	-
Other general corporate purposes	78.17	10.00%	-	-	78.17	-	-
Total	781.71	100.00%	130.87	111.50	762.34	19.37	

Note:

- (1) The R&D of OT-1001 has been completed with a balance of RMB21.77 million as of December 31, 2024. During the Reporting Period, it incurred an additional follow-up expenses of HK\$2.40 million primarily for post-completion activities. Following the completion of these activities, the carrying balance for OT-1001 R&D costs was HK\$19.37 million as of December 31, 2025. Our Group does not expect to incur any material additional R&D expenses for OT-1001 in the future, as such R&D program has been completed.

As of December 31, 2025, all the unused net subscription proceeds have been deposited into the bank account(s) maintained by our Group.

SUBSIDIARIES

Particulars of the Company's subsidiaries are set out in Note 34 to the consolidated financial statements in this annual report.

EVENTS AFTER REPORTING PERIOD

Save as disclosed herein, there was no event which has occurred after the year ended December 31, 2025 and up to the date of this annual report that would cause material impact on the Group.

AGM AND CLOSURE OF REGISTER OF MEMBERS

The Company will arrange the time of convening the AGM as soon as practicable and in accordance with the Listing Rules. A notice convening the AGM will be published and dispatched to the Shareholders in the manner required by the Listing Rules and the Articles of Association in due course. Once the date of the AGM is finalized, the Company will publish the period of closure of register of members of the Company in the notice of the AGM.

CORPORATE GOVERNANCE

A report on the principal corporate governance practices adopted by the Company is set out in the Corporate Governance Report on pages 32 to 48 of this annual report.

PUBLIC FLOAT

Based on information that is publicly available to the Company and to the knowledge of the Directors, the Company has maintained the amount of public float as required under the Listing Rules throughout the Reporting Period and up to the date of this annual report.

TAX RELIEF AND EXEMPTION

The Directors are not aware of any tax relief and exemption available to the Shareholders by reason of their holding of the Company's listed securities.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Articles of Association or the relevant laws of the Cayman Islands where the Company is incorporated which would oblige the Company to offer new Shares on a pro-rata basis to existing Shareholders.

AUDITORS

The Shares were listed on the Stock Exchange on July 10, 2020, and the Company has no change in auditors since the Listing Date. The consolidated financial statements for the year ended December 31, 2025 have been audited by Deloitte Touche Tohmatsu, the auditor of the Company, who will retire at the conclusion of the AGM and being eligible, offer themselves for re-appointment. A resolution for the re-appointment of Deloitte Touche Tohmatsu as auditor of the Company will be proposed at the AGM.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

All references above to other sections, reports or notes in this annual report form part of this annual report.

By order of the Board

Ocumension Therapeutics

Dr. Lian Yong CHEN

Chairman and non-executive Director

Shanghai, the People's Republic of China, March 26, 2026

Independent Auditor's Report



TO THE SHAREHOLDERS OF OCUMENSION THERAPEUTICS
(incorporated in the Cayman Islands with limited liability)

OPINION

We have audited the consolidated financial statements of Ocumension Therapeutics (the "Company") and its subsidiaries (collectively referred to as "the Group") set out on pages 87 to 154 which comprise the consolidated statement of financial position as at December 31, 2025, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information and other explanatory information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at December 31, 2025, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with IFRS Accounting Standards issued by the International Accounting Standards Board ("IASB") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSA") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

KEY AUDIT MATTERS (continued)

Key audit matter	How our audit addressed the key audit matter
<p><i>Impairment assessment of intangible assets</i></p> <p>As at 31 December 2025, the Group had intangible assets of RMB1,076 million (2024: RMB1,058 million) for in-licenses and capitalised development costs which are not ready for use and the amount of such intangible assets were significant to the consolidated financial statements. These intangible assets are subject to impairment assessment annually, or when there are indicators that these intangible assets might be impaired. The impairment assessment is based on the recoverable amounts of the cash generating units to which the intangible assets are related to.</p> <p>We identified the impairment assessment of intangible assets as a key audit matter due to its involvement of significant management estimates and judgements, including assumptions relating to the expected achievement of drug development milestones and the outcome of new drug development, revenue growth rate and discount rate.</p>	<p>Our procedures in relation to the impairment assessment of intangible assets:</p> <ul style="list-style-type: none"> • Understanding the key controls relating to management's impairment assessment of intangible assets, and evaluating the design of these controls; • Assessing the inherent risk of material misstatement by considering the degree of estimation uncertainty and level of other inherent risk factors such as complexity, subjectivity, changes and susceptibility to management bias or fraud; • Assessing the reasonableness of management's identification of cash generating units based on the Group's accounting policies and business arrangements; • Inquiring management and inspecting the relevant supporting documents about the expected achievement of drug development milestones and the outcome of new drug development for each drug candidate; • Evaluating the appropriateness of the discounted cash flow model used by management to determine the fair value of intangible assets in the impairment assessment and the reasonableness of key assumptions used, including revenue growth rate and discount rate by comparing with the Group's business plan and market data; • Performing retrospective review by evaluating the outcome of prior period forecast to assess the effectiveness of management's estimation process; • Assessing sensitivities over the key assumptions including revenue growth rate and discount rate in the discounted cash flow model to consider the sufficiency of headroom between recoverable amount and carrying amount of each individual asset; and • Evaluating the adequacy of disclosure of key assumptions used in the impairment assessment in the consolidated financial statement.

Independent Auditor's Report

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS Accounting Standards as issued by the IASB and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSA's will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

As part of an audit in accordance with HKSAAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

Independent Auditor's Report

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Zhou Sze on the Practising Certificate issued by the HKICPA (practising certificate number: P07660).

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
March 26, 2026

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended December 31, 2025

	NOTES	2025 RMB'000	2024 RMB'000
Revenue	5	804,352	417,307
Cost of sales		(443,430)	(192,242)
Gross profit		360,922	225,065
Other income	6	10,460	46,738
Other gains and losses	7	367	1,430
Impairment losses under expected credit loss ("ECL") model, net of reversal		(653)	(651)
Selling and marketing expenses		(265,691)	(227,698)
Research and development expenses		(75,081)	(113,935)
Administrative expenses		(179,701)	(189,212)
Other expenses		(6,648)	(6,831)
Finance costs	8	(2,445)	(2,163)
Loss before tax	9	(158,470)	(267,257)
Income tax expense	10	(350)	(1,017)
Loss for the year		(158,820)	(268,274)
Other comprehensive income (expense): <i>Item that will not be reclassified to profit or loss:</i>			
Fair value gain (loss) on investments in equity instruments at fair value through other comprehensive income ("FVTOCI")		8,449	(47,450)
		8,449	(47,450)
Total comprehensive expense for the year		(150,371)	(315,724)
Loss per share			
– Basic and diluted (RMB)	13	(0.20)	(0.39)

Consolidated Statement of Financial Position

At December 31, 2025

	NOTES	31/12/2025 RMB'000	31/12/2024 RMB'000
Non-current assets			
Property, plant and equipment	14	421,468	435,016
Right-of-use assets	15	35,138	16,514
Intangible assets	16	2,600,807	2,438,120
Equity instruments at FVTOCI	17	7,507	11,546
Financial assets at fair value through profit or loss ("FVTPL")		1,566	1,388
Deposits and prepayments	18	73,429	92,425
		3,139,915	2,995,009
Current assets			
Inventories	19	63,917	45,518
Trade and other receivables	18	339,618	164,072
Other financial assets	20	145,042	–
Bank balances and cash	21	402,462	769,205
		951,039	978,795
Current liabilities			
Trade and other payables	22	191,588	141,334
Income tax payables		31	1,038
Borrowings	23	52,170	2,056
Lease liabilities	24	10,221	6,843
Contract liabilities	26	2,309	3,289
Deferred income		441	441
		256,760	155,001
Net current assets		694,279	823,794
Total assets less current liabilities		3,834,194	3,818,803
Capital and reserves			
Share capital	25	58	58
Reserves		3,680,689	3,773,559
Total equity		3,680,747	3,773,617
Non-current liabilities			
Lease liabilities	24	19,110	2,393
Contract liabilities	26	28,302	28,302
Borrowings	23	106,035	14,491
		153,447	45,186

The consolidated financial statements on pages 87 to 154 were approved and authorised for issue by the board of directors on March 26, 2026 and signed on its behalf by:

Ye LIU
DIRECTOR

Zhaopeng HU
DIRECTOR

Consolidated Statement of Changes in Equity

For the year ended December 31, 2025

	Share capital RMB'000 (note 25)	Share premium RMB'000	Other reserves RMB'000 (Note)	Treasury share RMB'000	FVTOCI revaluation reserve RMB'000	Share-based payment reserve RMB'000 (note 28)	Accumulated losses RMB'000	Total RMB'000
At January 1, 2024	48	7,625,549	(581,779)	(3)	154,753	442,978	(4,721,578)	2,919,968
Loss for the year	-	-	-	-	-	-	(268,274)	(268,274)
Other comprehensive expense for the year	-	-	-	-	(47,450)	-	-	(47,450)
Total comprehensive expense for the year	-	-	-	-	(47,450)	-	(268,274)	(315,724)
Disposal of investments in equity instruments at FVTOCI	-	-	-	-	(106,920)	-	106,920	-
Exercise of share options granted	*	35,756	-	-	-	(29,447)	-	6,309
Exercise of RSUs	-	4,507	-	*	-	(3,555)	-	952
Vest of share awards	-	100,576	-	1	-	(100,577)	-	-
Purchase of shares (note 25)	-	(95,568)	-	(1)	-	-	-	(95,569)
Cancellation of treasury shares (note 25)	*	-	-	*	-	-	-	-
Recognition of equity-settled share-based payments (note 28)	-	-	-	-	-	84,632	-	84,632
Forfeited equity-settled share-based payments	-	-	-	-	-	(7,141)	7,141	-
Issuance of ordinary shares to Alcon Pharmaceuticals Ltd. ("Alcon")	10	1,173,039	-	-	-	-	-	1,173,049
At December 31, 2024	58	8,843,859	(581,779)	(3)	383	386,890	(4,875,791)	3,773,617
Loss for the year	-	-	-	-	-	-	(158,820)	(158,820)
Other comprehensive income for the year	-	-	-	-	8,449	-	-	8,449
Total comprehensive income (expense) for the year	-	-	-	-	8,449	-	(158,820)	(150,371)
Disposal of investments in equity instruments at FVTOCI	-	-	-	-	(6,142)	-	6,142	-
Exercise of share options granted	*	26,763	-	-	-	(21,877)	-	4,886
Exercise of RSUs	-	117	-	*	-	(46)	-	71
Vest of share awards	-	92,470	-	1	-	(92,471)	-	-
Purchase of shares (note 25)	-	(16,394)	-	*	-	-	-	(16,394)
Recognition of equity-settled share-based payments (note 28)	-	-	-	-	-	68,938	-	68,938
Forfeited equity-settled share-based payments	-	-	-	-	-	(8,110)	8,110	-
At December 31, 2025	58	8,946,815	(581,779)	(2)	2,690	333,324	(5,020,359)	3,680,747

Note: Other reserves included 1) effect of put option granted to Suzhou Frontline BioVentures Venture Capital Fund II L.P. and Suzhou 6 Dimensions Venture Capital Partnership L.P. (collectively referred to as the "Onshore Investors") to convert their equity interests in a subsidiary to Ocumension Therapeutics (the "Company") preferred shares ("Share Purchase Option"); 2) differences between the carrying amounts of net assets attributable to the additional non-controlling interests at the date of issuance of subsidiary's equity and the relevant proceeds received; 3) deemed capital contribution upon granting of restricted shares or options to employees of subsidiary attributable to non-controlling interests; 4) effect of exercise of put option granted to non-controlling shareholders; 5) effect of deemed distribution of offshore investors arose from the difference between the fair value of the Series A Preferred Shares at the date of issuance and the consideration received by the Company; and 6) warrants granted to Alimera Sciences Inc. ("Alimera") to subscribe the ordinary shares of the Company.

* Represented the relevant amount less than RMB1,000.

Consolidated Statement of Cash Flows

For the year ended December 31, 2025

	2025 RMB'000	2024 RMB'000
OPERATING ACTIVITIES		
Loss before tax	(158,470)	(267,257)
Adjustments for:		
Bank interest income	(6,396)	(22,219)
Depreciation of property, plant and equipment	30,547	30,474
Depreciation of right-of-use assets	11,298	11,547
Amortisation of intangible assets	101,889	46,593
Impairment loss under ECL model, net of reversal	653	651
Financial costs	2,445	2,163
Share-based payments	68,938	84,632
Gain from changes in fair value of other financial assets	(3,089)	(450)
(Gain)/loss from changes in fair value of financial assets at FVTPL	(178)	160
Gain from early termination of leases	–	(25)
Net unrealised foreign exchange loss/(gains)	3,030	(3,418)
Other losses related to Nicox SA (“Nicox”)	–	612
Others	(154)	(156)
Operating cash flow before movements in working capital	50,513	(116,693)
Increase in trade and other receivables	(179,386)	(47,351)
Increase in inventories	(18,399)	(13,045)
Decrease in contract assets	–	8,418
Increase (decrease) in trade and other payables	44,318	(11,338)
(Decrease) increase in contract liabilities	(980)	1,501
Cash used in operations	(103,934)	(178,508)
Income tax paid	(1,357)	(318)
NET CASH USED IN OPERATING ACTIVITIES	(105,291)	(178,826)

Consolidated Statement of Cash Flows

For the year ended December 31, 2025

	NOTE	2025 RMB'000	2024 RMB'000
INVESTING ACTIVITIES			
Interest received from banks		7,322	23,513
Proceeds from disposal of			
– equity instruments at FVTOCI		12,488	308,870
Payment for investment in Nicox		–	(5,878)
Release of pledged bank deposits		–	4,300
Placement of term deposits		(25,000)	(150,000)
Release of term deposits		40,000	317,014
Payments for rental deposits		(356)	(832)
Refund of rental deposits		45	168
Receipt of asset-related government grants		–	7,121
Payment for property, plant and equipment		(28,880)	(47,098)
Payment of intangible assets		(224,482)	(183,045)
Redemption of other financial assets		863,048	80,450
Placement of other financial assets		(1,005,000)	(80,000)
Loan to employees		(1,600)	–
Redemption of loan to employees		957	1,330
NET CASH (USED IN) FROM INVESTING ACTIVITIES		(361,458)	275,913
FINANCING ACTIVITIES			
Proceeds from exercise of share options granted		4,886	29
Proceeds from exercise of RSUs		71	952
Payment on purchase of shares		(16,394)	(95,569)
Payment of lease liabilities		(9,827)	(13,497)
New bank loans raised		158,063	46,547
Repayment of borrowing		(16,405)	(150,000)
Interest paid		(2,358)	(2,249)
NET CASH FROM (USED IN) FINANCING ACTIVITIES		118,036	(213,787)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(348,713)	(116,700)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR		729,205	842,839
Effects of exchange rate changes		(3,030)	3,066
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	21	377,462	729,205

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

1. GENERAL INFORMATION

The Company is a public limited company incorporated in the Cayman Islands and its shares are listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") effective from July 10, 2020. The addresses of the registered office and principal place of business of the Company are disclosed in the "Corporate Information" section to the annual report.

The Company (together with its subsidiaries, collectively referred to as the "Group") is a specialty biopharmaceutical platform company committed to discovering (through either in-licensing or self-development), developing and commercializing innovative and best-in-class therapies for ophthalmic patients in the People's Republic of China (the "PRC").

The consolidated financial statements are presented in Renminbi ("RMB"), which is also the functional currency of the Company.

2. APPLICATION OF NEW AND AMENDMENTS TO IFRS ACCOUNTING STANDARDS

Amendments to IFRS Accounting Standards that are mandatorily effective for the current year

In the current year, the Group has applied the following amendments to IFRS Accounting Standards issued by the International Accounting Standards Board ("IASB") for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2025 for the preparation of the consolidated financial statements:

Amendments to IAS 21	Lack of Exchangeability
----------------------	-------------------------

The application of the amendments to IFRS Accounting Standards in the current year has had no material impact on the Group's financial position and performance for the current and prior periods and/or on disclosures set out in these consolidated financial statements.

New and Amendments to IFRS Accounting Standards in issue but not yet effective

The Group has not early applied the following new and amendments to IFRS Accounting Standards that have been issued but are not yet effective:

Amendments to IAS 21	Translation to a Hyperinflationary Presentation Currency ³
Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments ²
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature – dependent Electricity ²
Amendments to IFRS 10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture ¹
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards - Volume 11 ²
IFRS 18	Presentation and Disclosure in Financial Statements ³

¹ Effective for annual periods beginning on or after a date to be determined.

² Effective for annual periods beginning on or after January 1, 2026.

³ Effective for annual periods beginning on or after January 1, 2027.

2. APPLICATION OF NEW AND AMENDMENTS TO IFRS ACCOUNTING STANDARDS (continued)

New and Amendments to IFRS Accounting Standards in issue but not yet effective (continued)

Except for the new and amendments to IFRS Accounting Standards mentioned below, the directors of the Company anticipate that the application of all other amendments to IFRS Accounting Standards will have no material impact on the consolidated financial statements in the foreseeable future.

Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments

The amendments to IFRS 9 clarify the recognition and derecognition for financial asset and financial liability and add an exception which permits an entity to deem a financial liability to be discharged before the settlement date if it is settled in cash using an electronic payment system if, and only if certain conditions are met.

The amendments also provide guidance on the assessment of whether the contractual cash flows of a financial asset are consistent with a basic lending arrangement. The amendments specify that an entity should focus on what an entity is being compensated for rather than the compensation amount. Contractual cash flows are inconsistent with a basic lending arrangement if they are indexed to a variable that is not a basic lending risk or cost. The amendments state that, in some cases, a contingent feature may give rise to contractual cash flows that are consistent with a basic lending arrangement both before and after the change in contractual cash flows, but the nature of the contingent event itself does not relate directly to changes in basic lending risks and costs. Furthermore, the description of the term “non-recourse” is enhanced and the characteristics of “contractually linked instruments” are clarified in the amendments. The disclosure requirements in IFRS 7 in respect of investments in equity instruments designated at fair value through other comprehensive income are amended. In particular, entities are required to disclose the fair value gain or loss presented in other comprehensive income during the period, showing separately those related to investments derecognised during the reporting period and those related to investments held at the end of the reporting period. An entity is also required to disclose any transfers of the cumulative gain or loss within equity related to the investments derecognised during the reporting period. In addition, the amendments introduce the requirements of qualitative and quantitative disclosure of contractual terms that could affect the contractual cash flow based on a contingent event not directly relating to basic lending risks and cost.

The amendments are effective for annual reporting periods beginning on or after 1 January 2026, with early application permitted. The application of the amendments is not expected to have significant impact on the financial position and performance of the Group.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

2. APPLICATION OF NEW AND AMENDMENTS TO IFRS ACCOUNTING STANDARDS (continued)

New and Amendments to IFRS Accounting Standards in issue but not yet effective (continued)

IFRS 18 Presentation and Disclosure in Financial Statements

IFRS 18 Presentation and Disclosure in Financial Statements, which sets out requirements on presentation and disclosures in financial statements, will replace IAS 1 Presentation of Financial Statements. This new IFRS Accounting Standard, while carrying forward many of the requirements in IAS 1, introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. In addition, some IAS 1 paragraphs have been moved to IAS 8 and IFRS 7. Minor amendments to IAS 7 Statement of Cash Flows and IAS 33 Earnings per Share are also made.

IFRS 18, and amendments to other standards, will be effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 requires retrospective application with specific transition provisions. The application of the new standard is not expected to have significant impact on the financial performance and positions of the Group in terms of recognition and measurement. However, it is expected to affect the structure and presentation of the consolidated statement of profit or loss. Additional disclosures required for the Group's MPMs will be disclosed in a separate note to the consolidated financial statements.

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION

3.1 Basis of preparation of consolidated financial statements

The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards issued by the IASB. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange ("Listing Rules") and by the Hong Kong Companies Ordinance.

3.2 Material accounting policy information

Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and;
- has the ability to use its power to affect its returns.

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Basis of consolidation (continued)

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary.

Profit or loss and each component of other comprehensive income (expense) are attributed to the owners of the Company.

When necessary, adjustments are made to the financial information of subsidiaries to bring their accounting policies in line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

Asset acquisitions

When the Group acquires a group of assets and liabilities that do not constitute a business, the Group identifies and recognizes the individual identifiable assets acquired and liabilities assumed by allocating the purchase price first to financial assets/financial liabilities at the respective fair values, the remaining balance of the purchase price is then allocated to the other identifiable assets and liabilities on the basis of their relative fair values at the date of purchase. Such a transaction does not give rise to goodwill or bargain purchase gain.

Revenue from contracts with customers

Information about the Group's accounting policies relating to contracts with customers is provided in note 5.

The Group recognizes revenue when (or as) a performance obligation is satisfied, i.e. when "control" of the goods or services underlying the particular performance obligation is transferred to the customer.

A performance obligation represents a good or service (or a bundle of goods or services) that is distinct or a series of distinct goods or services that are substantially the same.

A contract liability represents the Group's obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Intangible assets

Internally-generated intangible assets-research and development expenditure

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

An internally-generated intangible asset arising from development activities (or from the development phase of an internal project) is recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible assets;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is recognised in profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses (if any), on the same basis as intangible assets that are acquired separately.

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Property, plant and equipment

Property, plant and equipment are tangible assets that are held for use in the production or supply of goods or services, or for administrative purposes (other than properties under construction as described below). Property, plant and equipment are stated in the consolidated statement of financial position at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any.

Property and plant in the course of construction for production, supply or administrative purposes are carried at cost, less any recognised impairment loss. Costs include any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, including costs of testing whether the related assets is functioning properly and, for qualifying assets, borrowing costs capitalised in accordance with the Group's accounting policy. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

Depreciation is recognised so as to write off the cost of items of assets other than properties under construction less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Impairment on property, plant and equipment and intangible assets

At the end of the reporting period, the Group reviews the carrying amounts of its property, plant and equipment and intangible assets with finite useful lives to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss (if any). Intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that they may be impaired.

The recoverable amount of property, plant and equipment and intangible asset are estimated individually. When it is not possible to estimate the recoverable amount individually, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

In testing a cash-generating unit for impairment, corporate assets are allocated to the relevant cash-generating unit when a reasonable and consistent basis of allocation can be established, or otherwise they are allocated to the smallest group of cash generating units for which a reasonable and consistent allocation basis can be established. The recoverable amount is determined for the cash-generating unit or group of cash-generating units to which the corporate asset belongs, and is compared with the carrying amount of the relevant cash-generating unit or group of cash-generating units.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or a cash-generating unit) for which the estimates of future cash flows have not been adjusted.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Impairment on property, plant and equipment and intangible assets (continued)

If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or a cash-generating unit) is reduced to its recoverable amount.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit or a group of cash-generating units) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or a cash-generating unit or a group of cash-generating units) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Cash and cash equivalents

Cash and cash equivalents presented on the consolidated statement of cash flows include:

- (a) cash, which comprises of cash on hand and demand deposits; and
- (b) cash equivalents, which comprises of short-term deposits (generally with original maturity of three months or less). Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

Share-based payment

Equity-settled share-based payment transactions

Share options/RSU/share awards granted to employees

Equity-settled share-based payments to employees are measured at the fair value of the equity instruments at the grant date.

The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed on a straight-line basis over the vesting period, based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payment reserve). At the end of the reporting period, the Group revises its estimate of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting conditions. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share-based payment reserve.

When share options and RSUs are exercised and share awards are vested, the amount previously recognised in share-based payment reserve will be transferred to share premium. When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognised in share-based payment reserve will be transferred to accumulated losses.

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Financial instruments

Financial assets and financial liabilities are recognised when a group entity becomes a party to the contractual provisions of the instrument. All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the market place.

Financial assets and financial liabilities are initially measured at fair value except for trade receivable arising from contracts with customers which are initially measured in accordance with IFRS 15.

The effective interest method is a method of calculating the amortized cost of a financial asset or financial liability and of allocating interest income and interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Financial assets

Classification and subsequent measurement of financial assets

Financial assets that meet the following conditions are subsequently measured at amortized cost:

- the financial asset is held within a business model whose objective is to collect contractual cash flows; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

The Group may irrevocably elect to present subsequent changes in fair value of an equity investment in other comprehensive income (expense) if that equity investment is neither held for trading nor contingent consideration recognized by an acquirer in a business combination to which IFRS 3 Business Combinations applies.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Financial instruments (continued)

Financial assets (continued)

Classification and subsequent measurement of financial assets (continued)

(i) Amortized cost and interest income

Interest income is recognised using the effective interest method for financial assets measured subsequently at amortized cost. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortized cost of the financial asset from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit-impaired.

(ii) Equity instruments designated as at FVTOCI

Investments in equity instruments at FVTOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognised in other comprehensive income (expense) and accumulated in "FVTOCI revaluation reserve"; and are not subject to impairment assessment.

Impairment of financial assets and other item subject to impairment assessment under IFRS 9

The Group performs impairment assessment under a ECL model on financial assets (including trade and other receivables and bank balances and cash) and other item (contract assets) which are subject to impairment assessment under IFRS 9. The amount of ECL is updated at each reporting dates to reflect changes in credit risk since initial recognition.

Assessments are done based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions.

The Group always recognizes lifetime ECL for trade receivables and contract assets. The ECL on these assets are assessed individually.

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other item subject to impairment assessment under IFRS 9 (continued)

Measurement and recognition of ECL

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data and forward-looking information. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risks of default occurring as the weights.

Generally, the ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and the cash flows that the Group expects to receive, discounted at the effective interest rate determined at initial recognition.

Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit impaired, in which case interest income is calculated based on amortized cost of the financial asset.

The Group recognizes an impairment gain or loss in profit or loss for all financial instruments by adjusting their carrying amount, with the exception of trade and other receivables and contract assets, where the corresponding adjustment is recognised through a loss allowance account.

Derecognition of financial assets

The Group derecognizes a financial asset only when the contractual rights to the cash flows from the assets expire.

On derecognition of a financial asset measured at amortised cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in profit or loss.

On derecognition of an investment in equity instrument which the Group has elected on initial recognition to measure at FVTOCI, the cumulative gain or loss previously accumulated in the FVTOCI revaluation reserve is not reclassified to profit or loss, but is transferred to accumulated losses.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Financial instruments (continued)

Financial liabilities and equity

Classification as debt or equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Group are recognised at the proceeds received, net of direct issue costs.

Repurchase of the Company's own equity instruments is recognised and deducted directly in equity. No gain or loss is recognised in profit or loss on the purchase, sale, issue or cancellation of the Company's own equity instruments.

Financial liabilities

All financial liabilities are subsequently measured at amortized cost using the effective interest method.

Financial liabilities at amortized cost

Financial liabilities including trade and other payables, borrowings are subsequently measured at amortized cost, using the effective interest method.

Derecognition of financial liabilities

The Group derecognizes financial liabilities when, and only when, the Group's obligations are discharged, cancelled or expired. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable, is recognised in profit or loss.

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Financial instruments (continued)

Derivative financial instruments

Warrants

Warrants issued as consideration for assets with parties other than employees are equity settled share-based payment transactions measured in accordance with IFRS 2 Share-based Payment. The fair value of warrants granted are measured at the fair value of the assets received, except where that fair value cannot be estimated reliably, in which case they are measured at the fair value of equity instruments granted, measured at the date the entity obtains the assets, with a corresponding increase in equity (other reserve).

Taxation

Income tax expense represents the sum of current and deferred income tax expense.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from loss before tax because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary difference to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit and at the time of the transaction does not give rise to equal taxable and deductible temporary differences.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary differences will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

3. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (continued)

3.2 Material accounting policy information (continued)

Taxation (continued)

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on either:

- (a) the same taxable entity; or
- (b) different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income (expense) or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income (expense) as directly in equity, respectively.

Foreign currencies

In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognised at the rates of exchanges prevailing on the dates of the transactions. At the end of the reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognised in profit or loss in the period in which they arise.

4. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCE OF ESTIMATION UNCERTAINTY

In the application of the Group's accounting policies, the directors of the Company are required to make judgement, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Critical judgement in applying accounting policies

The following is the critical judgement, apart from those involving estimation (see below), that the directors of the Company have made in the process of applying the Group's accounting policies and that have the most significant effect on the amounts recognised in the consolidated financial statements.

Research and development expenses

The research and development expense incurred by the Group is mainly related to service fees paid to outsourced service providers including contract research organisations ("CRO") and clinical trial sites (collectively referred to as the "Outsourced Service Providers").

Development expenses incurred on the Group's drug product pipelines are capitalised and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, the Group's intention to complete and the Group's ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the pipeline and the ability to measure reliably the expenditure during the development. Development expenses which do not meet these criteria are expensed when incurred. Management will assess the progress of each of the research and development projects and determine the criteria are met for capitalization.

During the year ended December 31, 2025, the Group incurred significant research and development expenses of RMB312 million (2024: RMB279 million) (before capitalisation), out of which, development costs amounted to RMB237 million (2024: RMB165 million) have been capitalised and research and development expenses amounted to RMB75 million (2024: RMB114 million) are expensed when incurred.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

4. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCE OF ESTIMATION UNCERTAINTY (continued)

Key source of estimation uncertainty

The key assumption concerning the future, and other key source of estimation uncertainty at the end of the reporting periods, that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

Impairment assessment of capitalised development costs

Capitalised development costs are stated at cost less accumulated amortization and impairment, if any. For intangible assets not yet available for use, the Group would assess the assets individually for impairment annually. In determining whether an asset is impaired, the Group has to exercise judgment and make estimation, particularly in assessing: (1) whether the carrying value of an asset can be supported by the recoverable amount, in the case of value in use, the net present value of future cash flows which are estimated based upon the continued use of the asset; and (2) the appropriate key assumptions to be applied in estimating the recoverable amounts including cash flow projections and an appropriate discount rate. When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the assets belongs. Changing the assumptions and estimates, including the discount rates, estimated average selling price or the growth rate in the cash flow projections, could materially affect the net present value used in the impairment test.

As at December 31, 2025, the carrying amounts of license rights and capitalised development costs not yet available for use is RMB1,076 million (2024: RMB1,058 million). Details of the assessment of impairment of intangible assets not yet available for use are disclosed in note 16.

5. REVENUE AND SEGMENT INFORMATION

(i) Disaggregation of revenue from contracts with customers

The following is an analysis of the Group's revenue:

	2025 RMB'000	2024 RMB'000
Timing of revenue recognition		
<i>At a point in time</i>		
Sales of ophthalmic products	756,175	384,345
Pharmaceutical products promotion services	6,514	15,706
Sales-based royalty income	34,018	7,175
Contract development and manufacturing ("CDMO") services	7,645	10,081
	804,352	417,307

(ii) Performance obligations for contracts with customers

Sales of ophthalmic products

For the sale of ophthalmic products, revenue is recognised when control of the goods has transferred, being when the goods have been delivered to the customer's specific location, i.e. when the products are delivered and titles have passed to customers upon receipt by customer. Following delivery, the customer has the primary responsibility when selling the goods and bears the risk of obsolescence and loss in relation to the goods. A receivable is recognised by the Group when the goods are delivered to customers as this represents the point in time at which the right to consideration becomes unconditional, as only the passage of time is required before payment is due. The normal credit term is 30 to 90 days upon delivery. Under the Group's standard contract terms, customers can only return or request refund if the goods delivered do not meet required quality standards. Therefore, the probability of significant reversal in revenue in relation to sales return in the future is remote.

Pharmaceutical products promotion services

For pharmaceutical products promotion services, the Group is an agent under the pharmaceutical products promotion services contracts as its performance obligation is mainly to arrange for sales and/or delivery of pharmaceutical products supplied by another parties. In this regard, the Group does not control the products provided by another party before those goods sold and delivered to the end customers. The contracts of pharmaceutical products promotion services may contain variable consideration on sales basis. Accordingly, revenue is recognised at a point in time when the Group satisfies its obligation to arrange for sales and/or delivery of pharmaceutical products pursuant to the service contracts. The normal credit term is 30 to 45 days. Payment for services is not due from the customer until the Group's customer has received settlements for its sales or accepted the compliance report for promotion activities, as appropriate, and therefore a contract asset is recognised at the point of time in which the services are performed. No further obligation is borne by the Group after the promotion services have been completed.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

5. REVENUE AND SEGMENT INFORMATION (continued)

(ii) Performance obligations for contracts with customers (continued)

Sales-based royalty income

The contracts in relation to royalty income contain variable consideration. The Group grants its license right to a customer for product sales in exchange for sales-based royalty income. The income is based on the profit margin of each sale and is recognised at a point of time upon the customer completes its sales. Such income is settled by month with the normal credit period of 60 days.

CDMO services

The Group starts to earn revenues by providing CDMO services to its customer through fee-for-service ("FFS") contracts. Under FFS method, the contracts usually have multiple deliverable units, which are generally in the form of reports, samples and/or products, each with individual selling price specified within the contract. The Group identifies each deliverable unit as a separate performance obligation and recognizes FFS revenue of contractual elements at the point in time upon the units delivered.

(iii) Transaction price allocated to the remaining performance obligation for contracts with customers

All of the Group's remaining performance obligations for contracts with customers are for periods of one year or less. As permitted under IFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

Segment information

The Group's chief operating decision maker ("CODM"), being the executive directors of the Company, regularly reviews revenue by products; however, no other discrete information was provided. In addition, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing performance as a whole. Hence, no further segment information other than entity wide information was presented.

No analysis of the Group's assets and liabilities by operating segments is disclosed as it is not regularly provided to the CODM for review.

All revenue from external customers is attributed to the Group and RMB798,862,000 (2024: RMB413,759,000) of revenue was derived from the PRC. All non-current assets of the Group are located in the PRC.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

5. REVENUE AND SEGMENT INFORMATION (continued)

Information about major customers

Revenue from customers contributing over 10% of the total sales of the Group are as follows:

	2025 RMB'000	2024 RMB'000
Customer A (note)	652,883	305,002

Note: revenue on sales of ophthalmic products

6. OTHER INCOME

	2025 RMB'000	2024 RMB'000
Bank interest income	6,396	22,219
Compensation from Alcon (note i)	–	21,684
Government grant income (note ii)	3,042	1,703
Others	1,022	1,132
	10,460	46,738

Notes:

- (i) The amount represents the compensation from Alcon for potential higher than expected stock in the trade of a specific commercial product in relation to the original distributor of Alcon continuing to sell the inventory after Ocumension acquired the commercialization right of the commercial product.
- (ii) Government grants include unconditional subsidies from the PRC government which are specifically for research and development activities, employment support and training, innovation and development support.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

7. OTHER GAINS AND LOSSES

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Net foreign exchange (loss)/gain	(2,900)	1,919
Gain from changes in fair value of other financial assets	3,089	450
Fair value gain/(loss) of financial assets at FVTPL	178	(160)
Other losses related to Nicox	–	(612)
Others	–	(167)
	367	1,430

8. FINANCE COSTS

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Interest expense on lease liabilities	971	641
Interest expenses on borrowing	1,474	1,522
	2,445	2,163

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

9. LOSS BEFORE TAX

	2025 RMB'000	2024 RMB'000
Loss before tax for the year has been arrived at after charging:		
Directors' emoluments (note 11)	27,937	41,205
Other Staff costs:		
– salaries and other benefits	155,815	167,641
– discretionary bonus (note)	47,885	38,980
– retirement benefit scheme contributions	18,653	16,183
– share-based payments	50,867	54,154
Total staff costs	301,157	318,163
Depreciation of property, plant and equipment	30,547	30,474
Depreciation of intangible assets	101,889	46,593
Depreciation of right-of-use assets	11,298	11,547
Cost of inventory recognised as an expense	306,668	157,190
Write-down of inventories	3,061	1,886
Auditor's remuneration:		
– audit-related service	2,970	2,890
– non-audit related service	1,268	1,920
	4,238	4,810

Note: Discretionary bonus is determined based on their duties and responsibilities of the relevant individuals within the Group and the Group's performance.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

10. INCOME TAX EXPENSE

	2025 RMB'000	2024 RMB'000
Current tax – Hong Kong	104	420
Current tax – the PRC	–	597
Withholding tax – the PRC	211	–
Under provision for prior years	35	–
	350	1,017

The Company was incorporated in the Cayman Islands and is exempted from income tax.

Ocumension (Hong Kong) Limited (“Ocumension Hong Kong”) generated royalty income during the years ended December 31, 2025 and 2024. Under the two-tiered profits tax rates regime of Hong Kong Profits Tax, the qualifying group entity is calculated at 8.25% on the first HK\$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK\$2 million.

Pursuant to the Enterprise Income Tax Law and Implementation Regulations of the Law of the PRC, the applicable tax rate of the PRC subsidiaries is 25% for both years.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

10. INCOME TAX EXPENSE (continued)

The tax charge for the reporting period can be reconciled to the loss before tax per the consolidated statements of profit or loss and other comprehensive income as follows:

	2025 RMB'000	2024 RMB'000
Loss before tax	(158,470)	(267,257)
Tax charge at PRC EIT rated 25%	(39,618)	(66,814)
Tax effect of expense not deductible for tax purpose	25,560	37,094
Tax effect of income not taxable for tax purpose	(62,804)	(37,964)
Tax effect of tax losses not recognised	77,201	69,539
Utilization of tax loss not recognised	(414)	–
Tax effect of deductible temporary differences not recognised	451	–
Utilisation of tax effect of deductible temporary differences not recognised	–	(375)
Effect of different tax rate of subsidiary operating in other jurisdiction	(272)	(463)
Withholding tax on overseas interest income	211	–
Over provision in respect of prior year	35	–
Tax charge for the year	350	1,017

At December 31, 2025, the Group has unrecognised deductible temporary differences of RMB40,847,000 (2024: RMB39,043,000). In the opinion of the directors of the Company, no deferred tax asset is recognised in relation to such deductible temporary differences as it is not probable that taxable profit will be available against which the deductible temporary differences can be utilized.

At December 31, 2025, the Group has unrecognised tax losses of approximately RMB1,482,390,000 (2024: RMB1,188,480,000). No deferred tax asset has been recognised in respect of the tax losses due to the unpredictability of future profit streams.

The unrecognised tax losses will be carried forward and expire in years as follows:

	2025 RMB'000	2024 RMB'000
2025	-	9,730
2026	69,175	69,175
2027	128,885	128,885
2028	306,554	308,211
2029	355,012	355,792
2030	409,286	103,209
2031	106,951	106,951
2032	106,527	106,527
	1,482,390	1,188,480

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

10. INCOME TAX EXPENSE (continued)

For the purpose of presentation in the consolidated statement of financial position, certain deferred tax assets and liabilities have been offset. The following is the analysis of the deferred tax balances for financial reporting purposes:

	2025 RMB'000	2024 RMB'000
Deferred tax assets	6,978	2,248
Deferred tax liabilities	(6,978)	(2,248)
	-	-

As at December 31, 2025, the carrying amounts of right-of-use assets and lease liabilities which are subject to the deferred taxes amounted to RMB27,912,000 (2024: RMB8,991,000) and RMB29,331,000 (2024: RMB9,236,000) respectively, in which the Group recognised the related deferred tax assets and deferred tax liabilities of RMB6,978,000 (2024: RMB2,248,000) and RMB6,978,000 (2024: RMB2,248,000) respectively.

11. DIRECTORS' AND CHIEF EXECUTIVE OFFICER'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES

Directors' and chief executive's remuneration for the year, disclosed pursuant to the applicable Listing Rules and the Hong Kong Companies Ordinance, is as follows:

	Fees RMB'000	Salaries and other benefits RMB'000	Retirement benefit scheme contributions RMB'000	Discretionary bonus RMB'000	Total RMB'000
For the year ended December 31, 2025					
<i>Executive directors:</i>					
Mr. Ye LIU (Chief Executive Officer) (note i)	-	4,386	323	1,766	6,475
Dr. Zhaopeng HU (note ii)	-	2,028	42	222	2,292
<i>Non-executive directors:</i>					
Dr. Lian Yong CHEN (Chairman of the Board)	-	-	-	-	-
Dr. Wei LI	-	-	-	-	-
Mr. Yanling CAO	-	-	-	-	-
<i>Independent non-executive directors:</i>					
Mr. Ting Yuk Anthony WU	733	-	-	-	733
Mr. Yiran HUANG	183	-	-	-	183
Mr. Zhenyu ZHANG	183	-	-	-	183
	1,099	6,414	365	1,988	9,866

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

11. DIRECTORS' AND CHIEF EXECUTIVE OFFICER'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES (continued)

	Fees <i>RMB'000</i>	Salaries and other benefits <i>RMB'000</i>	Retirement benefit scheme contributions <i>RMB'000</i>	Discretionary bonus <i>RMB'000</i>	Total <i>RMB'000</i>
For the year ended December 31, 2024					
<i>Executive directors:</i>					
Mr. Ye LIU (Chief Executive Officer) (note i)	–	4,504	6	1,790	6,300
Dr. Zhaopeng HU (note ii)	–	2,058	47	1,227	3,332
<i>Non-executive directors:</i>					
Dr. Lian Yong CHEN (Chairman of the Board)	–	–	–	–	–
Dr. Wei LI	–	–	–	–	–
Mr. Yanling CAO	–	–	–	–	–
Ms. Yumeng WANG (note iii)	–	–	–	–	–
<i>Independent non-executive directors:</i>					
Mr. Ting Yuk Anthony WU	729	–	–	–	729
Mr. Yiran HUANG	183	–	–	–	183
Mr. Zhenyu ZHANG	183	–	–	–	183
	1,095	6,562	53	3,017	10,727

Notes:

- i. Mr. Ye LIU was granted with share options, restricted ordinary shares, RSUs and share awards in respect of his service to the Group. During the year ended December 31, 2025, RMB17,209,000 (2024: RMB29,530,000) was recognised as share-based payments in the consolidated statement of profit or loss and other comprehensive income and not included in the tables above. Details are set out in note 28.
- ii. Dr. Zhaopeng HU was granted with share options, restricted ordinary shares, RSUs and share awards in respect of his service to the Group. During the year ended December 31, 2025, RMB862,000 (2024: RMB948,000) was recognised as share-based payments in the consolidated statement of profit or loss and other comprehensive income and not included in the tables above. Details are set out in note 28.
- iii. Ms. Yumeng WANG ceased to be the non-executive director on October 21, 2024.

The executive directors' emoluments shown above were for their services as directors of the Company in connection with the management of the affairs of the Company and Group.

The independent non-executive directors' emoluments shown above were for their services as directors of the Company.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

11. DIRECTORS' AND CHIEF EXECUTIVE OFFICER'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES (continued)

Mr. Ye LIU is also the chief executive of the Company, and his emoluments disclosed above included those services rendered by him as the chief executive.

Discretionary bonus is determined based on their duties and responsibilities of the relevant individuals within the Group and the Group's performance.

During both years, no emoluments were paid by the Group to any of the directors or chief executive of the Group as an inducement to join or upon joining the Group or as compensation for loss of office.

There was no arrangement under which a director of the Company or the chief executive waived or agreed to waive any remuneration during both years.

Five highest paid employees

The five highest paid individuals of the Group during the year included two directors (2024: two directors) of the Company, details of whose remuneration are set out above. Details of the remunerations for the year of the remaining three (2024: three) highest paid in employees who are neither a director nor chief executive of the Company are as follow:

	2025 RMB'000	2024 RMB'000
Salaries and other benefits	4,433	3,886
Discretionary bonus (note)	70	721
Retirement benefit scheme contributions	214	212
Share-based payments	2,629	4,317
	7,346	9,136

Note: Discretionary bonus is determined based on their duties and responsibilities of the relevant individuals within the Group and the Group's performance.

The emoluments of these employees (excluding two directors (2024: two directors)) are within the following bands:

	2025 No. of employees	2024 No. of employees
Hong Kong Dollars ("HK\$") HK\$2,000,001 to HK\$2,500,000	1	–
HK\$2,500,001 to HK\$3,000,000	2	–
HK\$3,500,001 to HK\$4,000,000	–	3
	3	3

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

12. DIVIDENDS

No dividend was paid or declared during the year ended December 31, 2025, nor has any dividend been proposed since the end of the reporting period (2024: nil).

13. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to the owners of the Company is based on the following data:

	2025	2024
Loss:		
Loss for the year attributable to the owners of the Company for the purpose of basic and diluted loss per share (RMB'000)	(158,820)	(268,274)
Number of shares:		
Weighted average number of ordinary shares for the purpose of basic and diluted loss per share calculation	791,198,269	683,806,944

The computation of basic and diluted loss per share for the reporting period excluded the shares held by Coral Incentivization Limited for unexercised RSUs, the shares held by Computershare Hong Kong Trustees Limited ("Computershare") for unvested share awards and treasury shares held in the broker account of the Company.

The computation of diluted loss per share for the years ended December 31, 2025 and 2024 did not assume the exercise of share options and RSUs, the vesting of share awards and the exercise of warrants since their assumed exercise or vesting would result in a decrease in loss per share.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

14. PROPERTY, PLANT AND EQUIPMENT

	Leasehold improvement RMB'000	Furniture, fixtures and equipment RMB'000	Plant and Buildings RMB'000	Construction in process RMB'000	Total RMB'000
COST					
At January 1, 2024	13,489	137,980	245,147	86,220	482,836
Additions	1,723	(6,202)	–	25,621	21,142
Transfers	–	14,966	3,311	(18,277)	–
Disposals	–	(387)	–	–	(387)
At December 31, 2024	15,212	146,357	248,458	93,564	503,591
Additions	395	341	–	16,263	16,999
Transfers	–	11,150	2,911	(14,061)	–
At December 31, 2025	15,607	157,848	251,369	95,766	520,590
DEPRECIATION					
At January 1, 2024	5,805	23,720	8,946	–	38,471
Provided for the year	2,328	15,686	12,460	–	30,474
Disposals	–	(370)	–	–	(370)
At December 31, 2024	8,133	39,036	21,406	–	68,575
Provided for the year	2,109	16,375	12,063	–	30,547
At December 31, 2025	10,242	55,411	33,469	–	99,122
CARRYING VALUES					
At December 31, 2025	5,365	102,437	217,900	95,766	421,468
At December 31, 2024	7,079	107,321	227,052	93,564	435,016

The above items of property, plant and equipment except for construction in process, after taking into account of the residual value, are depreciated on a straight-line basis at the following rate per annum:

Leasehold improvement	Over the shorter of the terms of the leases or 10%
Furniture, fixtures and equipment	10 – 33%
Plant and Buildings	5%

Construction in process mainly relates to the manufacture site in Suzhou. During the current year, the Group has additions of RMB16,999,000 (2024: RMB21,142,000) after deducting government grants of RMB nil (2024: RMB6,680,000).

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

15. RIGHT-OF-USE ASSETS

	2025 RMB'000	2024 RMB'000
Carrying amount		
Vehicles	239	8
Properties	27,673	8,983
Leasehold lands	7,226	7,523
	35,138	16,514
Depreciation for the year		
Vehicles	114	103
Properties	10,887	11,147
Leasehold lands	297	297
	11,298	11,547
Expense relating to short-term and low-value assets leases	3,011	1,304
Total cash outflow for leases	14,128	15,442
Additions to right-of-use assets	30,158	8,898
Termination of right-of-use assets	–	(4,123)
Modification of right-of-use assets	(236)	–

For both years, the Group leases various properties, lands and vehicles for its operations. Lease contracts are entered into for fixed term of 1 month to 30 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. There were no extension or termination options in the current lease contracts. In determining the lease term and assessing the length of the non-cancellable period, the Group applies the definition of a contract and determines the period for which the contract is enforceable.

As at December 31, 2025, lease liabilities of RMB29,331,000 are recognised with related right-of-use assets of RMB27,912,000 (2024: lease liabilities of RMB9,236,000 are recognised with related right-of-use assets of RMB8,991,000). The lease agreements do not impose any covenants other than the security interests in the leased assets are held by the lessor. Leased assets may not be used as security for borrowing purposes.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

16. INTANGIBLE ASSETS

	Software License <i>RMB'000</i>	Supplier Relationship <i>RMB'000</i>	License rights and capitalised development costs <i>RMB'000</i>	Total <i>RMB'000</i>
COST				
At January 1, 2024	14,928	–	1,180,884	1,195,812
Additions	1,977	–	164,525	166,502
Acquisition from Alcon	–	–	1,178,030	1,178,030
At December 31, 2024	16,905	–	2,523,439	2,540,344
Additions	362	27,496	236,718	264,576
At December 31, 2025	17,267	27,496	2,760,157	2,804,920
AMORTISATION AND IMPAIRMENT				
At January 1, 2024	4,279	–	51,352	55,631
Charge for the year	2,948	–	43,645	46,593
At December 31, 2024	7,227	–	94,997	102,224
Charge for the year	2,183	225	99,481	101,889
At December 31, 2025	9,410	225	194,478	204,113
CARRYING VALUES				
At December 31, 2025	7,857	27,271	2,565,679	2,600,807
At December 31, 2024	9,678	–	2,428,442	2,438,120

Except for certain license rights and capitalised development costs not yet available for use, intangible assets are amortized on a straight-line basis over the following periods:

License rights	10 – 18 years
Software license	10 years
Supplier relationship	10 years

16. INTANGIBLE ASSETS (continued)**Impairment assessment**

As at December 31, 2025, the management determined that there is no impairment on the license rights and development costs not yet available for use with the carrying amount of RMB1,075,651,000 (2024: RMB1,058,081,000).

Intangible assets not yet ready for use are tested annually based on the recoverable amount of the cash-generating unit to which the intangible asset is related. The appropriate cash-generating unit is at the product level. The annual impairment test was performed for each drug by the management team to estimate the value in use as the recoverable amount of the drug. The value in use is estimated using discounted cash flow approach. The management determined the recoverable amount of the intangible assets based on the following approach and key assumptions:

- cash inflows are generated for each drug based on the progress of clinical development and regulatory approval, commercial ramp up to reach expected peak revenue potential, and up to the end of the exclusivity for the product. The estimated revenue of each drug is based on the management's estimate of timing of commercialization. The costs and operating expenses are estimated as a percentage over the revenue forecast period based on the current margin levels of comparable companies with adjustments made to reflect the expected future price changes. The management considers the length forecast period is appropriate because it generally takes longer for the Company to generate positive cash flows, compared to companies in other industries, especially when the related products are under clinical trial. Hence, the management believes that a forecast period for the cash-generating unit longer than five years is justifiable and consistent with industry practice; and
- The discount rate used is pre-tax and reflects specific risks relating to the relevant products that would be considered by market participants.

The range of certain key assumptions used for value in use calculation as of December 31, 2025 and 2024 are as follows:

	2025	2024
Pre-tax discount rate	17.4%~20.3%	17.8%~19.8%
Expected compound annual revenue growth rate	15.9%~44.9%	13.2%~34.7%

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

16. INTANGIBLE ASSETS (continued)

Impairment assessment (continued)

In addition to the aforesaid key assumptions, when testing the intangible assets not yet ready for use, our management also took into the account (i) the expected market penetration rate, which was based on the expected selling conditions considering the features of marketing and technology development, and was reflected in the expected compound annual revenue growth rate; and (ii) the expected success rate of commercialization by reference to market prevailing practices in the pharmaceutical industry, development of technologies and related regulations from administrations.

The intangible assets' total recoverable amount above their aggregated carrying amount (headroom) as at December 31, 2025 and 2024 are as follows:

	2025 RMB'000	2024 RMB'000
Recoverable amount	2,521,306	3,626,440
Headroom	1,444,569	2,568,359

17. EQUITY INSTRUMENTS AT FVTOCI

	2025 RMB'000	2024 RMB'000
Listed equity securities in the United States of America ("US")	–	5,367
Listed equity securities in France	7,507	6,179
	7,507	11,546

The above listed equity investments represent ordinary shares of listed equities in the US and France, EyePoint Pharmaceuticals, Inc. ("EyePoint") (NASDAQ: EYPT) and Nicox (Euronext Growth Paris: ALCOX). These investments are not held for trading, instead, they are held for long-term strategic purposes. The directors of the Company have elected to designate these investments in equity instruments as at FVTOCI as they believe that recognising short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for long-term purposes and realising their performance potential in the long run.

17. EQUITY INSTRUMENTS AT FVTOCI (continued)

Included in listed equity investment above is the Group's investment in Nicox with a carrying amount of RMB7,507,000, as at December 31, 2025 (December 31, 2024: carrying amount of EyePoint at RMB5,367,000 and Nicox at RMB6,179,000 respectively).

During the year ended December 31, 2025, the Group disposed of a total of 100,221 shares of EyePoint at an aggregate consideration of approximately RMB12,488,000 (equivalent to approximately US\$1,770,000) The Company transferred RMB6,142,000 cumulative gain previously accumulated in the FVTOCI revaluation reserve to accumulated losses.

For the year ended December 31, 2025, the fair value loss on investment in equity instruments at FVTOCI were recognised in other comprehensive income (expense) amounted to approximately income of RMB8,449,000 (2024: expense of RMB47,450,000), which consisted of the fair value gain on EyePoint of approximately RMB7,121,000 (2024: expense of RMB59,609,000), fair value gain on Alimera of nil (2024: gain of RMB10,797,000) and fair value gain on Nicox of approximately RMB1,328,000 (2024: gain of RMB1,362,000).

Details of fair value measurement are set out in Note 33.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

18. TRADE AND OTHER RECEIVABLES

Details of trade and other receivables are as follows:

	2025 RMB'000	2024 RMB'000
Trade receivables	325,110	125,688
Less: Allowance for credit loss	(1,970)	(1,427)
	323,140	124,261
Prepayments for		
– research and development expenses for projects (note a)	61,181	83,240
– acquisition of property, plant and equipment	218	1,599
– selling and marketing expenses	428	1,189
– inventories	–	20,604
Utility and rental deposits	4,130	4,771
Interest receivable	654	1,580
Value added tax recoverable	9,675	10,311
Others (note b)	13,987	9,198
Less: Allowance for credit loss	(366)	(256)
	413,047	256,497
Analysis as:		
Current	339,618	164,072
Non-current (note c)	73,429	92,425
	413,047	256,497

Notes:

- a) The Company made prepayments for research and development expenses for projects carried out by collaborators or contracted research organizations. Certain of the payments will be recognised as intangible assets in the future periods as the relevant pipelines have met the capitalization criteria in accordance with IAS 38 Intangible Assets as at the reporting period ended and classified as non-current assets.
- b) The amount mainly includes the receivable for government subsidy and loan to employees.
- c) The non-current portion mainly includes the prepayments for development costs, acquisition of property, plant and equipment, loan to employees and certain amount of value added tax recoverable expected to realize beyond twelve months at the end of the reporting period.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

18. TRADE AND OTHER RECEIVABLES (continued)

The Group allows an average credit period of 30 to 90 days to its trade customers, and the credit terms of certain trade customers are based on the timing of their actual sales. The following is an aged analysis of trade receivable, presented based on invoice date:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
0-90 days	324,959	125,470
91-180 days	151	218
	325,110	125,688

As at December 31, 2025, included in the Group's trade receivables balance are debtors with aggregate carrying amount of RMB151,000 (2024: RMB218,000) which are past due, of which none were overdue by more than 90 days as of the reporting date. The Group maintains adequate credit policy to access the credit quality of the customers and closely monitored to minimise any credit risk associated with the trade debtors. The Group's customers have good repayment history during the current year, and strong financial capacity as they are the subsidiaries of large listed corporate in the PRC.

Details of impairment assessment of trade receivables and other receivables are set out in note 33.

19. INVENTORIES

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Raw materials and consumables	11,805	10,581
Work in progress	770	808
Finished goods	51,342	34,129
	63,917	45,518

20. OTHER FINANCIAL ASSETS

The other financial assets measured at FVTPL of the Group are short term investments issued by banks with no predetermined or guaranteed return and are principal protected (the "Financial Products") for the years ended December 31, 2025 and 2024. The Financial Products are with expected rates of return (not guaranteed), depending on the market price of underlying financial instruments, including bonds, debentures and other financial assets. As of December 31, 2025, the amount of unredeemed Financial Products was RMB145,042,000 (2024: all of the Financial Products have been redeemed).

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

21. BANK BALANCES AND CASH

	2025 RMB'000	2024 RMB'000
Cash at bank	147,462	255,118
Term deposits	255,000	514,087
	402,462	769,205
Analysed as:		
Cash and cash equivalents	377,462	729,205
Term deposits with maturity date between three months to one year (note a)	25,000	40,000
	402,462	769,205

Notes:

- (a) The term deposits are under the Group's rights of early redemption at its principal before the maturity date. In the event of early withdrawal prior to maturity, a prevailing current account interest rate would be offered instead of the term deposits interest rate without any penalty.

Bank balances carry interests at market rates ranging as follows per annum:

	2025	2024
Cash at bank	nil to 1.150%	nil to 1.150%
Term deposits	1.40% to 1.85%	1.05% to 5.25%

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

22. TRADE AND OTHER PAYABLES

	2025 RMB'000	2024 RMB'000
Trade payables	68,331	34,419
Payables and accruals for		
– research and development expenses for projects (note a)	8,087	10,506
– intangible assets	56,722	37,612
– legal and professional fee	4,716	3,145
– selling and marketing expenses	17,041	8,768
– construction payables (note b)	4,951	17,978
– government grants received on behalf of the employees	76	3,855
– others	5,414	2,814
Other tax payables	4,174	2,594
Payroll payables	22,076	19,643
	191,588	141,334

Notes:

- a) Amount included service fees payable to outsourced service providers, including CRO and clinical trial sites.
- b) The construction payables mainly relate to the construction for manufacture site in Suzhou, the PRC.

The average credit period purchases of goods/services of the Group is within 60 days. Ageing analysis of the Group's trade payables based on the invoice dates at the end of the reporting period is as follows:

	2025 RMB'000	2024 RMB'000
0 – 30 days	62,241	30,888
31 – 60 days	4,970	2,798
More than 60 days	1,120	733
	68,331	34,419

23. BORROWINGS

	2025 RMB'000	2024 RMB'000
Guaranteed bank loans	158,205	16,547

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

23. BORROWINGS (continued)

The carrying amounts of the above borrowings are analysed based on contractual repayment date as follows:

	2025 RMB'000	2024 RMB'000
The carrying amounts of the borrowings are repayable:		
Within one year	52,170	2,056
Within a period of more than one year but not exceeding two years	52,259	4,112
Within a period of more than two years but not exceeding five years	53,776	10,379
	158,205	16,547
Less: Amount due for settlement with 12 months shown under current liabilities	(52,170)	(2,056)
Amount due for settlement after 12 months shown under non-current liabilities	106,035	14,491

Subsidiaries of the Group entered into loan agreements with banks. The interest rates are either fixed at one-year Loan Prime Rate ("LPR") minus 0.35% (2024: 0.35%) or floating, reset every 12 months, based on one-year LPR minus 0.76% or 0.10% (2024: one-year LPR minus 0.35%). The borrowings are guaranteed by the group entities.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

24. LEASE LIABILITIES

	2025 RMB'000	2024 RMB'000
Lease liabilities payable:		
Within one year	10,221	6,843
Within a period of more than one year but not exceeding two years	11,815	1,367
Within a period of more than two years but not exceeding five years	7,295	1,026
	29,331	9,236
Less: Amount due for settlement with 12 months shown under current liabilities	(10,221)	(6,843)
Amount due for settlement after 12 months shown under non-current liabilities	19,110	2,393

The weighted average incremental borrowing rates applied to lease liabilities range from 3.0% to 3.95% (2024: from 3.6% to 4.7%).

25. SHARE CAPITAL

	Number of shares	Share capital USD'000
Ordinary shares		
Ordinary shares of US\$0.00001 each		
Authorized		
At December 31, 2024 and January 1, 2025 and December 31, 2025	5,000,000,000	50

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

25. SHARE CAPITAL (continued)

	Number of shares	Amount USD'000	Equivalent amount of ordinary shares RMB'000
Issued and fully paid			
At January 1, 2024	690,903,850	7	48
Exercise of share options granted	4,711,000	*	*
Purchase of shares (note i)	–	–	–
Cancellation of shares	(1,960,000)	*	*
Issuance of ordinary shares to Alcon	139,159,664	1	10
At December 31, 2024	832,814,514	8	58
Exercise of share options granted	3,517,400	*	*
Purchase of shares (note i)	–	–	–
At December 31, 2025	836,331,914	8	58

* The relevant amount is less than US\$1,000.

Notes:

- (i) During the years ended December 31, 2025 and 2024, the Company purchased 3,863,500 and 1,090,500 shares from the open market, respectively.

	No. of ordinary shares	Price per share Highest HK\$	Lowest HK\$	Aggregate consideration paid RMB'000
January 2024	1,721,000	6.61	5.51	9,312
August 2024	11,679,000	6.60	5.17	59,233
September 2024	189,000	5.00	4.53	828
October 2024	2,440,500	6.81	5.20	13,316
November 2024	1,687,000	5.81	5.03	8,282
December 2024	1,090,500	5.34	4.37	4,598
January 2025	534,000	4.63	3.71	2,003
February 2025	745,500	4.61	3.97	2,908
April 2025	2,174,000	5.42	4.09	9,486
May 2025	410,000	5.41	5.17	1,997

- (ii) None of the Company's subsidiaries purchased, sold or redeemed any of the Company's listed securities during both years.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

26. CONTRACT LIABILITIES

	2025 RMB'000	2024 RMB'000
Advance for granting distribution right (note a)	28,302	28,302
Sublicense income (note b)	1,789	1,788
Advance for CDMO services	520	1,501
	30,611	31,591
Analysis as:		
Current	2,309	3,289
Non-current	28,302	28,302
	30,611	31,591

Notes:

- a) The Group granted an exclusion distribution right to a customer for certain product of the Group in the PRC for a period of five years at cash consideration of RMB28,302,000 excluding value added tax (RMB30,000,000 including value added tax). The Group agrees to supply the products after the product being approved for commercialization. The Group recognised the amount as non-current contract liabilities as the product is still under research and development and it takes more than one year to obtain the commercialization approval in the PRC.
- b) The Group received upfront payment relating to sublicense of exclusive distribution right in Taiwan market for a product of the Group. The Group agrees to supply the products after the product being approved for commercialisation.

27. WARRANTS

On April 14, 2021, the Company entered into an agreement with Alimera for the issuance of 1,000,000 non-transferable warrants which would entitle Alimera to subscribe for up to 1,000,000 fully paid ordinary shares of the Company at the exercise price of HK\$23.88 per share. The warrants were issued in conjunction with the acquisition of a license right from Alimera.

The warrants were granted on April 14, 2021, and the issuance was subsequently completed on August 13, 2021 with the expiry date on August 12, 2025. Such warrant reserve is included in other reserves until they are being exercised. For further details of the warrants issue, please refer to the Company's announcements dated April 14, 2021 and August 13, 2021, respectively. There was no exercise of warrants during the years ended December 31, 2025 and 2024. The warrants have been expired on August 12, 2025.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

28. SHARE-BASED PAYMENT TRANSACTIONS

(a) Share option scheme of the Company

The Company's share option scheme (the "Option Scheme") was adopted pursuant to a resolution passed on May 23, 2018 for the primary purpose of providing incentives to directors and eligible employees who render services to the Group. Under the Option Scheme, the Company may grant options to eligible employees, including the directors of the Company, to subscribe for shares in the Company.

The directors of the Company approved up to 23,964,800 shares of the Company, in which options may be granted under the Option Scheme. On January 22, 2020, a resolution was passed by the board of directors of the Company to increase the capacity of the Option Scheme to at a maximum of 60,328,890 shares.

The options granted to one director and certain employees of the Group in 2020 under the Option Scheme generally vest over 60-months with a cliff vesting of 20% on the first trading date after the expiry of one year after the commencement date of the director and staff employment and a vesting of 5 percent (5%) of each quarter for the following sixteen quarters and the vesting schedule shall be accelerated upon completion of initial public offering of the Company ("IPO").

The following table discloses movements of the outstanding options granted under the Option Scheme during the years:

	Number of share options held by		
	Directors of the Company	Employees	Weighted average exercise price
At January 1, 2024	21,425,710	101,606	US\$0.19
Exercised	(4,711,000)	–	US\$0.19
At December 31, 2024	16,714,710	101,606	US\$0.19
Exercised	(3,498,500)	–	US\$0.19
At December 31, 2025	13,216,210	101,606	US\$0.19

During the year ended December 31, 2025, the weighted average exercise price of share options exercised is US\$0.19 (2024: US\$0.19) for the directors of the Company and nil (2024: nil) for the employees respectively.

In respect of the share options exercised during the year ended December 31 2025, the weighted average share price at the dates of exercise was HK\$7.46 (2024: HK\$6.12).

As at December 31, 2025, total of 13,317,816 share options were outstanding (2024: 16,816,316), with the weighted average exercise price of US\$0.19 (2024: US\$0.19). Among them total of 13,317,816 share options were exercisable (2024: 16,816,316), with the weighted average exercise price of US\$0.19 (2024: US\$0.19).

The expenses in relation to the share option granted by the Company has been fully recognised in previous years.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(b) Restricted share unit Scheme (“RSU Scheme”) of the Company

On April 28, 2020, the Company adopted a RSU Scheme, under which, at the maximum of 24,000,000 shares can be issued by the Company under the RSU Scheme. For all granted RSUs, 20% of the shares are to be vested on the first anniversary of the vesting commencement date, and the remaining shares are to be vested with equal quarterly instalments over the following sixteen quarters.

The following table discloses movements of the Company’s RSUs held by grantees for the years:

	Number of RSU held by			Weighted average exercise price
	Directors of the Company	Employees	Consultant	
At January 1, 2024	11,217,735	764,673	300,000	US\$0.19
Exercised	(67,685)	(471,375)	–	US\$0.19
Forfeited	–	(2,827)	–	US\$0.19
At December 31, 2024	11,150,050	290,471	300,000	US\$0.19
Exercised	–	(7,000)	–	US\$0.19
At December 31, 2025	11,150,050	283,471	300,000	US\$0.19

In respect of the RSUs exercised during the year ended December 31, 2025, the weighted average share price at the dates of exercise was HK\$7.52 (2024: HK\$6.13).

During the year ended December 31, 2025, 7,000 (2024: 539,060) number of RSUs were exercised and settled by transferring treasury shares held in the trust to the directors and the employees. As at December 31, 2025, total of 11,133,323 (2024: 11,140,323) RSUs are vested but unexercised, whose weighted average exercise price is US\$0.19 (2024: US\$0.19).

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(b) Restricted share unit Scheme (“RSU Scheme”) of the Company (continued)

Fair value of the RSU granted

The fair value of the RSUs granted in 2022 was determined by using the binominal option pricing model. Key assumptions are acquired to be determined by the directors of the Company with best estimate. The range of fair value of shares and corresponding inputs for the RSUs were as follows:

	September 9, 2022
Grant date fair value of shares (note)	HK\$10.52
Exercise price (note)	US\$0.188
Expected volatility	55.0%
Expected life	10 years
Risk-free rate	3.19%
Expected dividend yield	nil
Fair value at grant date	RMB2,489,000

Note: The grant date fair value of shares and exercise price has been adjusted after the share subdivision as defined in the 2021 Annual Report.

The Company used the discounted cash flow method to determine the underlying share value of the Company. The directors of the Company estimated the risk-free interest rate based on the yield of Hong Kong Government Bonds for the grants during the year ended December 31, 2022 with a maturity life close to the year from the valuation date to the expected liquidation date. Volatility was estimated at grant date based on average of historical volatilities of the comparable companies with length commensurable to the time to maturity of the RSUs. Dividend yield is based on management estimation at the grant date. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.

The variables and assumptions used in computing the fair value of the RSUs are based on the directors’ best estimate. The value of an RSUs varies with different variables of certain subjective assumptions.

The Group recognised the total expense of RMB306,000 for the year ended December 31, 2025 in relation to the RSUs granted by the Company (2024: RMB858,000).

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(c) 2021 share option scheme (“2021 Share Option Scheme”) of the Company

On July 2, 2021, the board proposed the adoption of the 2021 Share Option Scheme for the purpose of providing incentive or reward to eligible persons for their contribution to, and continuing efforts to promote the interests of, the Group, and incentivizing them to remain with the Group. The maximum number of shares may be issued by the Company shall not exceed 10% of the total number of shares in issue at the date of adoption. The exercise period of the share options is ten years after the date of grant. The adoption of 2021 Share Option Scheme was approved by the shareholders on August 31, 2021.

For the share options granted to a director of the Company during the year ended December 31, 2021, and new granted share options during the year ended December 31, 2025, 25% of the options shall vest on the first anniversary of the grant date, and 75% of the options shall vest in twelve equal instalments in the following three years. For the share options granted to a director of the Company during the year ended December 31, 2022, the share options shall vest as follows.

- (a) 25% shall vest immediately on the date of grant;
- (b) 25% shall vest on the first anniversary of the date of grant, conditional upon the achievement of certain performance targets relating to the overall performance of the Company as set out in the grant letter, including research and development and registration progress of drug candidates, marketing and sales of commercialized products, daily operation and management of the Group. Partial achievement of the performance targets will result in proportionate vesting at the board’s discretion;
- (c) 25% shall vest on the second anniversary of the date of grant, conditional upon the performance targets to be achieved by the Company and/or the director, which shall be determined by the board in due course; and
- (d) 25% shall vest on the third anniversary of the date of grant, conditional upon the performance targets to be achieved by the Company and/or the director, which shall be determined by the board in due course.

For the share options granted to another director of the Company and employees, during the year ended December 31, 2022 and the new granted share options during the year ended December 31, 2025, the share options shall vest as follows.

- (a) 10% shall vest on the first anniversary of the grant date;
- (b) 20% shall vest in four equal installments during the period from the first anniversary of the grant date to the second anniversary of the grant date;
- (c) 30% shall vest in four equal installments during the period from the second anniversary of the grant date to the third anniversary of the grant date; and
- (d) 40% shall vest in four equal installments during the period from the third anniversary of the grant date to the fourth anniversary of the grant date.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(c) 2021 share option scheme (“2021 Share Option Scheme”) of the Company (continued)

On June 24, 2025, the Company resolved to cancel up to 4,018,842 number of share options granted during the year ended December 31, 2022 and re-grant up to 2,813,189 number of replacement options (“Re-Grant”). For further details of cancellation and re-grant of options and grants of options and awards, please refer to the Company’s Announcements dated June 24, 2025. For the share options re-granted to a director and employees of the Company for the year end December 31, 2025, the share options shall vest as follows.

- (a) 85.7% of the replacement options shall immediately vest on the grant date;
- (b) 14.3% of the Replacement Options shall vest on the first anniversary of the Grant Date.

The following table discloses movements of the outstanding options granted under the 2021 Option Scheme for the years:

	Number of share options held by		Weighted average exercise price
	Directors of the Company	Employees	
At January 1, 2024	11,115,000	13,783,952	HK\$18.34
Forfeited	–	(525,749)	HK\$12.95
At December 31, 2024	11,115,000	13,258,203	HK\$18.45
Granted	7,424,515	8,038,350	HK\$10.98
Re-Granted	105,000	2,515,090	HK\$10.98
Exercised	–	(18,900)	HK\$11.36
Cancelled	(150,000)	(3,620,624)	HK\$19.07
Forfeited	–	(947,508)	HK\$13.66
At December 31, 2025	18,494,515	19,224,611	HK\$15.31

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(c) 2021 share option scheme (“2021 Share Option Scheme”) of the Company (continued)

The fair value of the options granted was determined using the binominal option pricing model. The range of fair value of shares and corresponding inputs for the share options were as follows:

	June 24, 2025 Re-Grant	June 24, 2025
Grant date fair value of shares	HK\$3.970 – HK\$4.048	HK\$4.430 – HK\$4.507
Exercise price	HK\$10.98	HK\$10.98
Expected volatility	46.9%	46.9%
Expected life	5.00 years	5.00 years
Risk-free rate	2.10%	2.10%
Expected dividend yield	nil	nil
Fair value at grant date	RMB9,655,000	RMB63,016,000

The directors of the Company estimated the risk-free rate based on the yield of Hong Kong Government Bonds with a maturity life close to the option life of the share option. Volatility was estimated at grant date based on average of historical volatilities of the comparable companies with length commensurable to the time to maturity of the share option. Dividend yield is based on management estimation at the grant date. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.

The variables and assumptions used in computing the fair value of the share options are based on the directors’ best estimate. The value of an option varies with different variables of certain subjective assumptions.

As at December 31, 2025, 29,547,546 share options are exercisable (December 31, 2024: 16,816,316).

For the cancellation of share options, the Group accelerates the recognition of the expense.

The Group recognised the total expense of RMB33,121,000 (2024: RMB26,291,000) for the year ended December 31, 2025 in relation to share options granted by the Company.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(d) 2021 Share award scheme (“2021 Share Award Scheme”) of the Company

On July 2, 2021, the board resolved the adoption of the 2021 Share Awards Scheme to recognize the contributions of the eligible persons in order to incentivize them to remain with the Group, and to motivate them to strive for the future development and expansion of the Group. The 2021 Share Award Scheme is valid and effective for a period of ten (10) years. The maximum number of shares may be issued by the Company under the 2021 Share Award Scheme shall be 5% of the number of shares in issue from time to time during such period. Computershare was appointed by the Company as trustee for the administration of the 2021 Share Award Scheme. The trustee shall purchase the Company’s shares from the market out of cash contributed by the Company and shall hold such shares in trust until they are vested to the participants in accordance to the rules of the 2021 Share Award Scheme.

For the share awards granted to certain director of the Company during the year ended December 31, 2021, 25% of the share awards shall vest on the first anniversary of the grant date, and 75% of the share awards shall vest in twelve equal instalments in the following three years. For the share awards granted to a director of the Company during the year ended December 31, 2022, the share awards shall vest as follows.

- (a) 25% shall vest immediately on the date of grant;
- (b) 25% shall vest on the first anniversary of the date of grant, conditional upon the achievement of certain performance targets relating to the overall performance of the Company as set out in the grant letter, including research and development and registration progress of drug candidates, marketing and sales of commercialized products, daily operation and management of the Group;
- (c) 25% shall vest on the second anniversary of the date of grant, conditional upon the performance targets to be achieved by the Company and/or the director, which shall be determined by the board in due course; and
- (d) 25% shall vest on the third anniversary of the date of grant, conditional upon the performance targets to be achieved by the Company and/or a director, which shall be determined by the board in due course.

For the share awards granted to another director of the Company and employees, the share awards shall vest as follows.

- (a) 10% shall vest on the first anniversary of the grant date;
- (b) 20% shall vest in four equal installments during the period from the first anniversary of the grant date to the second anniversary of the grant date;
- (c) 30% shall vest in four equal installments during the period from the second anniversary of the grant date to the third anniversary of the grant date; and
- (d) 40% shall vest in four equal installments during the period from the third anniversary of the grant date to the fourth anniversary of the grant date.

28. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(d) 2021 Share award scheme (“2021 Share Award Scheme”) of the Company (continued)

The following table discloses movements of the outstanding awards granted under the 2021 Share Award Scheme for the years:

	Number of share award held by	
	Directors of the Company	Employees
At January 1, 2024	8,058,575	10,738,994
Vested	(4,410,075)	(3,428,895)
Forfeited	–	(404,624)
At December 31, 2024	3,648,500	6,905,475
Granted	840,835	8,111,350
Vested	(3,607,400)	(4,014,425)
Forfeited	–	(423,804)
At December 31, 2025	881,935	10,578,596

In respect of the share awards vested during the year ended December 31, 2025, the weighted average share price at the dates of vest was HK\$7.9 (2024: HK\$5.79).

The fair value of the share awards granted was determined by the market price of the Company at the grant date.

The total expenses recognised in the consolidated profit or loss and other comprehensive income for the share awards granted are approximately RMB35,511,000 (2024: RMB57,483,000) for the year ended December 31, 2025.

(e) 2024 share award scheme (“2024 Share Award Scheme”) of the Company

On March 21, 2024, the board resolved the adoption of the 2024 Share Awards Scheme for the purpose (i) to recognise the contributions of certain eligible participants and to provide them with incentives in order to retain them for the continual operation and development of the Group, and (ii) to attract suitable personnel for further development of the Group. The 2024 Share Award Scheme is valid and effective for a period of ten (10) years. The board shall not make any further award of the awarded Share which will result in the number of awarded shares granted by the board under the 2024 Share Award Scheme exceeding 10% of the issued shares of the Company as of the adoption date of the 2024 Share Award Scheme (e.g. 69,561,485).

From the adoption date of the 2024 Share Award Scheme to December 31, 2025, no award has been granted to any directors of the Company or employees.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

29. RETIREMENT BENEFITS PLANS

The employees of the Group's subsidiary in the PRC are members of the state-sponsored retirement benefit scheme organized by the relevant local government authority in the PRC. The subsidiary is required to contribute, based on a certain percentage of the payroll costs of its employees, to the retirement benefit scheme and has no further obligations for the actual payment of pensions or post-retirement benefits beyond the annual contributions. The total amount provided by the Group to the scheme in the PRC and charged to profit or loss are RMB19,018,000 (2024: RMB16,236,000) for the year ended December 31, 2025.

During the years ended December 31, 2025 and 2024, the Group contributions to the retirement benefit scheme are expensed as incurred and not reduced by contribution forfeited by those employees who leave the plan.

30. CAPITAL COMMITMENTS

	2025 RMB'000	2024 RMB'000
Capital expenditure contracted for but not provided in the consolidated financial statements:		
Acquisition of property, plant and equipment	594	5,005

31. RELATED PARTY DISCLOSURES

Compensation of key management personnel

The remuneration of the directors of the Company and other members of key management during the years were as follows:

	2025 RMB'000	2024 RMB'000
Short term benefits	12,903	25,734
Discretionary bonus (note)	565	1,494
Post-employment benefits	2,888	7,414
Share-based payments	26,880	35,253
	43,236	69,895

Note: The remuneration of key management personnel is determined by the directors of the Company having regard to the performance of individuals and market trends.

32. CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximizing the return to investors through the optimization of the debt and equity balance. The Group's overall strategy remains unchanged from prior year.

The capital structure of the Group consists of cash and cash equivalents, borrowings and equity attributable to owners of the Company, comprising share capital and reserves.

The management of the Group reviews the capital structure regularly. As part of this review, the management of the Group considers the cost of capital and the risks associated with each class of capital. Based on recommendations of the management of the Group, the Group will balance its overall capital structure through the new share issues as well as the issue of new debt.

33. FINANCIAL INSTRUMENTS

(a) Categories of financial instruments

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Financial assets		
Financial assets at FVTPL	146,608	1,388
Equity instruments at FVTOCI	7,507	11,546
Amortized cost (including cash and cash equivalents)	735,570	904,501
Financial liabilities		
Amortized cost	319,612	131,789

(b) Financial risk management objectives and policies

The Group's major financial assets and liabilities include trade and other receivables, other financial assets, equity instruments at FVTOCI, financial assets at FVTPL, bank balances and cash, trade and other payables and borrowings. Details of these financial assets and liabilities are disclosed in respective notes.

The risks associated with these financial assets and liabilities include market risks (currency risk, interest rate risk and other price risk), credit risk and liquidity risk. The policies on how to mitigate these risks are set out below. The management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

Market risk

The Group's activities expose it primarily to currency risk, interest rate risk and other price risk. There has been no change in the Group's exposure to these risks or the manner in which it manages and measures the risks.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(b) Financial risk management objectives and policies (continued)

Market risk (continued)

(i) Currency risk

Certain bank balances and cash, equity instruments at FVTOCI, financial assets at FVTPL, trade and other receivables, trade and other payables are denominated in foreign currencies of respective group entities which are exposed to foreign currency risk. The Group currently does not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

The carrying amounts of the Group's foreign currency denominated monetary assets and liabilities at the end of each reporting period are mainly as follows:

	2025 RMB'000	2024 RMB'000
Assets		
US\$	50,966	264,655
HK\$	4,139	12,334
Liabilities		
US\$	59,401	41,356
HK\$	–	22

Sensitivity analysis

The following table details the Group's sensitivity to a 5% increase and decrease in RMB against US\$ and HK\$, the foreign currency with which the Group may have a material exposure. 5% represents management's assessment of the reasonably possible change in foreign exchange rate. The sensitivity analysis uses outstanding foreign currency denominated monetary items as a base and adjusts their translation at the end of the reporting period for a 5% change in foreign currency rate. A negative/positive number below indicates an increase/decrease in loss where RMB strengthens 5% against US\$ and HK\$. For a 5% weakening of RMB against US\$ and HK\$, there would be an equal and opposite impact on loss for the year.

	2025 RMB'000	2024 RMB'000
Impact on profit or loss		
US\$	422	(11,165)
HK\$	(207)	(616)

The directors of the Company considered the sensitivity analysis is unrepresentative of the inherent foreign exchange risk as the exposure at the end of the reporting period does not reflect the exposure during the reporting period.

33. FINANCIAL INSTRUMENTS (continued)

(b) Financial risk management objectives and policies (continued)

Market risk (continued)

(ii) Interest rate risk

The Group is primarily exposed to fair value interest rate risk in relation to lease liabilities, certain bank borrowings, fixed-rate term deposit and bank deposits. The Group currently does not have an interest rate hedging policy to mitigate interest rate risk; nevertheless, the management monitors interest rate exposure and will consider hedging significant interest rate risk should the need arise.

The Group is also exposed to cash flow interest rate risk in relation to variable-rate bank balances and certain bank borrowings. The Group's cash flow interest rate risk is mainly concentrated on the fluctuation of interest rates on bank balances. A rise or fall of 50 basis points in interest rates would result in an estimated impact of RMB694,000 on the Group's profit or loss, primarily due to changes in interest income from variable-rate bank balances.

(iii) Other price risk

The Group was exposed to other price risk arising from equity instruments at FVTOCI.

Sensitivity analysis

The sensitivity analysis below have been determined based on the exposure to equity price risk at the reporting date for equity instruments at FVTOCI. If the equity value of the ordinary shares of investment had been changed based on the 5% higher/lower, the other comprehensive income of the Group for the year ended December 31, 2025 would increase or decrease by approximately RMB375,000 (2024: RMB577,000) as a result of the changes in fair value of equity instruments at FVTOCI.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial losses to the Group. The Group's credit risk exposures are primarily attributable to trade receivables, bank balances, other receivables and contract assets.

In order to minimize credit risk, the Group has tasked its finance team to develop and maintain the Group's credit risk gradings to categorize exposures according to their degree of risk of default. Management uses publicly available financial information and the Group's own historical repayment records to rate other debtors. The Group's exposure and the credit ratings of its counterparties are continuously monitored and the aggregate value of transactions concluded is spread among approved counterparties.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(b) Financial risk management objectives and policies (continued)

Credit risk (continued)

The Group's current credit risk grading framework comprises the following categories:

Category	Description	Trade receivables and contract assets	Other financial assets
Low risk	The counterparty has a low risk of default and does not have any past due amounts	Lifetime ECL – not credit-impaired	12m ECL
Watch list	Debtor frequently repays after due dates but usually settle in full	Lifetime ECL – not credit-impaired	12m ECL
Doubtful	There have been significant increase in credit risk since initial recognition through information developed internally or external resources	Lifetime ECL – not credit-impaired	Lifetime ECL – not credit-impaired
Loss	There is evidence indicating the asset is credit-impaired	Lifetime ECL – credit-impaired	Lifetime ECL – credit-impaired
Write-off	There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery	Amount is written off	Amount is written off

Trade receivables arising from contracts with customers and contract assets

The Group has concentration of credit risk as 78% and 94% of the total trade receivables were due from the Group's largest customer and the five largest customers respectively (2024: 88% and 94% of the total trade receivables were due from the Group's largest customer and the five largest customers respectively). In order to minimize the credit risk with customers, the management of the Group has delegated its finance team responsible for determination of credit limits and credit approvals. Before accepting any new customers, the Group uses an internal credit scoring system to assess the potential customer's credit quality and defines credit limits by customer. Other monitoring procedures are in place to ensure that follow-up action is taken to recover overdue debts.

In addition, the Group has performed impairment assessment under the ECL model on trade balances and contract assets individually, based on the past default experience of the debtor, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forward-looking information that is available without undue cost or effort at the end of each year.

According to individual assessment of the management, since all of the trade receivables balances and contract assets are due from reputable pharmaceutical companies which have low risk of default and usually settled within credit period. The exposure to credit risk for the balance is assessed within lifetime ECL, in the opinion of the management, the impairment loss for the trade receivables from the customers is amounting to RMB1,970,000 as at the year ended December 31, 2025 (2024: RMB1,427,000).

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(b) Financial risk management objectives and policies (continued)

Credit risk (continued)

Other receivables

For the purpose of impairment assessment for other receivables, the loss allowance is measured at an amount equal to 12m ECL. In determining the ECL for these financial assets, the directors of the Company have taken into account the financial positions of the counterparties in estimating the probability of default of each of the other receivables occurring within their respective loss assessment time horizon, as well as the loss upon default in each case. The directors of the Company considered that the 12m ECL allowance is assessed to be RMB366,000 as at December 31, 2025 (2024: RMB256,000)

Bank balances

The credit risk on bank balances is limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

The tables below detail the credit risk exposures of the Group's financial assets, which are subject to ECL assessment:

	Notes	External credit rating	Internal credit rating	12m or lifetime ECL	2025 Gross carrying amount RMB'000	2024 Gross carrying amount RMB'000
Financial assets at amortized cost						
Bank balances	21	A1-A3	N/A	12m ECL	402,462	769,205
Other receivables	18	N/A	N/A (note a)	12m ECL	10,334	11,291
Trade receivables from contracts with customers	18	N/A	N/A (note b)	Lifetime ECL	315,179	125,688

Notes:

- (a) For the purpose of internal credit risk management, the Group uses repayment history or other relevant information to assess whether credit risk has increased significantly. As at December 31, 2025 and 2024, the balances of other receivables and rental deposits are not past due and the internal credit rating of these balances are considered as low risk.
- (b) For trade receivables and contract assets, the Group has applied the simplified approach in IFRS 9 to measure the loss allowance at lifetime ECL. The ECL on trade receivables and contract assets are assessed individually, based on the past default experience of the debtor, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forward-looking information that is available without undue cost or effort at the end of each year.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(b) Financial risk management objectives and policies (continued)

Credit risk (continued)

Bank balances (continued)

As at the year ended December 31, 2025, the Group provided RMB1,970,000 (2024: RMB1,427,000) impairment allowance for trade receivables, based on individual assessment.

The following table shows the movement in lifetime ECL that has been recognised for trade receivables under the simplified approach.

	Lifetime ECL not credit- impaired RMB'000
At January 1, 2024	849
Impairment losses reversed	(849)
New financial assets originated	1,427
At December 31, 2024	1,427
Impairment losses reversed	(1,427)
New financial assets originated	1,970
At December 31, 2025	1,970

Liquidity risk

In the management of the liquidity risk, the Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and mitigate the effects of fluctuations in cash flows.

The following table details the Group's remaining contractual maturity for its financial liabilities. The table has been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay. The table includes both interest and principal cash flows.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(b) Financial risk management objectives and policies (continued)

Liquidity table

	Weighted average effective interest rate %	Within 1 year and on demand <i>RMB'000</i>	1 to 2 years <i>RMB'000</i>	2 to 5 years <i>RMB'000</i>	Total <i>RMB'000</i>	Carrying amount <i>RMB'000</i>
At December 31, 2025						
Trade and other payables	N/A	165,262	–	–	165,262	165,262
Borrowings	2.24%~3.2%	56,019	53,862	54,188	164,069	158,205
Lease liabilities	3%~3.95%	10,953	12,225	7,376	30,554	29,331
		232,234	66,087	61,564	359,885	352,798
At December 31, 2024						
Trade and other payables	N/A	115,242	–	–	115,242	115,242
Borrowings	3.00	2,547	4,505	10,824	17,876	16,547
Lease liabilities	3.60~4.70	7,083	1,430	1,040	9,553	9,236
		124,872	5,935	11,864	142,671	141,025

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(c) Fair value measurements of financial instruments

(i) Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis

Some of the Group's financial assets are measured at fair value at the end of the reporting period. The following table gives information about how the fair values of these financial assets are determined (in particular, the valuation techniques and inputs used).

Financial assets/ financial liabilities	Notes	Fair value as at		Fair value hierarchy	Valuation Techniques and key inputs	Significant Unobservable inputs	Relationship of unobservable inputs to fair value
		2025 RMB'000	2024 RMB'000				
Other financial assets	20	145,042	–	Level 3	Discounted cash flow, which was estimated based on expected return, discounted at a rate that reflects the risk of underlying investments.	Expected return	N/A
Financial assets at FVTPL		466	288	Level 1	Quoted bid prices in an active market	N/A	N/A
Financial assets at FVTPL		1,100	1,100	Level 3	Monte Carlo simulation	Annual growth rate of revenue; the volatility stated on annual basis; risk-free interest rate; time step	N/A
Listed equity securities at FVTOCI	17	7,507	11,546	Level 1	Quoted bid prices in an active market	N/A	N/A

There were no transfers between level 1 and level 2 during the years.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

33. FINANCIAL INSTRUMENTS (continued)

(c) Fair value measurements of financial instruments (continued)

(ii) Reconciliation of Level 3 fair value measurements

The following table presents the reconciliation of Level 3 measurements of other financial assets during the years:

	Financial assets at FVTPL RMB'000	Other financial assets RMB'000
At December 31, 2024	–	–
Recognition of CVR	1,100	–
Purchase of other financial assets	–	80,000
Redemption of other financial assets	–	(80,450)
Fair value changes	–	450
At December 31, 2024	1,100	–
Recognition of CVR	–	–
Purchase of other financial assets	–	1,005,000
Redemption of other financial assets	–	(863,047)
Fair value changes	–	3,089
At December 31, 2025	1,100	145,042

(iii) Fair value of financial assets and financial liabilities that are not measured at fair value on a recurring basis

The directors of the Company consider that the carrying amount of the Group's financial assets and financial liabilities recorded at amortized cost in the consolidated financial statements approximate their fair values. Such fair values have been determined in accordance with generally accepted pricing models based on a discounted cash flow analysis.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

34. PARTICULARS OF SUBSIDIARIES

As at December 31, 2025 and 2024 and the date of this annual report, the Group's subsidiaries are as follows:

Name of subsidiaries	Place/country and date of establishment/ incorporation/operation	Issued and fully paid share capital/registered capital		Equity interest attributable to the Group as at December 31		Principal activities
		2025	2024	2025 %	2024 %	
Ocumension Hong Kong	Hong Kong March 7, 2018	Issued capital of US\$1 and paid-up capital of US\$1	Issued capital of US\$1 and paid-up capital of US\$1	100	100	Investment holding
Ocumension Shanghai* 歐康維視生物醫藥(上海)有限公司	the PRC March 25, 2018 (note ii)	Registered capital of RMB725,481,152 and paid-up capital of RMB714,171,818.20	Registered capital of RMB725,481,152 and paid-up capital of RMB378,871,818	100	100	Researching, developing and commercialising therapies for ophthalmic patients
Suzhou Ocumension Biotech Co., Ltd.* 蘇州歐康維視生物科技有限公司	the PRC February 11, 2020 (note i)	Registered capital of US\$247,961,400 and paid-up capital of US\$176,402,428.86	Registered capital of US\$206,581,400 and paid-up capital of US\$129,660,200	100	100	Researching, developing and commercialising therapies for ophthalmic patients
Ocumension (Zhejiang) Therapeutics Co., Ltd.* 歐康維視(浙江)醫藥有限公司	the PRC May 11, 2020 (note ii)	Registered capital of RMB191,603,000 and paid-up capital of RMB135,443,500	Registered capital of RMB191,603,000 and paid-up capital of RMB135,443,500	100	100	Researching, developing and commercialising therapies for ophthalmic patients
Suzhou Xiayang* 蘇州夏翔生物醫藥有限公司	the PRC October 18, 2019 (note ii)	Registered capital of RMB200,000,000 and paid-up capital of RMB35,000,000	Registered capital of RMB200,000,000 and paid-up capital of RMB35,000,000	100	100	Plant construction and trading of pharmaceutical products
Ocumension (Shanghai) Supply Chain Co., Ltd. 歐康維視(上海)供應鏈有限公司	the PRC October 9, 2020 (note i)	Registered capital of US\$2,000,000 and paid-up capital of US\$2,000,000	Registered capital of US\$2,000,000 and paid-up capital of US\$2,000,000	100	100	Trading of pharmaceutical products
Suzhou Ocumension Biotech Co., Ltd.* 蘇州中賢生物醫藥有限公司	the PRC January 20, 2022 (note i)	Registered capital of US\$31,500,000 and paid-up capital of US\$nil	Registered capital of US\$31,500,000 and paid-up capital of US\$nil	100	100	Trading of pharmaceutical products
Ocuarmor MedTech	Cayman Islands November 19, 2021	Issued capital of US\$50,000 and paid-up capital of US\$nil	Issued capital of US\$50,000 and paid-up capital of US\$nil	100	100	Investment holding

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

34. PARTICULARS OF SUBSIDIARIES (continued)

Name of subsidiaries	Place/country and date of establishment/ incorporation/operation	Issued and fully paid share capital/registered capital		Equity interest attributable to the Group as at December 31		Principal activities
		2025	2024	2025 %	2024 %	
Ocuarmor Medtech (HK) Limited	Hong Kong December 1, 2021	Issued capital of US\$1 and paid-up capital of US\$1	Issued capital of US\$1 and paid-up capital of US\$1	100	100	Investment holding
Ocuarmor Medtech * (Zhejiang) Co., Ltd. 浙江歐鹿醫療器械有限公司	the PRC January 5, 2022 (note iii)	Registered capital of RMB30,000,000 and paid-up capital of RMB nil	Registered capital of RMB30,000,000 and paid-up capital of RMB nil	100	100	Trading of pharmaceutical products
Ocumension Hainan* 歐康維視生物醫藥(海南)有限公司	the PRC May 29, 2024 (note i)	Registered capital of RMB1,000,000 and paid-up capital of RMB nil	Registered capital of RMB1,000,000 and paid-up capital of RMB nil	100	100	Researching, developing and commercialising therapies for ophthalmic patients
Jiangsu Ocumension Biotech Co., Ltd.* 江蘇歐康維視生物科技有限公司	the PRC June 26, 2024 (note i)	Registered capital of RMB50,000,000 and paid-up capital of RMB38,800,000	Registered capital of RMB10,000,000 and paid-up capital of RMB nil	100	100	Trading of pharmaceutical products
Steri-Dock, LLC	USA December 14, 2018 (note iv)	N/A	N/A	100	-	Researching, developing and commercialising therapies for ophthalmic patients

* English translated name of identification only.

Notes:

- (i) The subsidiary is a wholly foreign invested limited liability company incorporated in the PRC.
- (ii) The subsidiaries are domestic limited liability companies incorporated in the PRC.
- (iii) The subsidiary was acquired on June 16, 2023.
- (iv) The subsidiary was acquired on December 22, 2025.

None of the subsidiaries had issued any debt securities at the end of the years.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

35. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES

The table below details changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group's consolidated statement of cash flows as cash flows from financing activities.

	Borrowings <i>RMB'000</i>	Interest payable <i>RMB'000</i>	Lease liabilities <i>RMB'000</i>	Total <i>RMB'000</i>
At January 1, 2024	120,000	101	17,983	138,084
Financing cash flows	(103,453)	(1,608)	(14,138)	(119,199)
Interest expenses	–	1,522	641	2,163
New leases entered	–	–	8,898	8,898
Termination of leases	–	–	(4,148)	(4,148)
At December 31, 2024	16,547	15	9,236	25,798
Financing cash flows	141,658	(1,387)	(10,798)	129,473
Interest expenses	–	1,474	971	2,445
New leases entered and modification	–	–	29,922	29,922
At December 31, 2025	158,205	102	29,331	187,638

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

36. STATEMENT OF FINANCIAL POSITION AND RESERVES OF THE COMPANY

	NOTE	2025 RMB'000	2024 RMB'000
Non-current assets			
Investments in subsidiaries		1,282,390	1,207,542
Intangible asset		293,707	264,357
Prepayments		57,451	62,602
Equity instruments at FVTOCI		7,507	11,546
Financial assets at FVTPL		1,566	1,388
Amounts due from subsidiaries		3,407,256	3,182,879
		5,049,877	4,730,314
Current assets			
Other receivable		514	1,952
Amounts due from subsidiaries		50,000	50,000
Other financial assets		70,026	–
Bank balances and cash		143,277	475,869
		263,817	527,821
Current liability			
Trade and other payables		151,029	122,725
		151,029	122,725
Net Current assets		112,788	405,096
Total assets less current liability		5,162,665	5,135,410
Net Assets		5,162,665	5,135,410
Capital and reserves			
Share capital	25	58	58
Reserves		5,162,607	5,135,352
Total Equity		5,162,665	5,135,410

Notes to the Consolidated Financial Statements

For the year ended December 31, 2025

36. STATEMENT OF FINANCIAL POSITION AND RESERVES OF THE COMPANY

(continued)

The movement of the reserves of the Company are as follows:

	Share premium RMB'000	Other reserves RMB'000	Treasury share RMB'000	FVTOCI revaluation reserve RMB'000	Share-based payment reserve RMB'000	Accumulated losses RMB'000	Total RMB'000
At January 1, 2024	7,625,549	(280,791)	(3)	154,753	442,978	(3,892,087)	4,050,399
Loss and total comprehensive expense for the year	-	-	-	(47,450)	-	(36,960)	(84,410)
Disposal of investments in equity instruments at FVTOCI	-	-	-	(106,920)	-	106,920	-
Exercise of share options granted	35,756	-	-	-	(29,447)	-	6,309
Exercise of RSUs	4,507	-	*	-	(3,555)	-	952
Vest of share award	100,576	-	1	-	(100,577)	-	-
Purchase of shares (note 25)	(95,568)	-	(1)	-	-	-	(95,569)
Cancellation of treasury shares (note 25)	-	-	*	-	-	-	-
Issuance of ordinary shares to Alcon (note 28)	1,173,039	-	-	-	-	-	1,173,039
Recognition of equity-settled share-based payments (note 28)	-	-	-	-	84,632	-	84,632
Forfeited equity-settled share-based payments	-	-	-	-	(7,141)	7,141	-
At December 31, 2024	8,843,859	(280,791)	(3)	383	386,890	(3,814,986)	5,135,352
Loss and total comprehensive expense for the year	-	-	-	8,449	-	(38,695)	(30,246)
Disposal of investments in equity instruments at FVTOCI	-	-	-	(6,142)	-	6,142	-
Exercise of share options granted	26,763	-	-	-	(21,877)	-	4,886
Exercise of RSUs	117	-	*	-	(46)	-	71
Vest of share award	92,470	-	1	-	(92,471)	-	-
Purchase of shares (note 25)	(16,394)	-	*	-	-	-	(16,394)
Recognition of equity-settled share-based payments (note 28)	-	-	-	-	68,938	-	68,938
Forfeited equity-settled share-based payments	-	-	-	-	(8,110)	8,110	-
At December 31, 2025	8,946,815	(280,791)	(2)	2,690	333,324	(3,839,429)	5,162,607

* Represented the relevant amount less than RMB1,000.

Definitions and Acronyms

“2021 Share Award Scheme”	the share award scheme adopted by the Company in accordance with the scheme rules thereof on July 2, 2021 and amended from time to time, the details of which are set out in the circular of the Company dated May 24, 2024
“2021 Share Option Scheme”	the share option scheme adopted by the Board in accordance with the rules thereof on July 2, 2021, approved by the Shareholders on the extraordinary general meeting of the Company held on August 31, 2021 and amended from time to time, the details of which are set out in the circular of the Company dated May 24, 2024
“2024 Share Award Scheme”	the share award scheme adopted by the Company on March 21, 2024 involving its existing Shares in accordance with the scheme rules thereof, as amended from time to time
“6 Dimensions Affiliates”	6 Dimensions Affiliates Fund, L.P., a limited partnership established under the laws of Cayman Islands on October 25, 2017 and one of our controlling Shareholders
“6 Dimensions Capital”	6 Dimensions Capital, L.P., a limited partnership established under the laws of Cayman Islands on August 16, 2017 and one of our controlling Shareholders
“AGM”	the annual general meeting of the Company
“Alcon”	Alcon Inc., the global leader in eye care with complementary businesses in surgical and vision care and a stock corporation organized under the laws of Switzerland, the shares of which are listed on SIX Swiss Exchange and the New York Stock Exchange under the ticker symbol ALC, one of our substantial Shareholder
“Alcon Group”	Alcon and its subsidiaries (including Alcon Pharma)
“Alcon Pharma”	Alcon Pharmaceuticals Ltd, a company organized and existing under the laws of Switzerland and a wholly owned subsidiary of Alcon, one of our substantial Shareholder
“Alcon Research”	Alcon Research, LLC, a company organized under the laws of Delaware in the U.S. and a wholly owned subsidiary of Alcon
“Alcon Transaction”	the acquisition of the Transferred Products and the royalty payments under the Asset Purchase Agreement, the in-licensing of the Pipeline Product and the Commercial Product and the royalty payments and sales milestone payments under the License Agreement, the issue of Share to Alcon Pharma under the Subscription Agreement and the purchase arrangements under the Manufacture and Supply Agreement
“Alimera”	Alimera Sciences, Inc., a biopharmaceutical company organized and existing under the laws of the State of Delaware of the United States, whose shares of common stock are traded on the NASDAQ (ticker symbol: ALIM)
“AMD”	age-related macular degeneration, a disease that causes damage to the macula and leads to progressive loss of central vision

Definitions and Acronyms

“APAC”	Asia-Pacific
“Articles of Association”	the articles of association of the Company conditionally adopted on July 10, 2020 and effective on the Listing Date, as amended from time to time
“Asset Purchase Agreement”	the asset purchase agreement entered into by and between Ocumension HK and Alcon Research on August 12, 2024 in respect of the acquisition of the Transferred Products
“Audit Committee”	the audit committee of the Board
“Board”	the board of directors of the Company
“CDE”	the Center for Drug Evaluation of NMPA (國家藥品監督管理局藥品審評中心), a division of the NMPA mainly responsible for review and approval of IND and NDA
“CDMO”	contract development and manufacturing
“CG Code”	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules as amended from time to time
“China” or “the PRC”	the People’s Republic of China, but for the purpose of this annual report and for geographical reference only and except where the context requires, references in this annual report to “China” and the “PRC” do not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“chronic NIU-PS”	chronic non-infectious uveitis affecting the posterior segment of the eye
“CMC”	chemistry, manufacturing and controls which cover the various procedures used to assess the physical and chemical characteristics of drug products, and to ensure their quality and consistency during manufacturing. CMC data is essential in the submissions to regulatory authorities
“Commercial Product”	Systane® Ultra (Lubricant eye drops)
“Company”	Ocumension Therapeutics (歐康維視生物), a company incorporated under the laws of the Cayman Islands with limited liability on February 27, 2018, the shares of which were listed on the Main Board of the Stock Exchange on July 10, 2020
“Core Product”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for purposes of this annual report, our Core Product refers to OT-401 (YUTIQ®, fluocinolone intravitreal implant, trade name: Youshiyiqing® (優施瑩®))
“CTA”	the clinical trial application
“Director(s)”	the director(s) of our Company, including all executive directors, non-executive directors and independent non-executive directors

“DME”	diabetic macular edema
“ESOP”	the employee stock option plan adopted by our Company on May 23, 2018, as amended from time to time, the details of which are set out in the Prospectus
“EyePoint”	EyePoint Pharmaceuticals, Inc., a company whose shares of common stock are listed on the NASDAQ (ticker symbol: EYPT) and a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases
“FDA”	the United States Food and Drug Administration
“FVTOCI”	fair value through other comprehensive income
“FVTPL”	fair value through profit or loss
“Greater China”	the PRC, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Group” or “Ocumention”	the Company and its subsidiaries
“Grade III hospitals”	the top-level hospital(s) in China, as hospitals in China are divided into three classes by National Health Commission of the PRC (中華人民共和國國家衛生健康委員會), among which, Class III hospitals are at the highest level, typically having more than 500 beds, providing high-level specialist medical and healthcare services to several regions and performing advanced teaching and research tasks
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Huonland”	Beijing Huonland Pharmaceutical Co., Ltd. (北京匯恩蘭德製藥有限公司), a limited liability company established under the laws of the PRC on August 3, 2012 and one of our licensing partners. Huonland primarily engages in development, production and sales of ophthalmology products
“IFRS”	International Financial Reporting Standards
“IND”	investigational new drug, the application for which is the first step in the drug review process by regulatory authorities to decide whether to permit clinical trials. Also known as CTA in China
“Independent Third Party(ies)”	party or parties that, to the best of our Directors’ knowledge, information and belief, having made all reasonable inquiries, is or are not a connected person or connected persons of the Company

Definitions and Acronyms

“License Agreement”	the license agreement entered into between Ocumension HK and Alcon Pharma on August 12, 2024 in respect of the exclusive license to develop, manufacture and commercialize the Pipeline Product for dry eye uses and to commercialize the Commercial Product obtained by Ocumension HK from Alcon Pharma in the PRC
“Listing”	the listing of our Shares on the Main Board of the Stock Exchange
“Listing Date”	July 10, 2020, being the date on which dealings in our Shares first commenced on the Main Board of the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Manufacture and Supply Agreement”	the manufacture and supply agreement entered into by and between Ocumension HK and Alcon Pharma on August 12, 2024 in respect of, pursuant to which, Ocumension HK agreed to purchase from Alcon Pharma relevant products during the periods agreed by the parties
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
“nAMD”	Neovascular (Wet) Age-Related Macular Degeneration (Wet AMD)
“NASDAQ”	The Nasdaq Stock Market LLC
“NDA”	new drug application, an application through which the drug sponsor formally proposes that the relevant regulatory authority approve a new drug for sales and marketing
“Nicox”	Nicox S.A., a corporation incorporated under the laws of France on February 15, 1996, one of our licensing partners whose shares are listed on the Euronext exchange (ticker symbol: COX)
“NMPA”	National Medical Products Administration (國家藥品監督管理局), formerly the China Food and Drug Administration (國家食品藥品監督管理局), or CFDA
“Nomination Committee”	the nomination committee of the Board
“NRDL”	National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance 《國家基本醫療保險、工傷保險和生育保險藥品目錄》
“Ocumension HK”	Ocumension (Hong Kong) Limited, a company incorporated under the laws of Hong Kong and a wholly owned subsidiary of the Company
“Pipeline Product”	dry eye product candidate known as AR-15512
“Prospectus”	the prospectus issued by the Company dated June 29, 2020

“RMB”	Renminbi Yuan, the lawful currency of China
“Remuneration Committee”	the remuneration committee of the Board
“Reporting Period”	the one-year period from January 1, 2025 to December 31, 2025
“RSU(s)”	the restricted share unit
“RSU Scheme”	the restricted share unit scheme adopted by the Company on April 28, 2020, the details of which are set out in the Prospectus
“R&D”	research and development
“SFC”	Securities and Futures Commission of Hong Kong
“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Scheme Mandate Limit”	being 53,424,000 Shares, which account for approximately 7.95% of the total Shares in issue as of November 25, 2022, the date of approval by the Shareholders rounded down to nearest whole board lot of 500 Shares and is applicable to all share schemes of the Company
“Service Provider(s)”	person(s) who provide services to the Group on a continuing or recurring basis in its ordinary and usual course of business which are material to the long-term growth of the Group as determined by the Remuneration Committee, including advisers, consultants, distributors, contractors, suppliers, agents, business partners, joint venture partners, promoters, service providers of any member of the Group, but excluding placing agents or financial advisers providing advisory services for fundraising, mergers or acquisitions, or consultants providing professional services to the Group
“Service Provider Sublimit”	a sublimit under the Scheme Mandate Limit, being 5,342,000 Shares, which account for approximately 0.795% of the total Shares in issue as of the date of approval by the Shareholders rounded down to nearest whole board lot of 500 Shares and is applicable to all share schemes of the Company
“Share(s)”	ordinary shares in the share capital of our Company of US\$0.00001 each
“Shareholder(s)”	holder(s) of Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“Subscription Agreement”	the subscription agreement entered into by and between the Company and Alcon Pharma on August 12, 2024, pursuant to which the Company agreed to conduct the Alcon Consideration Issue

Definitions and Acronyms

“Suzhou 6 Dimensions”	Suzhou 6 Dimensions Venture Capital Partnership L.P. (蘇州通和毓承投資合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on August 4, 2017 and one of our controlling shareholders
“Suzhou Frontline II”	Suzhou Frontline BioVentures Venture Capital Fund II L.P. (蘇州通和二期創業投資合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on March 8, 2016 and one of our controlling shareholders
“Suzhou Xiaxiang”	Suzhou Xiaxiang Biomedicine Co., Ltd. (蘇州夏翔生物醫藥有限公司), a limited liability company established in the PRC on October 18, 2019
“Transferred Products”	six products under the Asset Purchase Agreement, namely Tears Naturale® Forte (Lubricant eye drops), Tears Naturale® II (Lubricant eye drops), Bion® Tears (Lubricant eye drops), Alcaine® (Topical local anesthetic eye drops), Fluorescite® (Diagnostic agent for IV administration) and Cyclogyl® (Muscarinic antagonist eye drops), collectively
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US\$”	United States dollars, the lawful currency of the United States
“wAMD”	wet age-related macular degeneration
“Written Guidelines”	the Guidelines for Securities Transactions by Directors adopted by the Company
“%”	Per cent

In this annual report, the terms “associate”, “connected person”, “controlling shareholder” and “subsidiary” shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires.



OcuMension

欧康维视